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ABSTRACT 
 
Antimicrobial resistance (AMR) is one of the most widely recognized threats to global 
health, and one that continues to grow as new mechanisms of resistance evolve and resistant 
pathogens spread. Antibiotics are a cornerstone of modern medicine, but their misuse and 
overuse has constantly and consistently reduced their efficacy to the critically low levels we 
observe today. As a result, the rate of mortality as a direct result of AMR is approaching over 
a million deaths annually, with 20-year projections in the ten-millions. Rapid, phenotypic 
antimicrobial susceptibility testing (AST) that could be performed at the point of care (most 
notably in ≤ 30 min) would decrease the overuse of antimicrobials, allow physicians to make 
informed choices about which antimicrobials to prescribe, and improve patient outcomes. 
Today no such method exists. The ultimate goal of the below work is to allow physicians to 
choose, instead of guess, which antibiotics to use. We envision that development of these 
tests into distributable diagnostics will drastically improve patient outcomes, curb the spread 
of resistance, strengthen global antibiotic stewardship, and forestall the post-antibiotic era. 
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C h a p t e r  1  
Introduction 
 
Antibiotic resistance is potentially the greatest global health threat facing humanity today, 
with a direct annual mortality rate of > 700,0001. Antibiotics are a foundational part of 
modern medicine2-4. Without antibiotics, it would be impossible to treat fatal infections, 
perform surgery, or protect immunosuppressed patients. The current gold-standard 
practice requires days to determine the phenotypic susceptibility profile of a patient’s 
infection, meaning physicians do not have this information when choosing which 
antibiotic to prescribe5. There is an international need for solutions to this problem that is 
currently unmet3,6,7. The primary focus of my research has been to develop antibiotic 
susceptibility tests (ASTs) that could be performed at the point of care, before antibiotic 
are prescribed, in order to allow physicians to make informed prescriptions8. Providing 
clinicians with this information would i) re-enable the use of older antibiotics, ii) improve 
patient outcomes (save lives), and iii) dramatically slow the spread of antibiotic 
resistance. 
 
Antibiotic resistance is a natural phenomenon, and one that will occur as long as 
antibiotics are used. The problem is not the existence of antibiotic resistance, but the rate 
at which it is emerging and spreading9. This rate is directly proportional to the amount of 
antibiotics used. The more any single antibiotic is used, the greater the chance that 
bacteria evolve resistance, and that resistance will spread. In order to ensure patient 
safety, physicians treat with broad-spectrum and even last-line antibiotics (according to 
consensus guidelines issued by the CDC10 and WHO11,12), which further drives 
resistance. When resistance does emerge, it does not mean all infections are immediately 
resistant. However, even when rates of resistance are low (5-10%), physicians cannot risk 
prescribing an antibiotic that will not cure their patient’s infection. Therefore, antibiotic 
treatment is escalated, and antibiotics that would otherwise be reserved for serious 
infections are used in routine cases. The use of these second- and third-line antibiotics 
 2 
then increases the rates of resistance, leading to further escalation. This cycle (Figure 1-
1) has led to the current global health emergency we face today. An antibiotic 
susceptibility test that could be performed before antibiotic prescriptions are made would 
enable physicians to make the most rational antibiotic choice while ensuring positive 
patient outcome. 
 
 
Figure 1-1. The antibiotic resistance cycle. Sufficiently fast diagnostics would allow 
physicians to make informed choices about which antibiotics to prescribe. This would 
lead to de-escalated treatments and preservation of antibiotics. 
 
There are two types of antibiotic susceptibility tests: phenotypic and genotypic. The gold 
standard method in antibiotic susceptibility testing is broth or agar microdilution13,14, a 
phenotypic method15. Phenotypic methods measure the response of the infecting 
pathogen to antibiotics, and are thus agnostic to the mechanism of resistance. These 
culture-based methods provide the most general and complete antibiotic susceptibility 
profiles; however, they currently require isolation and cultivation of the infecting 
pathogen and are thus too slow to be used at the point of care. Genotypic tests predict 
resistance based on the presence or absence of known resistance genes. Genotypic tests 
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can never prove susceptibility, they can only predict resistance with a given predictive 
value. However, because genotypic tests only require isolation and amplification of 
nucleic acids (and do not require the isolation of viable bacteria), they can be fast in 
certain scenarios. However, they remain under-utilized due to their lack of generality6,7. 
The goal of the majority of my thesis work has been to develop methods that determine 
phenotype (thus achieving the same general and complete susceptibility information 
achieved with culture-based gold-standard methods) using molecular methods after a 
short antibiotic exposure (thus achieving the same or faster time-scales as genotypic 
tests). 
 
Chapters II and III of this work summarize our efforts to design a rapid phenotypic 
antibiotic susceptibility test suitable for use (in terms of assay time and simplicity) at the 
point of care. The method described in these chapters is based on measuring total nucleic 
acid concentration following a short antibiotic exposure in order to determine phenotypic 
antibiotic susceptibility. We first demonstrate that the antibiotic exposure step, a required 
step for any phenotypic test, can be shortened to 15 min16. We demonstrate this is 
possible for the four major classes of antibiotics used to treat urinary tract infections 
(UTIs) if digital nucleic acid quantification methods are used to assess DNA replication. 
Digital quantification was critical in shortening the antibiotic exposure step due to its 
higher precision and inherent partitioning step, which was important in the case of the b-
lactam amoxycillin. 
 
We then demonstrate that direct measurement of clinical samples is possible17. We show 
that extremely rapid readout of nucleic acid concentration is achievable using an 
isothermal nucleic acid amplification chemistry we have optimized, capable of 
amplifying and counting single DNA molecules in < 5 min in a microfluidic format 
suitable for implementation at the point of care. This unique combination of short 
exposure and ultra-fast digital quantification allows the susceptibility profile of bacteria 
in urine samples from patients with UTIs to be determined in less than 30 min. This 
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breakthrough shortens the time required to obtain AST results from 48 hours (the 
shortest possible time using culture-based methods) to the time span of a patient visit.  
 
Chapter IV describes our work discovering and using RNA markers to test for 
ciprofloxacin susceptibility in Neisseria gonorrhoeae18. The use of RNA presents several 
challenges compared to DNA. However, we demonstrate that through screening and 
selection of appropriate RNA markers, susceptibility can be determined after an 
extremely short antibiotic exposure time. 
 
Chapters V and VI describe two related but distinct methods for measuring susceptibility 
to b-lactams based on quantifying nucleic acid accessibility. The first is a novel test we 
have developed for measuring phenotypic b-lactam susceptibility in carbapenem-resistant 
Enterobacteriaceae (CRE)19. CRE represent some of the most lethal antibiotic-resistant 
infections encountered in the healthcare setting. We demonstrate determination of b-
lactam susceptibility in all three major genera of CRE (E. coli, K. pneumonia, and 
Enterobacter spp.) in less than 30 min, and show that the method is completely agnostic 
to genotype. The second method is a nucleic acid accessibility-based test for measuring 
susceptibility of Neisseria gonorrhoeae to b-lactams20. We show that susceptibility can 
be measured much faster than cell division using a surfactant-based enhancement step in 
the presence of exogenously added nuclease, following antibiotic exposure. This method 
allows us to determine the phenotypic susceptibility of Neisseria gonorrhoeae isolates to 
b-lactams on unprecedented time scales. 
 
Chapters VII – IX of this work summarize additional methods for improving nucleic acid 
diagnostic workflows. Chapter VII describes the design and validation of a 3D printed 
meter-mix device for use with clinical samples21. Chapter VIII describes a method for the 
capture and detection of extremely low concentrations of nucleic acids from large 
volumes of solution22. Chapter IX describes validation of a digital loop-mediated 
isothermal amplification (LAMP) system based on commercially available parts23. This 
system can be used to optimize LAMP assays or perform rapid digital quantification. 
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Chapter II 
 
Digital Quantification of DNA Replication and Chromosome Segregation 
Enables Determination of Antimicrobial Susceptibility After Only 15 
Minutes of Antibiotic Exposure1 
 
Abstract 
 
Rapid antimicrobial susceptibility testing (AST) would decrease misuse and overuse of 
antibiotics. To achieve the “holy grail” of AST, a phenotype-based test that can be 
performed within a doctor visit, requires determining a pathogen’s susceptibility after a 
short antibiotic exposure. We used digital PCR (dPCR) to test whether assessing DNA 
replication of the target pathogen via digital single-molecule counting would shorten the 
required antibiotic exposure. Partitioning bacterial chromosomal DNA into many small 
volumes during dPCR enabled AST via (i) precise quantification and (ii) a measure of 
how antibiotics affect the states of macromolecular assembly of bacterial chromosomes. 
This digital AST (dAST) determined susceptibility of clinical isolates from urinary tract 
infections (UTI) after 15 min of exposure for all four antibiotic classes relevant to UTI. 
This work lays the foundation to develop a rapid, point-of-care AST and strengthen 
global antibiotic stewardship. 
 
Introduction, Results, and Discussion 
 
The increasingly liberal use and misuse of antibiotics (ABX) has led to widespread 
development of antibiotic resistance.[1] To address this crisis, we need rapid and reliable 
tests of a pathogen’s susceptibility to the drugs available (antimicrobial susceptibility test, 
AST) to provide correct, life-saving treatment, facilitate antibiotic stewardship[2] and 
drastically decrease hospital costs.[1a,3] Having a rapid AST that provides results within 
                                               
1This chapter was first published in Angewandte Chemie with authorship belonging to Nathan G. Schoepp, 
Eugenia M. Khorosheva, Travis S. Schlappi, Matthew S. Curtis, Romney M. Humphries, Janet A. Hindler and 
Rustem F. Ismagilov. The original manuscript can be found at: http://dx.doi.org/10.1002/anie.201602763. 
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the period of a doctor visit would lead to improved patient outcomes and reduced spread 
of antibiotic resistance.[4] Development of a rapid AST is currently the focus of 
significant research efforts[5] that aim to supplant traditional clinical methods. To reduce 
the spread of resistance, one urgently needed AST is for urinary tract infections (UTIs), 
which are among the most common bacterial infections, yet can progress to 
pyelonephritis or sepsis.[6]  
 
Two types of ASTs are currently used in clinical settings: traditional culture-based 
methods and genotypic methods. Culture-based tests remain the gold standard for 
determining antibiotic susceptibility because they detect phenotypic susceptibility to a 
drug, however these tests require a long period of antibiotic exposure (typically 16–24 
h).[7] We[8] and others[5a,5b,5k,9] have proposed using confinement of single, or a 
small number of, bacterial cells in small volumes to reduce the duration of antibiotic 
exposure required to read out the phenotype of the target pathogen. However, these 
methods typically do not differentiate between the pathogen and the potential 
contamination of the sample with commensal bacteria. Alternative genotypic methods 
(detecting genes responsible for known mechanisms of resistance) are more rapid than 
culture-based approaches.[10] However, these resistance genes constitute only a fraction 
of all possible mechanisms of resistance,[11] and new forms of resistance evolve 
quickly.[12] Therefore, predicting resistance by analyzing a few known resistance genes 
is not a general solution.[13] 
 
To develop more rapid and specific phenotypic tests, hybrid approaches have been 
proposed that use quantification of nucleic acids to determine the susceptibility or 
resistance phenotype after a short antibiotic exposure. These tests do not rely on detecting 
specific resistance genes.[5g,5i] For example, quantification of RNA has allowed 
determination of susceptibility to ciprofloxacin (cip) and rifampin,[5i] which impair 
transcription, after exposures as short as 15 min. However, these methods require longer 
incubation times when using antibiotics with different mechanisms of action. Using 
quantitative PCR (qPCR), quantification of DNA after 2–9 h of antibiotic exposure was 
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used to detect bacterial growth and determine susceptibility,[5d,5e] however an ideal 
exposure time would be shorter than one cell division. 
 
Here we tested the hypothesis that digital methods of nucleic acid quantification,[14] 
such as digital PCR (dPCR), would enable use of DNA markers to perform a phenotypic 
AST after short antibiotic exposure. Digital methods partition bacterial chromosomal 
DNA into thousands of compartments and then use targeted amplification to determine 
the number of “positive” compartments containing DNA carrying one or more copies of 
the target gene. This partitioning should enable more precise and robust measurements of 
concentrations of bacterial DNA, achieving higher statistical power with fewer replicates 
relative to qPCR.[14c,15] Further, we hypothesized that this partitioning would provide 
unique capabilities for AST when analyzing target genes present in a macromolecular 
assembly, such as a bacterial chromosome during replication. In contrast to qPCR, dPCR 
results should reflect the state of the macromolecular assembly, providing a different 
count for a pair of segregated chromosomes (two positives) vs the chromosomal 
assembly just prior to segregation (one positive). We test our hypotheses in the context of 
four of the main antibiotics used in UTI treatment: ciprofloxacin (cip), nitrofurantoin 
(nit), sulfamethoxazole/trimethoprim (sxt), and amoxicillin/clavulanic acid 
(amc).[6a,7b,16] 
 
We first determined the minimum antibiotic exposure time necessary to differentiate 
susceptible and resistant clinical UTI isolates using qPCR analysis of DNA after 
incubation in the presence (“treated”) or absence (“control”) of antibiotics (see SI). Cycle 
thresholds were used to calculate relative fold change
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compared to t = 0 min (Fig. 2-1). When treated with cip, DNA replication in susceptible 
isolates was significantly inhibited, resulting in an increasing difference in fold change 
between target concentration in treated and control samples. If the isolate was resistant, 
DNA replication continued regardless of exposure.  To align with FDA requirements for 
very major errors[17] we used a conservative alpha, 0.02 (see SI). Susceptibility to cip 
could be determined after 15 min of exposure. We obtained similar results using isolates 
pre-cultured in media and in urine (SI Fig. 2-S1), and chose to conduct all subsequent 
experiments in media in order to reduce the work with human samples and to ensure 
reproducibility. The focus of this work is to evaluate the differences in minimum 
antibiotic exposure time necessary to determine susceptibility when quantification of 
changes in DNA is performed with qPCR vs dPCR. 
 
 
Figure 2-1. Quantitative PCR (qPCR) time course for exposure of (A) susceptible and 
(B) resistant UTI E. coli isolates to ciprofloxacin. For cycle thresholds (Ct) error bars are 
2.8 S.D. (see SI), N=3. Fold change values represent change from t = 0 min; error bars 
represent the upper and lower bounds of the 98% C.I. (see SI), N=2. Significant 
differences (p-value ≤ 0.02) are marked with a green check. 
  
These results are the first evidence of detection of phenotypic susceptibility based on 
DNA quantification after only 15 min of antibiotic exposure. The rapid effect of cip on 
DNA replication is logical because the drug’s mechanism of action is to inhibit DNA-
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gyrase and topoisomerase IV, producing double stranded breaks in DNA and directly 
inhibiting DNA replication.[18] To test generality, we evaluated AST with three other 
antibiotics: nit,[19] sxt,[20] and amc (which is not known to specifically affect DNA 
replication) (see SI). Using qPCR, 15 min of exposure to these three antibiotics was not 
sufficient to detect a significant difference in DNA replication in susceptible isolates 
(Fig. 2-2 B–D), while statistically significant differences were detectable with cip 
treatment (Fig. 2-2 A).  
 
 
Figure 2-2. Comparison of susceptible and resistant isolates from UTI samples after a 15 
min exposure with each of four antibiotics, analyzed by quantitative PCR. Fold change 
values represent change from t = 0 min; error bars are 98% C.I. (see SI), N=3. Significant 
(p-value ≤ 0.02) and nonsignificant differences detected using the susceptible isolate are 
marked with a green check and red x respectively. 
 
We then tested AST with digital quantification by quantifying the same DNA samples 
using digital PCR (Fig. 2-3). For cip, we observed a more statistically significant 
difference (smaller p value) between target concentrations in treated and control 
susceptible isolates (Figure 2-3A), while target concentrations did not differ between 
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treated and control resistant isolates (Figure 2-3B). A significant difference was also 
detected after 15 min exposures to nit (Figure 2-3C) or sxt (Fig. 2-3C). 
 
Interestingly, neither qPCR or dPCR detected susceptibility after exposure to amc when 
samples were denatured and treated with protease during extraction (SI Figure 2-S2). 
This confirmed that genome replication proceeded (resulting in an increase in the total 
number of amplifiable targets) during incubation with amc regardless of phenotype. We 
therefore tested the hypothesis that dPCR would be sensitive not only to the total gene 
copy number, but also to the state of macromolecular assembly of chromosomal DNA. If 
exposure to amc causes changes in chromosome segregation, even without affecting 
replication, dPCR should still be able to differentiate susceptible and resistant 
phenotypes. To preserve chromosome structure and macromolecular complexes, we 
performed DNA extraction in non-denaturing conditions without protease treatment. 
Under these conditions, dPCR provided susceptibility phenotype after 15 min of exposure 
to amc (Figure 2-3D).
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Figure 2-3. AST results using dPCR. (A,B) Time course results for exposure of 
susceptible (A) and resistant (B) UTI E. coli isolates to ciprofloxacin. (C,D) Fold changes 
after treatment with all four antibiotics tested. Significant (p-value ≤ 0.02) and 
nonsignificant p-values for susceptible isolates are denoted with a green check and red x 
respectively. Samples treated with amoxicillin/clavulanic acid (D) were extracted using a 
non-denaturing protocol. Concentrations are calculated using Poisson statistics. Fold 
change values represent change from t = 0 min; all error bars are 98% C.I. (see SI), N=3 
for qPCR, N=2 for dPCR. 
 
To test whether dPCR differentiated susceptible and resistant isolates via quantifying 
macromolecular assemblies, we designed control experiments in which all assemblies 
were sheared into ~1000 bp DNA fragments, much smaller than the average distance 
between 23S genes within the genome (see SI). As expected, shearing caused an increase 
in measured target concentration when quantified using dPCR, but not using qPCR (Fig. 
2-4 A–B). In samples that were not sheared, dPCR detected the susceptible phenotype 
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after 15 min of amc exposure (Fig. 4C). Shearing these samples to disrupt 
macromolecular assemblies eliminated the ability to detect susceptibility (Fig. 4D); qPCR 
measurements confirmed this was not due to loss of DNA. This suggests that in amc-
susceptible isolates short exposure to amc does not result in a change of the total number 
of target gene copies, but does change the macromolecular assembly of these copies.
 
Figure 2-4. A mechanistic investigation of AST by digital PCR (dPCR) after beta lactam 
exposure and non-denaturing DNA extraction using shearing to disrupt macromolecular 
assemblies; error bars for qPCR are 2.8 S.D. (see SI), N=3; error bars are 98%C.I. for 
dPCR (see SI), N=2. Significant (p-value ≤ 0.02) and nonsignificant p-values for 
susceptible isolates quantified using dPCR are denoted with a green check and red x 
respectively (see SI).
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Our results suggest a previously unknown effect of brief beta-lactam antibiotic exposure: 
 a delay in chromosome segregation. Using dPCR (but not qPCR) this effect can be 
quantified by counting the number of macromolecular DNA assemblies containing 23S 
target genes, and used for AST. The high resolution of digital quantification enables 
measuring small (less than two-fold) changes in chromosome replication and segregation 
after antibiotic exposure shorter than the average time of cell division. The dAST 
approach developed here adds chromosome segregation to the list of the phenotypic 
markers suitable for rapid antibiotic susceptibility detection. The ability to partition 
macromolecular assemblies allows dAST to be used even when genome replication 
proceeds on the timescale of antibiotic exposure, while the high precision of digital 
quantification allows accurate determination of susceptibility after shorter exposure times 
than would be required using less-precise methods such as qPCR. 
 
These dAST results warrant a follow-up study with a wide range of Gram-positive and 
Gram-negative bacterial isolates from urine, blood, and other sample types, and then a 
clinical study comparing dAST directly from patient samples to the gold standard culture-
based methods. Elucidating the effects of using variable clinical samples with a range of 
background matrices is a critical next step in the development of a rapid, sample-to-
answer AST. Ultimately, a sample-to-answer AST at the point of care must be robust, 
rapid, and require minimal sample handling and instrumentation. Ideally, such a 
workflow will integrate sample handling, antibiotic exposure, and quantification into a 
single device. We anticipate that digital isothermal amplification chemistries will replace 
dPCR in dAST.[15a,21] When integrated with sample preparation[22] and combined with 
simple readouts,[23] we envision that digital quantification will establish a new paradigm 
in rapid point of care AST. 
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Experimental Section 
 
Materials and reagents 
All reagents purchased from commercial sources were used as received unless otherwise 
stated. BBL Trypticase Soy Agar plates with 5% Sheep Blood and Bacto Brain Heart 
Infusion (BHI) media were purchased from BD (Franklin Lakes, NJ, USA). BHI was 
dissolved in deionized water at the manufacturers recommended concentration and 
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autoclaved prior to use. All antibiotic stock solutions and PCR reactions were prepared 
using sterile, nuclease-free water (NF-H2O) purchased from Thermo Fisher (Waltham, 
MA, USA).  
 
All antibiotics and clavulanic acid were purchased from Sigma-Aldrich (St. Louis, MO, 
USA), with the exception of amoxicillin, which was purchased from Alfa-Aesar (Ward 
Hill, MA, USA). Ciprofloxacin and clavulanic acid were prepared as a 1 mg/mL stock 
solutions in NF-H2O. Nitrofurantoin was prepared as a 10 mg/mL stock solution in 
dimethylformamide (DMF). Sulfamethoxazole was prepared as a 10 mg/mL stock 
solution in dimethyl sulfoxide (DMSO). Trimethoprim was prepared as a 1 mg/mL stock 
solution in DMSO. All antibiotic stock solutions were stored at -20 °C. Amoxicillin was 
prepared fresh as a 1 mg/mL stock solution in NF-H2O before each experiment. 
 
QuickExtract DNA Extraction Solution and QuickExtract RNA Extraction Kit were 
purchased from Epicentre (Madison, WI, USA). SsoFast EvaGreen Supermix (2X) and 
QX200 ddPCR EvaGreen Supermix was purchased from Bio-Rad Laboratories 
(Hercules, CA, USA) and used for all qPCR and dPCR experiments respectively. 
 
Pooled human urine (catalog no. 991-03-P) was obtained from Lee Biosolutions 
(Maryland Heights, MO, USA). 
 
Isolate maintenance 
Ten E. coli isolated from the urine of 10 unique patients were obtained from the 
University of California Los Angeles (UCLA) Clinical Microbiology Laboratory with 
approval from the UCLA and Veterans Affairs Institutional Review Boards and 
appropriate Health Insurance Portability and Accountability Act exemptions. All isolates 
were identified as E. coli using the Vitek2 GNID panel (bioMerieux, Durham, NC, USA), 
and chosen for use based on their determined MICs. Urine cultures were performed by 
routine semi-quantitative methods, by inoculating 1 µL of urine to a BBL Trypticase Soy 
Agar plate with 5% Sheep Blood (BAP, BD, Sparks MD) and a MacConkey plate 
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followed by overnight incubation at 35 +/-2 °C in ambient air. In all cases, the E. coli 
grew in pure culture at  >100,000 colony forming units. Minimum inhibitory 
concentrations (MIC) for each isolate was determined by UCLA for ciprofloxacin (cip), 
nitrofurantoin (nit), sulfamethoxazole/trimethoprim (sxt), and amoxicillin/clavulanic acid 
(amc) using the Clinical and Laboratory Standards Institute (CLSI) reference broth 
microdilution method,[1] in panels prepared by UCLA with cation-adjusted Mueller-
Hinton broth (MHB). BMD tests were incubated at 35 +/- 2 oC in ambient air conditions 
for 16-20 h. MICs were interpreted using CLSI M100S 26th edition breakpoints.[1]  E. coli 
isolates were stored at -80 °C in Brucella broth with 20% glycerol (Becton, Dickinson, 
Sparks, MD, USA). Isolates were subcultured twice on BAP and well-isolated colonies 
were used for antibiotic exposure time course experiments. 
 
Antibiotic exposure time course experiments 
In order to generate liquid culture for use in experiments, E. coli isolates were cultured 
overnight (10-12 hours) after scraping a small portion of the plate and inoculating in 4 
mL BHI. Overnight cultures were re-inoculated into 4 mL of fresh BHI and grown for an 
additional 4–6 h until early logarithmic phase. Cultures were then diluted 10 fold into 
pre-warmed BHI, and optical density (600 nm) was measured using a portable 
spectrophotometer (GE Healthcare Ultrospec 10). OD was converted to approximate cell 
count using the correlation factor OD600 1.0 = 8.0*10^8 cells/mL). The dilutions 
prepared for OD measurements were then immediately diluted a second time into 2 mL 
polypropylene tubes to a final volume of 500 µL (dilution factor dependent on desired 
final cell concentration). These tubes were incubated for 5 min at 37 °C with shaking at 
500 rpm in a heating/shaking block (Thermo Fisher Digital Heating Shaking Drybath) to 
ensure thorough mixing. During this time, separate 2 mL polypropylene tubes containing 
450 µL of BHI with and without antibiotics were prepared. All exposure time courses 
were conducted with antibiotic concentrations above the minimum inhibitory 
concentration (MIC) of the susceptible isolate and below the MIC of the resistant isolate 
being tested. Ciprofloxacin exposure in media and urine was conducted at a final 
antibiotic concentration of 2.00 and 0.75 µg/mL respectively. Nitrofurantoin experiments 
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were performed at 64.00 µg/mL. Sulfamethoxazole/trimethoprim experiments were 
performed at 76.00/4.00 µg/mL. For amoxicillin experiments, susceptible isolates were 
exposed to a final concentration of 12.00 µg/mL, and resistant isolates were exposed to a 
final concentration of 14.00 µg/mL. Cultures were then diluted a final 10 fold (50 µL 
culture into 450 µL) into single tubes containing media with or without antibiotics, and 
time was started. 10 µL aliquots were removed at 0, 15, and 30 min., and immediately 
mixed with 90 µL of a one-step extraction buffer suitable for direct use in PCR. 
Denaturing extraction conditions used Epicentre QuickExtract DNA Extraction Solution. 
Cells were mixed with Epicentre QuickExtract DNA Extraction Solution, pipette mixed, 
incubated at 65 °C for 6 min., 98 °C for 4 min., then chilled on ice. Non-denaturing 
extraction conditions used Epicentre Quick Extract RNA Extraction solution. Aliquots 
were mixed with RNA extraction immediately via pipette, gently vortexed to ensure 
thorough mixing, and chilled on ice. All samples were stored at -20 °C for several days 
during use before being moved to -80 °C for long-term storage. 
 
DNA fragmentation 
DNA was fragmented to a predicted 1000 bp fragment size using a Covaris 220M 
ultrasonicator. Samples were diluted 10 fold into a 130 µL microTUBE AFA Fiber Snap-
Cap, and sheered for 90 seconds at 20 °C with a Peak Incident Power of 50 W, duty 
factor of 2%, and 200 cycles per burst. This size was chosen to ensure that all copies of 
the 23S gene will be separated from each other. Based on an analysis of 11 E.coli strains 
isolated from UTIs, the average distance between 23S genes is 1,169 kb with the closest 
genes being 38 kb apart. These genomes may be accessed with the following accession 
numbers: CP011018.1; HG941718.1; CP007265.1; CP007391.1; CP002797.2; 
CP002212.1; CP001671.1; CU928163.2; CP000247.1; CP000243.1; CP011134.1. 
 
DNA quantification 
All qPCR reactions were performed using a Roche LightCycler 96. All reactions 
contained only SsoFast EvaGreen Supermix at a final concentration of 1X, forward and 
reverse primers (forward primer TGCCGTAACTTCGGGAGAAGGC, reverse primer 
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TCAAGGCTCAATGTTCAGTGTC) specific for Enterobacteriaceae[2] at a final 
concentration of 500 nM, template DNA at variable concentrations, and NF-H2O. A 
single master mix containing supermix, primers, and NF-H2O was prepared and aliquoted 
into PCR tubes. Template was then added, bringing the final volume to 30 µL. Each tube 
was then mixed thoroughly via pipette and technical triplicates (9 µL each) were 
aliquoted into the 96 well plate. Cycling conditions consisted of an initial denaturation 
step at 95 °C for 3 min. followed by 30 cycles of 95 °C for 20 s, 62 °C for 20 s, and 72 
°C for 20 s. Following amplification a continuous melt curve was obtained between 55 
and 95 °C. Total cycling time (including melt analysis) was 60 min. 
 
Digital PCR reactions were carried out in a BioRad QX200 Droplet Digital PCR system 
according to the manufacturer's instructions. Samples were prepared in identical fashion 
as those prepared for qPCR. For each sample, two wells of the droplet generation chip 
and well plate were used to generate and thermocycle droplets, respectively. This resulted 
in approximately 40,000 droplets being analyzed for each sample. Cycling conditions 
consisted of an initial denaturation step at 95 °C for 5 min followed by 40 cycles of 95 °C 
for 30 s, 60 °C for 30 s, and 72 °C for 30 s. Following initial thermocycling, the sample 
was cooled to 4 °C for 5 min followed by a final heating step at 95 °C for 5 min. All 
thermocycling steps were performed with a 2 °C/s ramp rate. Total cycling time was 115 
min. 
 
Statistical analyses 
Raw Ct values are not normally distributed; therefore, a typical plot showing the mean Ct 
+/- 2·SD does not mean that the true mean will lie in the confidence interval 95% of the 
time.  Understanding this fact, we would still like to represent the variability in qPCR 
measurements for the raw Ct plot.  We did this with a standard confidence interval 
calculation: 
 
 𝐶𝑡$/& = 𝐶𝑡()* 	± 𝑡-./0 ∙ 𝑠34√𝑛 (1) 
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The critical 𝑡 value (𝑡-./0) for a 98% confidence interval with 2 degrees of freedom is 
4.85; with 𝑛 = 3 replicates, this results in the SD being multiplied by 2.80 for the 
confidence intervals.  This does not mean that the true Ct is within this interval 98% of 
the time, but it does give a representation of the variability in Ct measurements. 
 
In order to calculate the p-value for comparing treated and untreated samples, the raw Ct 
values (which are exponential) were linearized into a relative quantity (𝐹𝐶) with t = 0 
min as the reference point using 𝐹𝐶 = 230(0)<30(=).  The log ratio of these linearized 
quantities was compared to ln(1.1) using a one-tailed 𝑡 test.  A one-tailed test was chosen 
because the untreated sample should have a higher concentration than the treated sample; 
if by some random event the treated sample has a statistically significant higher 
concentration than untreated, we don’t want to draw the false conclusion that the isolate 
is susceptible.  To account for pipetting variation (the treated sample could have 
randomly had 10% more bacteria pipetted into its media at time = 0 than the untreated 
sample), the null hypothesis is ln @A3BCA3C D − ln(1.1) = 0 instead of ln @A3BCA3C D = 0.  This 
makes the AST more conservative (reducing very major errors) by requiring that the 
untreated sample have at least 1.1 fold more copies than the treated sample. P-values for 
digital PCR were calculated with a one-tailed 𝑍 test comparing ln @A3BCA3C D to ln	(1.1), with 𝐹𝐶J0 representing the fold change in concentration of the untreated sample with respect 
to time = 0 and 𝐹𝐶0 representing the same quantity, but for the treated sample. 
 
Discussion of mechanism of action of antibiotics tested 
In addition to ciprofloxacin, we evaluated three other antibiotics used in the treatment of 
UTIs: (i) nitrofurantoin, which is reduced to a reactive radical inside the cell, reacting 
with multiple cellular targets including enzyme involved in DNA synthesis[3], which 
would directly affect replication; (ii) the combination of sulfamethoxazole and 
trimethoprim, which synergistically inhibit folic acid biosynthesis, subsequently 
impairing multiple metabolic reactions including thymidine synthesis[4]; and (iii) 
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amoxicillin, which disrupts the synthesis of the peptidoglycan layer of bacterial cell 
walls leading to lysis[5], but is not known to specifically affect DNA replication. 
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Figures and Tables 
 
 
Table 2-S1. Minimum inhibitory concentrations for all isolates tested, as determined by 
broth dilution. AMC = amoxicillin/clavulanic acid, CIP = ciprofloxacin, NIT = 
nitrofurantoin, SXT = sulfamethoxazole/trimethoprim. ND = not determined. 
 
 
Table 2-S2. Raw data and additional experiments performed with multiple isolates. “S or 
R” refers to susceptible or resistant as determined by MIC. ABX = antibiotic. * indicates 
samples were sheared prior to quantification (see methods section of SI). Experiment 
exposing isolate 1 to ciprofloxacin was performed in 1:1 media:urine, all other 
experiments were performed in media. 
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Figure 2-S1. qPCR time course for exposure of (A) susceptible and (B) resistant UTI E. 
coli isolates to ciprofloxacin pre-cultured in urine and exposed to antibiotics in 1:1 
urine:BHI. Raw cycle thresholds represent the average of technical triplicates; error bars 
represent 2.8 standard deviations (see SI). Fold change values represent change from t = 0 
min; error bars represent the upper and lower bounds of the 98% confidence interval. 
Significance was defined as a p-value <= 0.02 when comparing the fold change in 23S 
concentration of samples incubated without antibiotics (blue) to 1.1 times the fold change 
in 23S concentration of samples with antibiotics (brown) at a specific time point. 
Significant differences detected using the susceptible isolate are marked with a green 
check.  
 
 
Figure 2-S2. Comparison of susceptible isolate analyzed by qPCR and digital PCR after 
a 15 min exposure to amoxicillin/clavulanic acid and extracted using a denaturing buffer 
with protease treatment (A) and a non-denaturing buffer without protease treatment (B). 
Fold change values represent change from t = 0 min; error bars are 98% confidence 
intervals. Significance was defined as a p-value <= 0.02 when comparing the fold change 
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in 23S concentration of samples incubated without antibiotics (blue) to 1.1 times the 
fold change in 23S concentration of samples with antibiotics (brown) at a specific time 
point. Significant and non-significant differences are marked with a green check and red 
x respectively. 
 
 
Figure 2-S3. Fold change plots from Figures 1 and 3 with corresponding Ct and 
concentration plots to demonstrate conversion from either Ct or concentration to fold 
change. (A, B) AST results using qPCR. Time course for exposure of (A) susceptible and 
(B) resistant UTI E. coli isolates to ciprofloxacin. For cycle thresholds (Ct) error bars are 
2.8 S.D. Fold change values represent change from t = 0 min; error bars represent the 
upper and lower bounds of the 98% C.I. Significant differences (p-value ≤ 0.02) are 
marked with a green check. (C, D) AST results using dPCR. Time course for exposure of 
susceptible (C) and resistant (D) UTI E. coli isolates to ciprofloxacin. Concentrations are 
calculated using Poisson statistics; error bars represent the upper and lower bounds of the 
98% C.I. Fold change values represent change from t = 0 min; error bars represent the 
upper and lower bounds of the 98% C.I. Significant (≤ 0.02) p-values for susceptible 
isolates are denoted with a green check.  
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Chapter III 
 
Rapid pathogen-specific phenotypic antibiotic susceptibility testing using 
digital LAMP quantification in clinical samples 2 
 
Abstract 
 
Rapid antimicrobial susceptibility testing (AST) is urgently needed for informing 
treatment decisions and preventing the spread of antimicrobial resistance resulting from 
the misuse and overuse of antibiotics. To date, no phenotypic AST exists that can be 
performed within a single patient visit (30 min) directly from clinical samples. We show 
that AST results can be obtained by using digital nucleic acid quantification to measure 
the phenotypic response of Escherichia coli present within clinical urine samples exposed 
to an antibiotic for 15 min. We performed this rapid AST using our ultrafast (~7 min) 
digital real-time loop-mediated isothermal amplification (dLAMP) assay [area under the 
curve (AUC), 0.96] and compared the results to a commercial (~2 hours) digital 
polymerase chain reaction assay (AUC, 0.98). The rapid dLAMP assay can be used with 
SlipChip microfluidic devices to determine the phenotypic antibiotic susceptibility of E. 
coli directly from clinical urine samples in less than 30 min. With further development 
for additional pathogens, antibiotics, and sample types, rapid digital AST (dAST) could 
enable rapid clinical decisionmaking, improve management of infectious diseases, and 
facilitate antimicrobial stewardship. 
 
Introduction 
 
                                               
2This chapter was first published in Science Translational Medicine with authorship belonging to Nathan G. 
Schoepp, Travis S. Schlappi, Matthew S. Curtis, Slava S. Butkovich, Shelley Miller, Romney M. Humphries, 
and Rustem F. Ismagilov. The original manuscript can be found at: 
http://dx.doi.org/10.1126/scitranslmed.aal3693. 
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The emergence of antibiotic resistance is an impending threat to global health. It is 
projected to cause 10 million deaths and more than $1 trillion in total economic impact 
by 2050 if left unchecked (1, 2). To combat antimicrobial resistance, facilitate 
stewardship, and improve patient outcomes, health care providers need to be able to 
determine antibiotic susceptibility rapidly and ideally at the point of care (POC) (3–6). 
The need for rapid antimicrobial susceptibility testing (AST) to guide antibiotic treatment 
is recognized by all major health organizations, including the Centers for Disease Control 
and Prevention and the World Health Organization (7–11). 
  
Urinary tract infections (UTIs) are among the most common bacterial infections, 
accounting for ~8 million primary care visits annually, and are almost always treated with 
antibiotics (12, 13). In the absence of a rapid AST, UTIs are among the many infections 
that are treated with second-line antibiotics, such as the fluoroquinolone ciprofloxacin 
(cip), instead of first-line antibiotics, such as nitrofurantoin (nit) (14). This increased use 
of fluoroquinolones is accompanied by the emergence of fluoroquinolone resistance, 
limiting treatment options, which is especially critical in life-threatening cases, such as 
when UTIs progress to sepsis. Thus, UTIs are a specific clinical scenario where an 
inexpensive and rapid (within the ~30-min duration of a patient visit) AST would notably 
improve patient outcomes and antimicrobial stewardship. 
  
No such AST diagnostic currently exists. Phenotypic AST methods based on culture of 
the target pathogen are the current gold standard but are too slow to support immediate 
treatment decisions or to be implemented at the POC (15). Genotypic methods, which 
detect known resistance genes, are faster because they do not require a culturing step 
(16–18). Genotypic methods have shown promise in select clinical settings where the 
presence of a single gene yields high predictive value, such as testing for mecA to detect 
methicillin-resistant Staphylococcus aureus (19–21). However, genotypic tests have not 
been implemented more broadly because they are not generalizable to different pathogens 
or mechanisms of resistance, especially in the case of Gram-negative bacteria, for which 
more than 800 resistance genes are known for b-lactam class antibiotics alone (22). 
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An ideal AST would test the phenotypic response of a pathogen to antibiotics in a 
pathogen-specific manner and provide an AST answer (susceptible or resistant) in less 
than 30 min (23, 24). This is a critical bar to meet because if the AST result can be 
obtained within the time span of a patient visit, then the information can be used to 
inform treatment and facilitate antimicrobial stewardship at the POC. Additionally, in 
some infections, such as sepsis, accelerated time to treatment is correlated with improved 
patient outcome (25). To achieve this speed, the AST method needs to work directly from 
a clinical sample. Several methods, including our previous work (26), have improved the 
speed of individual steps of the phenotypic AST workflow (such as pathogen isolation 
and identification, antibiotic exposure time, sample preparation, and readout), but few of 
these papers report performing the entire workflow from start to finish using a clinical 
sample. 
  
To date, no phenotypic AST has achieved a sample-to-answer result in less than 30 min 
directly from a clinical sample. Most of the methods under development were validated 
with clinical isolates of pathogens, which before the assay were grown in culture to a 
high density and not directly with clinical samples. Among the rapid phenotypic AST 
methods used with clinical samples, one microscopy-based method could differentiate 
susceptible and resistant isolates after only 10 min of antibiotic exposure but did not test 
clinical samples (27). A similarly rapid microscopy-based method could detect 
differences in bacterial growth during antibiotic treatment after as short as 6 min of 
antibiotic exposure using isolates, but the total assay time for a clinical sample was 155 
min (28). As discussed in (28), clinical sample matrices, such as urine, present a 
challenge for rapid microscopy-based ASTs, affecting the speed and sensitivities 
(required cell concentrations) of these assays. 
  
Furthermore, identification and differentiation of target pathogens from commensal 
organisms can be challenging if these steps rely only on imaging, without the molecular 
specificity offered by other methods. A microfluidic-based microscopy method using 
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isolates reported AST in ~3 to 4 hours without an identification step and estimated that 
the total assay time from a clinical sample would be 52 hours (29). Another microscopy-
based method in clinical testing performs identification and AST from a positive culture 
in 5 to 6 hours, with additional overnight or longer time required to first grow the culture 
from a clinical sample (30, 31). An electrochemical method was used to determine 
susceptibility in as short as 25 min using nonspecific redox markers for reference strains 
(32), but the workflow lacked a pathogen identification step and the AST was not 
pathogen-specific. Other electrochemical methods are pathogen-specific but require at 
least 45 min of assay time when using isolates (33). Pathogen-specific electrochemical 
methods have also been used to determine susceptibility from clinical samples, but assay 
times were on the order of hours (34). Methods that perform phenotypic AST by 
quantifying nucleic acids (NAs) are promising because they provide molecular 
specificity, but so far, most have required long antibiotic exposures (~2 hours or more) in 
addition to the time required for measurement, which was as fast as 1.5 hours using 
isothermal amplification (35–37). This promise of an NA-based AST was highlighted in 
a study that used RNA gene expression markers and demonstrated antibiotic exposure 
times as short as 10 min for isolates and as short as 30 min for clinical samples, although 
in that landmark study, the total assay time was more than 23 hours as a result of using 
slow quantification technology (38). 
  
We have shown previously that the antibiotic exposure time in a phenotypic AST can be 
shortened to 15 min by measuring DNA concentrations in a digital format (26). That 
work was performed with bacterial UTI isolates and required a 2-hour measurement step 
using commercial droplet digital polymerase chain reaction (dPCR). The transition from 
cultures of clinical isolates to clinical samples is invariably challenging for phenotypic 
AST methods, and previous works have highlighted these challenges (28, 38, 39). 
  
Here, we asked and answered two salient questions: For clinical samples, (i) can digital 
single-molecule counting of pathogen DNA enable phenotypic AST after a short (15 min) 
antibiotic exposure, and (ii) is there a quantification strategy faster than PCR that can be 
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used in a digital format to achieve a pathogen-specific, sample-toanswer phenotypic 
AST within 30 min directly from a clinical sample? To answer these questions, we 
developed an ultrafast digital isothermal amplification assay to shorten the readout step 
and demonstrated that the entire contiguous sample-to-answer workflow could enable an 
AST result in less than 30 min from a clinical UTI urine sample. We tested the rapid 
digital loop-mediated isothermal amplification (dLAMP) assay we developed with 51 
clinical UTI urine samples and compared the results to commercial dPCR analysis. 
 
Results 
 
Key processes and operational space of digital AST  
 
A phenotypic AST consists of two key processes: antibiotic exposure and measurement 
of the AST marker. To meet the demands of a rapid AST, these two processes, plus 
sample handling, must occur within 30 min. The workflow of the digital AST (dAST) 
method involved the following steps: aliquoting and diluting a clinical urine sample into 
two equal volumes of media—one with an antibiotic and a control without antibiotic; 
incubation at 37°C for 15 min; quantification of a target NA sequence (AST marker) in 
each sample; and calculation of the ratio of the marker concentrations in the control and 
antibiotic-treated samples, defined as the control/treated (CT) ratio (Fig. 1A). 
  
 
Fig. 3-1. Experimental workflow of the dAST method and computationally estimated 
operational space. (A) The workflow for detecting antibiotic susceptibility by measuring 
the quantity of a specific NA sequence (AST marker). Urine samples are incubated 
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without and with antibiotics (ABX) (steps 1 and 2), AST markers are quantified in 
control (−ABX) and treated (+ABX) samples (step 3), and the CT ratios are analyzed 
(step 4). (B) Theoretical model that predicts a CT ratio as a function of pathogen DNA 
doubling time and antibiotic exposure time. The operational space gained by using digital 
counting compared with qPCR is outlined in red. 
 
Antibiotic susceptibility was determined by comparing a CT ratio to a previously 
determined threshold value (susceptibility threshold). Sample pairs that yield a CT ratio 
that falls above this threshold are called susceptible, and samples with a ratio below this 
threshold are called resistant. A CT ratio that is higher than the susceptibility threshold 
shows that DNA replication continued in the control (−ABX) sample but was slowed or 
halted in the antibiotic-treated (+ABX) sample, indicating that the sample was susceptible 
to that antibiotic. CT ratios lower than the susceptibility threshold indicate that DNA 
replication continued in both the control (−ABX) and antibiotictreated (+ABX) samples 
at the same rate, indicating that the sample was resistant to that antibiotic (Fig. 1A, step 
4). 
  
The time period of the antibiotic exposure step affects the resolution requirements for the 
quantification step: a shorter antibiotic exposure results in a smaller difference in the 
concentration of the target AST marker between the antibiotic-treated and control 
samples. Thus, at shorter exposure periods, quantification with higher resolution is 
required to reliably quantify an AST marker. To illustrate the interplay of antibiotic 
exposure time and required measurement resolution, we explored the trade-off of these 
three parameters (exposure time, required resolution, and DNA replication rate) 
computationally and made predictions about the resolution needed to detect 
susceptibility. We defined this combination of parameters as the operational space (Fig. 
1B). For simplicity, we assumed that for an antibiotic-susceptible pathogen, DNA 
replication halts upon exposure to the antibiotic. Under this assumption, the DNA 
replication rate (which differs for different pathogens) directly determines the CT ratio at 
a given antibiotic exposure time. We also assumed that there was no lag phase upon 
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transitioning from urine to liquid media; if there is a lag phase, then the requirements 
for resolution become even more stringent, further emphasizing the need for high-
precision digital measurements. For example, if the measurement method is limited to 
twofold resolution, such as in quantitative PCR (qPCR), and the pathogen’s DNA 
doubles every 30 min, then the minimum exposure time necessary to achieve a CT ratio 
of 2 is 30 min. If the measurement method can instead resolve a 1.2-fold difference in 
concentrations, then the minimum exposure time decreases to 8 min. Measuring changes 
in DNA concentration with high resolution therefore allows the detection of a pathogen’s 
response to antibiotic even faster than cell division time (26). Compared with bulk 
methods (such as qPCR or isothermal amplification), digital quantification can resolve 
the difference between the two concentrations with greater precision (26, 40, 41), which 
in turn enables shorter antibiotic exposure times (26). 
  
Digital quantification achieves higher resolution by partitioning target molecules into 
thousands of compartments such that each compartment contains a single molecule. 
Amplifying each partitioned molecule to a detectable concentration and counting the 
number of positive compartments at the end point yield precise quantification. Resolution 
can be increased, and antibiotic exposure time reduced, by increasing the number of 
digital compartments. However, the benefit of adding more digital compartments 
decreases beyond ~1000 compartments, and additional compartments are better used for 
multiplexing of multiple markers or antibiotics. For example, at UTI-relevant 
concentrations of DNA (106 copies/ml), 1000 digital compartments with 1-nl volume 
each provides 1.23-fold resolution. Increasing the number of these compartments to 
10,000 or 100,000 while correspondingly reducing their volumes to 0.1 and 0.01 nl each, 
to maintain the same sample volume and total number of target molecules, provides 
1.18and 1.17-fold resolution, respectively (fig. S1). With 10,000 1-nl compartments, the 
resolution is 1.08, whereas 2000 1-nl compartments provide a resolution of 1.16 each, 
enabling a fourplex dAST (one control and four antibiotic-treated samples) to be 
performed with the same number of wells (fig. S1C). 
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We have previously demonstrated that a 15-min exposure step is sufficient to generate 
detectable differences in DNA concentrations between the control and antibiotic-treated 
samples using UTI isolates and four antibiotics commonly prescribed for UTIs (26). For a 
15-min exposure period, which is shorter than the fastest reported uropathogenic 
Escherichia coli doubling time of 16 min (42), we predicted the DNA concentration in 
the control sample to increase 1.4× to 1.6× (Fig. 1B, green star). Other uropathogenic 
organisms have doubling times of 13 min (Klebsiella pneumoniae), 25 min (Proteus 
mirabilis), and 29 min (Staphylococcus saprophyticus) (43, 44). Therefore, theoretical 
estimates suggested that a 15-min exposure should provide a 1.4to 2.2-fold change, 
which is within the resolution of digital measurements. Historically, such measurements 
have required 90 min or more (45, 46). For the total assay time to remain less than 30 
min, digital NA quantification must be performed in less than 10 min, assuming sample 
handling (including NA extraction) of at least 5 min and an antibiotic exposure of 15 min. 
On the basis of these theoretical calculations, we developed a method of digital NA 
quantification that could be performed in less than 10 min.  
 
dAST in the presence of commensal organisms  
 
A factor that may challenge phenotypic ASTs that are run directly on clinical samples is 
that commensal or contaminating organisms present in the sample may respond 
differently to a given antibiotic than the target pathogen. If the measurement method 
cannot differentiate between the response of the target pathogen and commensals, then 
susceptibility cannot be determined accurately. NA amplification can be designed to 
target a sequence specific to a potential pathogen species or families of interest. 
Therefore, we hypothesized that when using a pathogen-specific NA target, the CT ratio 
(and, therefore, the determination of the pathogen as susceptible or resistant by the AST) 
would not be affected by varying amounts of commensal bacteria. dAST was performed 
in the presence of Lactobacillus jensenii (Lj), a common commensal bacterium found in 
urine. An E. coli culture [~106 colony-forming units (CFU)/ml] was mixed with each of 
the three concentrations of Lj (0.1×, 1×, and 10× the optical density of the target 
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pathogen) and exposed to cip for 15 min. The response was measured using droplet 
dPCR, and susceptibility of E. coli was determined correctly at all concentrations of the 
commensal organism (Fig. 2).  
 
 
Fig. 3-2. dAST using dPCR is robust to the presence of high concentrations of 
commensal bacteria due to the specificity of NA amplification. (A) A cip-susceptible E. 
coli isolate and (B) a cip-resistant E. coli isolate from the urine of patients diagnosed with 
UTIs were exposed to cip (1.0 mg/ml) in the presence of varying amounts of Lj, a 
common urine commensal. Fold changes relative to time 0 were compared as described 
in (26) and used to determine susceptibility. (C) Susceptibility determined using the CT 
ratios after 15 min of antibiotic exposure for each concentration of Lj tested. n = 2 
technical replicates for each biological sample. Error bars are 98% confidence intervals. 
 
Optimization of isothermal amplification (LAMP)  
 
We next focused on shortening the measurement time from 2 hours (time of amplification 
using dPCR) to <10 min. We investigated dLAMP first because it has been demonstrated 
previously by us and others (40, 47–50). However, these dLAMP assays previously took 
>45 min and were not shown to resolve small differences (~1.5×) in NA concentrations. 
Fast LAMP reactions often show background amplification in negative control 
experiments, so we aimed to also solve this problem. 
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We designed primers and optimized real-time LAMP in bulk solutions to maximize 
amplification speed while eliminating background amplification. At very high NA 
concentrations, real-time bulk LAMP assays have been reported to be as fast as 5 min 
(18, 51), but at the lower concentrations of a single target molecule present in a single 
digital partition (~1 copy/nl = 106 copies/ml), amplification takes 10 min or more (52–
55). To mimic the concentration of a template in a single digital partition, we performed 
our bulk optimization experiments at ~106 copies/ml. We selected the E. coli 23S 
ribosomal DNA gene as the pathogen-specific NA sequence (dAST marker) and as the 
target for primer design because we showed previously that this was a reliable marker for 
DNA replication in the context of AST (26). PanEnterobacteriaceae primers would be 
useful for targeting other UTI pathogens. Although we did not purposefully design our 
primers to exclude other Enterobacteriaceae pathogens, we were able to detect K. 
pneumoniae and P. mirabilis in pilot experiments using the same primers. Sensitivity and 
specificity of these primers remain to be further validated for additional pathogens and 
commensals. 
  
The LAMP optimization process (Fig. 3A) consisted of four steps: (1) screening multiple 
LAMP primer sets for speed and lack of background amplification, (2) screening multiple 
loop primer pairs with the selected primer set from step 1 for speed and lack of 
background amplification, (3) testing the selected LAMP and loop primers with a range 
of magnesium ion (Mg) concentrations, and (4) selecting the optimal amplification 
temperature from the data obtained in step 3. Each parameter was tested using a 
temperature gradient, which proved to be critical to minimizing the time to positive 
(TTP), the reaction time to detect a positive sample. Of the four tested LAMP primer sets, 
we selected set B because it showed the fastest amplification and no background 
amplification (Fig. 3A, step 1). No loop primer pair showed much earlier TTPs than any 
other pair, and no pair showed theoretical or experimental evidence of primer-dimers, so 
we arbitrarily chose the loop A set (Fig. 3A, step 2). Four concentrations of Mg were 
tested using the DNA polymerase Bst 3.0. The resulting TTPs varied by as much as 11 
min depending on the amplification temperature. This optimization process resulted in 
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TTPs as fast as ~4 to 5 min for ~700 target copies in a 6-ml amplification volume, with 
the fastest TTP (4.4 min) obtained using 6 mM Mg at 71°C. 
  
 
Fig. 3-3. Real-time LAMP optimization and compatibility with clinical samples. (A) 
Assay optimization protocol used to reduce the TTP from 15 to <5 min. Optimization 
was performed at a template concentration of ~700 or 0 copies per reaction. NTC, no 
template control. A value of 0.5 indicates that no amplification was observed. n = 1 for 
all TTP values. (B) Real-time fluorescence readout of amplified DNA for UTI urine 
samples containing E. coli (blue lines), healthy urine samples, urine samples containing 
gDNA of Lj, and urine samples containing human (Hs) gDNA (dashed brown lines). (C) 
TTP values for clinical UTI urine samples containing a range of pathogen concentrations. 
Error bars represent a single SD from the average of technical triplicates. n = 3 technical 
replicates for each TTP value. 
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Once LAMP primers and protocols had been optimized, we further tested their 
specificity for the dAST marker. No positive signals were obtained when we ran real-
time LAMP using Lj genomic DNA (gDNA), human gDNA, or urine from healthy 
donors without any symptoms of UTI (Fig. 3B). When testing clinical UTI samples, a 
positive signal was only obtained when E. coli DNA was present. TTPs ranged from 4 to 
5 min for clinical UTI samples (Fig. 3C). However, using this LAMP method in a 
standard well-plate format to resolve a 1.5× difference in concentration would require 
detecting a difference in TTP of ~8 s, which is difficult in practice to perform robustly 
(40).  
 
dAST using ultrafast single-molecule counting (dLAMP)  
 
Our next goal was to test whether using this optimized LAMP chemistry in a digital 
format would yield an accurate determination of antibiotic susceptibility while preserving 
the speed observed in bulk solutions. This would require the ability to resolve small 
changes in NA concentrations that occur after a 15-min exposure to antibiotic, despite 
any heterogeneity in TTPs (the difference in amplification kinetics of individual 
molecules), which has been observed previously (50, 56). Because sample matrices might 
increase the heterogeneity in TTPs and thus decrease the resolution, we tested clinical 
urine samples, which can contain urea, proteins, blood (including heme as a potent PCR 
inhibitor), and other cellular components that can interfere with assay detection. To 
eliminate extracellular DNA present in clinical urine as a potential source of error, we 
modified the dAST procedure that we previously developed for isolates (26) to include 
deoxyribonuclease (DNase) during the exposure step to digest any extracellular DNA 
(see the Supplementary Materials). We used the optimized LAMP assay (Fig. 3) with 
SlipChip microfluidic devices in a digital format (57). The SlipChip partitioned the 
samples into 1280 digital compartments. In each compartment, single molecules were 
amplified if present, and the total number of positive compartments was counted in real 
time (56). In a clinical setting, decisions are typically made from single assay runs, and 
thus, we tested whether differences in NA concentrations between the control and 
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antibiotic-treated samples could be resolved reliably using a single 1280-well SlipChip 
for each measurement. 
  
Using dLAMP (Fig. 4), most (>80%) single molecules amplified between 4 and 10 min, 
as shown by the fluorescence curves plotted in Fig. 4 (A and F). As expected, 
heterogeneity in TTP was observed, likely as a result of the stochasticity of single-
molecule amplification (50, 58). Despite heterogeneity and matrix effects of clinical 
urine, we detected a significant difference in NA concentration (P = 6.1 × 10−4) after 
only 5 min of amplification time for the cip-susceptible clinical urine sample (Fig. 4C). 
For the cip-resistant sample, no significant difference in concentration was detected 
during the dLAMP assay (P > 0.05) (Fig. 4H). In both samples, the CT ratios were stable 
after 6 min and 40 s (6.7 min) of amplification (Fig. 4, D and I), were consistent with the 
ratios obtained by dPCR (Fig. 4, E and J), and yielded the correct AST call (susceptible 
or resistant). We then repeated this dLAMP assay for one nit-susceptible and one nit-
resistant clinical urine sample. After 6.7 min of dLAMP amplification time, the CT ratios 
for both samples were stable, and the correct antibiotic-susceptibility call was determined 
(fig. S2). This demonstrates that the optimized dLAMP assay yields correct AST calls in 
only 6.7 min, below the 10-min limit necessary to achieve a 30-min dAST. Further, 
individual DNA target molecules were detected, and the DNA concentration was 
accurately quantified even after dilution during antibiotic exposure and sample 
preparation (table S1).  
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Fig. 3-4. High-resolution single-molecule NA amplification using ultrafast dLAMP for 
dAST of clinical UTI urine samples. UTI urine samples with (A to E) antibiotic- 
susceptible and (F to J) antibiotic-resistant E. coli. (A and F) Real-time fluorescence 
amplification traces (200 of 1280 traces shown for clarity). NFU, normalized fluo- 
rescence units; dotted line, positive threshold. When the normalized fluorescence 
intensity of a compartment crosses the threshold, that compartment is counted as positive. 
(B and G) TTP distribution determined by counting the number of compartments that 
crossed the positive threshold at each time point. (C and H) Detected concentrations of 
the target dAST marker in control and antibiotic-treated samples for successive image 
cycles. Note that these curves are distinct from the amplification curves shown in (A) and 
(F). Gray lines represent 95% confidence intervals. P values were calculated using a Z 
test (see Statistical analysis). (D and I) Detected CT ratios over time. Dashed line 
indicates susceptibility threshold. (E and J) Comparison of the CT ratios for droplet 
digital PCR (ddPCR) after 2 hours and dLAMP after 6.7 min of amplification. 
 
Thirty-minute sample-to-answer dAST directly from clinical urine samples 
 
Next, we tested whether the entire dAST workflow (antibiotic exposure, sample 
preparation, measurement, and data analysis) could be performed in less than 30 min 
(Fig. 5). To accomplish this goal, we shortened the sample preparation time from 10 to 2 
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min while maintaining compatibility with dLAMP. In parallel with antibiotic exposure 
of a clinical sample, rapid real-time LAMP was used to confirm the presence of E. coli 
and to measure the approximate NA concentration of the dAST marker in the sample 
(Fig. 5B). This step provided the identification of the pathogen and could be used to 
select the amount of NAs loaded on the chip to maximize the performance of the digital 
assay without adding time to the workflow; it also avoided the AST quantification step 
for the samples lacking the pathogen or containing subclinical amounts. We also 
modified the real-time image analysis software we developed previously (56) to calculate 
the concentrations of the dAST marker in real time from each image, instead of after 
completion of amplification. 
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Fig. 3-5. Workflow of a sample-to-answer AST performed in less than 30 min. (A) A 
clinical UTI sample was added to media with and without cip and incubated for 15 min. 
(B) During the antibiotic exposure step, the optimized bulk LAMP as- say was performed 
on NAs prepared from an aliquot of the urine sample. Amplification indicated the 
presence of E. coli at clinically relevant concentrations. (C) Aliquots of the control and 
antibiotic-treated samples were added to extrac- tion buffer, NAs were prepared for 
quantification using dLAMP, and samples were rapidly partitioned using SlipChips. (D) 
dLAMP was monitored in real time, and a susceptibility call was determined after 6.7 
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min of amplification; data for one resist- ant and one susceptible sample are shown. P 
values were calculated using a Z test (see Statistical analysis). Gray lines represent 95% 
confidence intervals. 
 
After these modifications, we calculated that all steps could be performed within ~24 min 
[15 min (exposure) + 2 min (sample preparation) + 6.7 min (readout)]. We tested whether 
these steps could be performed in succession to provide a full sample-to-answer 
workflow, including all fluid transfer steps and data analysis, within 30 min. We started a 
timer when an infected clinical urine sample was added to media with and without cip. 
After 29.8 min of total elapsed time (6.7 min of dLAMP amplification time), the software 
reported the control and treated concentrations for the cip-susceptible sample to be 
significantly different (P = 7.4 × 10−10), with a CT ratio of 1.59. For the cip-resistant 
sample, no significant difference in concentration was reported through the entire 
dLAMP assay (P > 0.05). At 29.2 min (6.7 min of dLAMP amplification time), the CT 
ratio for the cip-resistant sample was 1.08 (Fig. 5D). This result shows how a 
combination of rapid partitioning, fast isothermal amplification, and high-resolution 
digital measurements enabled antibiotic susceptibility to be determined in less than 30 
min.  
 
dAST using a set of 51 clinical samples  
 
Having established that the dAST method could be performed, sampleto-answer, in less 
than 30 min, we next tested dAST with 51 clinical samples using both dPCR and dLAMP 
readouts. Samples were exposed to antibiotic for 15 min, and NA extraction was 
performed on a total of 51 clinical UTI samples containing ≥5 × 104 CFU/ml E. coli (17 
cip-susceptible, 14 cip-resistant, 18 nit-susceptible, and 5 nit-resistant). Three clinical 
samples were tested separately with cip and nit, for a total of 54 tests. We focused on 
categorical agreement of our binary susceptibility determination (susceptible or resistant) 
and did not test intermediate samples due to the variability in minimum inhibitory 
concentration (MIC) determination of gold standard AST methods (59, 60). It is common 
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to only challenge new AST methods against susceptible and resistant samples (34, 35, 
61), which excludes a small fraction of samples for cip (62). To ensure that there were no 
special issues with bacteria with intermediate MICs, we used the dAST method on a 
small set of cip-intermediate isolates to better understand its performance (fig. S3). 
  
We quantified the DNA AST marker of the control and treated extractions on all 54 
samples with both dPCR and dLAMP. For each sample, the CT ratio was calculated and 
compared to a susceptibility threshold [1.10; determined in (26)] to classify the samples 
as resistant or susceptible (Fig. 6A). Discordant CT ratios were observed for five samples 
when compared with the gold standard broth microdilution method. To resolve the 
discrepancy, we reran three of these five discordant samples, averaging the second CT 
ratio with the CT ratio from the first run to obtain a consensus value of the CT ratio (table 
S2, samples #28, #29, and #36). As a control, we also reran one sample that was not 
discordant (table S2, sample #122). To ensure clinical samples yielded reproducible CT 
ratios, we used the dAST method to test a small set of cip-susceptible isolates in triplicate 
(fig. S4). 
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Fig. 3-6. dAST directly from clinical samples using dPCR and dLAMP for 
quantification. (A and C) Antibiotic suscep- tibility of 51 clinical E. coli–infected UTI 
samples determined using the CT ratios after 15 min of exposure to nit and cip (35 
susceptible and 19 resistant; 3 samples were tested for both antibiotics). NA 
concentrations were quantified with dPCR (A) and dLAMP (C). (B and D) ROC curves 
for the dAST method as measured by dPCR (B) and dLAMP (D). 
 
With 1.10 as the susceptibility threshold for dPCR measurements, the dAST method 
returned 51 correct calls (94.4% categorical agreement), 2 very major errors for 19 
resistant samples (10.5%), and 1 major error for 35 susceptible samples (2.9%). Because 
1.10 was a threshold based on experiments with isolates (26), we generated a receiver 
operating characteristic (ROC) curve to inform the optimal threshold for clinical UTI 
samples (Fig. 6B). ROC curves show the ability of a diagnostic test to discriminate 
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positives and negatives based on a threshold: Values below the threshold are called 
negative (resistant), and values above the threshold are called positive (susceptible). The 
area under the curve (AUC) for the generated ROC was 0.98. Using the optimal threshold 
given by the ROC curve (1.14), 53 of 54 dAST calls matched the gold standard AST call 
(98.1% categorical agreement) with 1 very major error (5.3%) and 0 major errors (0%). 
  
We also used dLAMP to quantify the same 54 samples. The CT ratios at 6.7 min were 
calculated and plotted in Fig. 6C, along with the ROC curve for dLAMP (Fig. 6D). With 
1.10 as the susceptibility threshold for dLAMP measurements at 6.7 min, the dAST 
method returned 51 correct calls (94.4% categorical agreement), 2 very major errors for 
19 resistant samples (10.5%), and 1 major error for 35 susceptible samples (2.6%). The 
AUC for the generated ROC curve was 0.96. Using the optimal threshold given by the 
ROC curve (1.11), 52 of 54 dAST calls matched the gold standard AST call (96.3% 
categorical agreement) with 1 very major error (5.3%) and 1 major error (2.9%). These 
data show that although the optimal thresholds derived from the ROC curves (1.14 for 
dPCR and 1.11 for dLAMP) slightly improve the categorical agreement, they are 
consistent with the threshold established for isolates [1.10 (26)] and are consistent with 
each other. Quantifying DNA with dLAMP at 6.7 min produces similar CT ratios and 
susceptibility calls as dPCR. 
 
Discussion 
 
Here, we solved three problems to determine phenotypic antibiotic susceptibility in 
clinical samples within 30 min. First, we used digital quantification of a DNA marker to 
reduce the antibiotic exposure time to 15 min. Second, we showed that dAST is robust to 
the presence of commensal bacteria and clinical urine matrices. Third, we developed and 
optimized a rapid, high-resolution measurement method for quantifying NA targets that 
shortens the measurement step to less than 10 min. 
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The dLAMP assay developed here was capable of amplifying single target DNA 
molecules in less than 5 min. Despite the heterogeneity of single-molecule amplification 
times, high-resolution measurements were obtained even before all partitions with a 
target DNA molecule had amplified (~6.7 min). This makes dLAMP a strong tool for 
real-time, high-resolution, rapid measurements of NAs. Rapid, high-resolution 
measurements increase the information gained in shorter times and will be invaluable for 
other assays, such as viral load measurements and genotyping (50, 63, 64). LAMP was 
chosen for translation to a digital format because it is a well-established amplification 
chemistry (51, 65, 66) with several readout methods (67–70). If necessary, other 
amplification chemistries—including NASBA (NA sequencebased amplification), RPA 
(recombinase polymerase amplification), NEAR (nicking enzyme amplification reaction), 
and HDA (helicase-dependent amplification)—could be tested and optimized for a digital 
format and used to measure a marker of interest. Additionally, we show that the LAMP 
assay is compatible with a rapid, one-step extraction method, which considerably reduces 
the sample preparation time. Because of the speed of extraction and amplification, the 
same LAMP assay can be used in a real-time bulk format for rapid pathogen 
identification in parallel with the 15-min antibiotic exposure step. This step, completed in 
<10 min including sample preparation, did not extend the total assay time but provided 
two critical pieces of information before digital quantification: (i) whether a sample was 
infected with the pathogen of interest and (ii) whether a sample contained clinically 
relevant concentrations of the pathogen. UTI-positive samples gave TTP values of 4 to 5 
min (corresponding to ~105 to ~106 DNA copies/ml, n = 7) (Fig. 3C), whereas healthy 
urine samples remained negative for at least 20 min (n = 5) (Fig. 3B). This specificity is 
critical in working with clinical samples because it enables the dAST to provide 
information specific to the pathogens of interest rather than commensals, contaminating 
organisms, or mixtures of pathogens. Additionally, using dLAMP to calculate the CT 
ratios and determine susceptibility was informative for estimating pathogen concentration 
in the urine sample (see table S1). 
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Most of the previous rapid AST methods used cultures of clinical isolates instead of 
clinical samples (see table S3 for a quantitative summary of the published state of the 
art). The introduction of commensal or contaminating organisms and clinical sample 
matrices to diagnostic workflows can cause major challenges in the development and 
translation of laboratory methods. It is therefore critical to prove that AST methods are 
compatible with clinical samples. Here, we have shown that the dAST method is 
compatible with a wide range of urine samples. Urine color of the samples included 
colorless, yellow, dark yellow, and red; pH ranged from <5.0 to 8.0; and protein 
concentrations ranged from 0.0 to 1.0 mg/ml (71). Additionally, red and white blood cell 
counts were as high as >106 cells/ml each in separate samples, and several samples 
demonstrated elevated glucose. One sample contained a lactose-positive Gram-negative 
rod bacterium (3 × 104 CFU/ml) in addition to the infecting E. coli. Although this study 
warrants more extensive follow-up investigation into more detailed correlations between 
urine composition and dAST speed and does not establish whether this method would 
work in a more complex matrix like whole blood, our results indicate that dAST is 
compatible with a wide range of urine matrices and contaminants in clinical samples. 
  
The dAST method described herein was demonstrated with a specific scenario, and thus, 
there are inherent limitations to the extrapolations we can make to other pathogens and 
antibiotics. These limitations will guide future work in this area. We demonstrated dAST 
using a single clinical sample set of UTI urine samples infected with E. coli, which 
causes 80% of UTIs, using a threshold of 1.10 previously established with isolates. This 
is similar to other studies at this stage of technology development (72–74); multiple 
clinical sets should be run in the future. 
  
Cip was chosen because it has become one of the most commonly prescribed antibiotics 
for UTIs, despite being a second-line therapy that should be preserved for more severe 
cases (12, 13, 75). Nit was chosen because it is the recommended treatment for acute 
uncomplicated cystitis (6). Nit is a highly effective first-line antibiotic that is often 
overlooked because of a lack of susceptibility data. The lack of AST data becomes 
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especially important because nit is sometimes used as a prophylactic treatment for 
recurrent UTIs and, despite its effectiveness, is not used to treat acute cases due to 
susceptibility concerns (12). Multiplexing with more pathogens and antibiotics in a 
blinded study is an important next step that, if successful, would further validate and 
prove the clinical utility of this rapid dAST assay. 
  
Other UTI pathogens may have slower growth rates and smaller differences in control 
and treated concentrations (Fig. 1B); however, these differences are theoretically 
resolvable with digital NA quantification. Furthermore, alternative dAST markers might 
yield larger CT ratios after shorter antibiotic exposure times. In particular, changes in 
RNA in response to antibiotic exposure have been shown to be both large and fast (38) 
and should be rapidly discernable with digital methods such as the ones described here. 
For example, we have demonstrated quantification of viral RNA on digital SlipChips (64, 
76), including a 5-plex chip for multiplexed measurements. With chip designs properly 
adjusted for appropriate multiplexing and desired resolution (fig. S1), multiplexed 
measurements could be useful for analyzing combinations of RNA markers (38). 
Additionally, RNA markers (38) and alternative DNA markers may be required for 
antibiotics with different mechanisms of action, such as b-lactams (26), to achieve a 30-
min sample-to-answer dAST. 
  
Pathogen concentration is also considered when working with clinical samples. 
Quantifying NAs with high resolution is challenging if the NA concentration drops below 
the optimal dynamic range of the system. For example, in sepsis, the concentration of 
pathogens in blood can be as low as ~1 to 10 CFU/ml (77). Although blood cultures, 
which require overnight or longer incubations, are currently used to increase the 
concentration of pathogens, they are too slow to inform the initial treatment because each 
additional hour of delayed treatment in sepsis results in a 7.6% increase in mortality (25), 
emphasizing the need for rapid AST. This major challenge of low concentrations of 
pathogens must be overcome to perform dAST in cases of sepsis and will require 
alterations to the methodology, such as the addition of a pathogen-concentrating step 
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before antibiotic exposure. Last, we have not tested dAST against heteroresistant 
microbial populations, which have been documented in Gram-positive organisms (78) but 
are not common in Gram-negative organisms. 
  
We have streamlined many aspects of the workflow for the dAST demonstration and 
believe this workflow can be performed by trained personnel in diagnostic laboratories. 
However, because this process requires several pipetting and handling steps, operator 
error is possible. We anticipate that dAST would have the greatest impact on antibiotic 
stewardship if it could be performed by minimally trained personnel at the POC. This 
would require integration of the dAST workflow into an inexpensive, simple-to-use 
device operated with inexpensive equipment. An integrated dAST device would increase 
throughput and reduce the potential biohazard risks associated with open pipetting steps, 
which are a limitation of our current protocol. Although not demonstrated here, an 
integrated device should be feasible due to the straightforward nature of the dAST 
workflow. Isothermal digital quantification can be performed using a range of 
technologies and amplification chemistries (40, 47, 49, 63, 79), including SlipChips, 
which are compatible with untrained users (80) and can be read with inexpensive optics 
such as a camera phone (40, 70). Whereas reusable glass SlipChips require cleaning (76), 
disposable injection-molded SlipChips further simplify the workflow. Furthermore, the 
SlipChip platform supports multiplexed digital measurements (45), which is desired to 
perform AST on multiple antibiotics and/or pathogens simultaneously. Finally, the 
robustness of isothermal digital amplification to temperature, imaging conditions, 
reaction time (40), sample preparation methods (81, 82), and inhibitors (83–85) could 
further simplify the instrument requirements. This rapid dAST, if fully developed and 
validated for additional microorganisms, antibiotics, and sample types and transitioned to 
a Clinical Laboratory Improvement Amendments– waived POC device approved by the 
regulatory bodies, would enable rapid clinical decision-making, improve management of 
infectious diseases, and increase antimicrobial stewardship. 
 
Materials and Methods 
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Study design  
 
The objective of this study was to develop a rapid phenotypic AST using digital NA 
quantification. The two key hypotheses of this work were as follows: (i) 15 min of 
antibiotic exposure can cause sufficient differences in pathogen-specific DNA 
concentrations between control and antibiotic-treated samples such that a high-resolution 
digital quantification measurement method such as dPCR can reliably detect a difference 
in NA concentrations for a susceptible sample and (ii) a rapid dLAMP assay can resolve 
these small differences in NA concentration in less than 10 min. To test the first 
hypothesis, 51 clinical human urine samples were tested using the dAST method (three 
samples run with both antibiotics for a total of 54 antibiotic-susceptibility calls), and the 
results were compared to the gold standard broth microdilution. Clinical UTI samples 
with E. coli as the pathogen of interest were chosen as a test case for the dAST method 
using one first-line antibiotic (nit) and one second-line antibiotic (cip). To test the second 
hypothesis, the rapid dLAMP assay was compared with a commercial dPCR system for 
calculating the CT ratios and determining antibiotic susceptibility from clinical UTI 
samples. 
  
To calculate the sample size, the methods and Equation 5 from (86) were used. We define 
the true-positive rate (sensitivity) as the proportion of gold standard–susceptible samples 
that are correctly identified as susceptible by the dAST method and the true-negative rate 
(specificity) as the proportion of gold standard–resistant samples that are correctly 
identified as resistant by the dAST method. We suspected that the specificity and 
sensitivity of the dAST method would be 95% with a desired margin of error of ±10%. 
Under these conditions, 18.2 (or 19) samples must be tested with the dAST method and 
compared to the gold standard. We tested 19 resistant samples and 35 susceptible 
samples. Experimental details of LAMP primer design, optimization, and specificity and 
the rapid dLAMP assay are described in the Supplementary Materials.  
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dAST in the presence of commensal organisms  
 
Antibiotic-susceptible and antibiotic-resistant isolates of E. coli from patients diagnosed 
with UTIs were obtained from the University of California, Los Angeles, Clinical 
Microbiology Laboratory (UCLA CML). These isolates were treated separately with and 
without antibiotics (±ABXs) in the presence of varying concentrations of Lj (also isolated 
from a clinical UTI urine sample by the UCLA CML). Lj was spiked into clinical urine 
samples at varying concentrations relative to the concentration of E. coli. Concentrations 
were determined by measuring the optical density at 600 nm. Samples were exposed to 
cip (1 mg/ml; Sigma-Aldrich) for 30 min (26). A 10-ml aliquot of the sample was 
removed after 0, 15, and 30 min of exposure and added to 90 ml of QuickExtract DNA 
Extraction Solution (Epicentre). Target DNA was quantified using droplet dPCR (26). 
The fold change in the concentration of target DNA after 15 min of antibiotic exposure 
relative to time 0 in the control and antibiotic-treated samples was compared (Fig. 2, A 
and B), measuring the significance of this difference by P value as described previously 
(26). The CT ratios at 15 min (Fig. 2C) were calculated as the ratios of the marker 
concentrations in the control and antibiotic-treated samples. 
  
The primers used for all dPCR amplification experiments target the 23S gene of the 
Enterobacteriaceae family (26). The concentrations of the components in the dPCR mix 
used for these experiments and all subsequent dPCR experiments were as follows: 1× 
QX200 ddPCR EvaGreen Supermix (Bio-Rad), 500 nM forward primer, and 500 nM 
reverse primer. The NA extraction comprised 10% of the final volume in the dPCR mix. 
The remaining volume was nuclease-free water (NF-H2O).  
 
dAST using clinical UTI samples.  
 
Clinical urine samples were obtained under an approved institutional review board (IRB) 
protocol at the UCLA CML (#15-001189) and analyzed at the California Institute of 
Technology (Caltech) under an approved protocol (IRB #15-0566). Samples were 
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deidentified before being transported to Caltech. Samples were stored in Vacutainer 
Plus C&S Boric Acid Sodium Borate/Formate tubes (Becton Dickinson), transported at 
ambient temperature, and stored at 4°C once received at Caltech. Urine samples were 
from otherwise healthy patients suspected of having a UTI (based on urinalysis results). 
The presence of E. coli was confirmed by the UCLA CML, and MICs were determined 
as described previously (26). Urine samples were selected for dAST analysis based on the 
determined MIC of the infecting E. coli. Samples were considered cip-susceptible if the 
determined MIC was ≤0.25 mg/ml and considered cip-resistant if the MIC was ≥4 mg/ml. 
Samples were considered nit-susceptible if the MIC was ≤16 mg/ml and considered nit-
resistant if the MIC was ≥128 mg/ml. Viable bacteria are a requirement of phenotypic 
ASTs. Nonviable samples were excluded if a decrease in DNA concentration was 
observed (indicating digestion of DNA from nonviable cells). If the change in DNA 
concentration was not easily discernible by dPCR after 15 min of growth in media, then 
the DNA concentration at 30 min was measured to determine whether the sample was 
viable (DNA concentration increased at 30 min) or nonviable (DNA concentration 
decreased at 30 min). 
  
Before the start of each experiment, urine as received, still containing boric acid, was 
warmed to 37°C over 30 min to mimic the temperature of fresh urine samples. At the 
start of each dAST experiment (t = 0), warmed urine was added to media (prewarmed to 
37°C) with or without antibiotics (±ABXs) to initiate DNA replication and begin 
exposure. This addition to media dilutes the boric acid in the transport media, allowing 
bacterial replication to proceed. The final 500-ml sample mixture in the control and 
treated tubes contained 250 ml of brain heart infusion media (Becton Dickinson), 25 ml 
of DNase I (New England Biolabs), 5 ml of DNase buffer (100 mM trisHCl, 25 mM 
MgCl2, and 5 mM CaCl2), and an aliquot of the urine, with the remaining volume of NF-
H2O. Either cip (1 mg/ml) or nit (16 mg/ml) was added to the +ABX sample, with an 
equal volume of NF-H2O (in the case of cip) or dimethylformamide (in the case of nit) 
added to the control sample (−ABX). Antibiotic concentrations were chosen on the basis 
of our previous work with isolates (26) and are near the Clinical and Laboratory 
  
59 
Standards Institute and European Committee on Antimicrobial Susceptibility Testing 
breakpoints. A 10-ml aliquot of urine was added to control and treated tubes in the cip 
treatments, and a 25-ml aliquot was added in the nit treatments. Samples were shaken at 
750 rpm at 37°C for 30 min. After 0, 15, and 30 min of exposure, 10-ml aliquots of the 
control and treated samples were removed and added to 90 ml of QuickExtract DNA 
Extraction Solution. The extracted samples were heated according to a modified version 
of the manufacturer’s protocol (65°C for 6 min, 95°C for 4 min, and chilled on ice), 
vortexed, and centrifuged. Next, 5 ml of each extraction was added to 45 ml of ddPCR 
mix and quantified using dPCR. If the DNA concentration of the sample was too high, 
then the template was diluted in NF-H2O and dPCR was rerun. The CT ratios were 
calculated; if the dAST call did not match the gold standard AST call, then the sample 
was rerun several hours later on the same day. For the four samples that were rerun, only 
the second set of NA extractions were quantified by dLAMP.  
 
Sample-to-answer dAST in less than 30 min  
 
Clinical urine samples were treated with (“treated”) and without (“control”) cip (1 
mg/ml) for 15 min as described above. A timer was started as soon as urine was added to 
the media with and without cip. After 0 and 15 min, a 20-ml aliquot of each sample was 
added to 80 ml of QuickExtract DNA Extraction Solution (Epicentre). The two samples 
were then heated at 65°C for 1 min followed by 98°C for 1 min, after which they were 
chilled by incubation on an ice block for 30 s, vortexed, and centrifuged. 
  
In parallel with the 15-min antibiotic exposure step, we used the semiquantitative ability 
of quantitative LAMP to predict the appropriate dilution factor for our 1280-well digital 
SlipChips. A 2-ml aliquot from each of the control and treated DNA extractions from 
time 0 was added to 8 ml of LAMP mix. The samples, along with two standards with 
known DNA concentrations (S1, 128.5 copies/ml; S2, 766.0 copies/ml), were then 
incubated at 72°C for 5 min on a Roche LightCycler 96, and fluorescent traces were 
monitored in real time. If the TTP of the average of the samples was earlier than the TTP 
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of S1, then 3 ml of the NA aliquot extracted at 15 min was added to 24 ml of dLAMP 
mix, along with 3 ml of NF-H2O. If the TTP of the sample was between the TTPs of S1 
and S2, then 6 ml of the 15-min NA extraction was added to 24 ml of dLAMP mix, with 
no additional NF-H2O added. This step was completed within the 15 min of antibiotic 
exposure. In the experiments with both antibiotic-resistant and antibiotic-susceptible 
samples (Fig. 5), the TTP was earlier than the TTP of S1. 
  
After semiquantification and mixture of the dLAMP mix with the template, the dLAMP 
solutions were pipette-mixed, loaded into SlipChips, partitioned into 1280 compartments, 
and placed on the thermal cycler of a digital real-time imaging instrument at 72°C. 
  
Images were taken every 26 s, and concentrations were calculated on the basis of the 
number of positive and negative wells [as described in Rapid digital LAMP (dLAMP) in 
the Supplementary Materials]. Software developed in (56) was modified to enable 
realtime image processing and concentration calculations as each image was taken 
instead of after the assay completed. The CT ratios were also calculated for each time 
point; the value of the CT ratio after 6.7 min of amplification time is plotted in Fig. 5D 
and was compared to a threshold of 1.10 to determine susceptibility or resistance. The 
timer was stopped at this time point; 29.8 min had elapsed when running dAST with the 
susceptible sample, and 29.2 min had elapsed with the resistant sample.  
 
Statistical analysis  
 
Poisson statistics was used to calculate the 95 or 98% confidence interval of the NA 
concentration for each digital measurement (45). To calculate the error in fold change, we 
used standard error propagation methods (87). With l as a concentration and s as the SD, 
the equation is 
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Kreutz et al. (45) demonstrated that results from a Z test (assuming a normal distribution) 
and a permutation test are in very good agreement for various SlipChip designs; 
therefore, it is appropriate to calculate P values comparing digital NA concentrations with 
a one-sided Z test. This Z test asks whether the control NA concentration (l ) control is 
1.10× higher than the treated NA concentration (lABX) (26, 45).  
 𝑍 = ln(𝜆-LY0.LZ) − ln(1.10 ∙ 𝜆[\])^𝜎_`(OabcCdbe)T + 𝜎_`(Ofgh)T  
 
Concentration (l) and SD (s) for each digital NA measurement were calculated from the 
number of positive and negative compartments with Poisson statistics as described in (45) 
for single-volume digital NA quantification. A significance level of 0.05 was used. 
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Supplementary Materials 
 
Materials and Methods 
 
Supplementary materials and sample handling 
 
Materials and reagents 
 
All reagents purchased from commercial sources were used as received unless otherwise 
stated. BBL trypticase soy agar (TSA) plates with 5% sheep blood and Bacto brain heart 
infusion (BHI) media were purchased from BD Biosciences. All antibiotic stock solutions 
and nucleic acid amplification reactions were prepared using sterile, nuclease-free water 
(NF-H2O) purchased from Thermo Fisher. Ciprofloxacin was purchased from Sigma-
Aldrich and prepared as a 1 mg/mL stock solution in NF-H2O. Nitrofurantoin was 
purchased from Sigma-Aldrich and prepared as a 10 mg/mL stock solution in NF-H2O. 
QuickExtract DNA Extraction was purchased from Epicentre. QX200 ddPCR EvaGreen 
Supermix was purchased from Bio-Rad Laboratories. Bst 3.0 and 10 mM dNTPs were 
purchased from NEB. Pooled healthy human urine was obtained from Lee Biosolutions. 
Primer sequences were ordered as dried stocks from IDT. 
 
Digital quantification with dPCR  
 
Droplet digital PCR reactions were carried out as described previously (26).  
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Design, fabrication and preparation of SlipChips  
 
Details of the design, fabrication, preparation, and assembling of the single-volume 
1,280-well SlipChip glass devices are described in previous work (50). For this 
manuscript, the workflow in Fig. 5 was performed with lab-made reusable glass 
microfluidic chips (Samples 28-29,48-51). To run the rest of the 54 samples with the 
rapid dLAMP assay, we obtained a set of disposable injection molded chips (5,376 2.4-
nL compartments) from SlipChip Corp, which enabled shorter turnaround times between 
experiments (Samples 1-27,30-47).  
 
Clinical sample handling and gold-standard broth microdilution AST  
 
Urine from patients suspected of having urinary tract infections (UTIs) was collected and 
transported in a BD Vacutainer Urine Collection Tube containing formate and borate as 
preservatives. Next, pathogens from the urine samples were isolated and identified using 
mass spectrometry. Broth microdilution AST was performed on samples positive for E. 
coli.  
 
dAST with clinical samples  
 
One modification to our original dAST protocol (26) is the addition of DNase to digest 
extracellular DNA. We did this to eliminate the confounding effect that extracellular 
DNA could have on the CT ratio. Consider an antibiotic-susceptible sample with 500 
cop/µL of cell-free DNA and 300 cop/µL DNA inside cells. If the genomes replicate 
1.5X over a 15 min exposure time, then the CT ratio in the case where cell-free DNA is 
also detected would be 950 cop/uL ÷ 800 cop/uL = 1.19; in the case where cell-free DNA 
is digested by DNase and not detected, the CT ratio would be 450 cop/uL ÷ 300 cop/uL = 
1.50.  
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If discordant AST calls (compared to the gold-standard) were noticed on the same day, 
we re-ran that sample to resolve the discordancy. Some reruns are accepted even in the 
FDA submissions of diagnostic AST devices, so rerunning samples in itself is not a 
problem. It would have been better to rerun the samples twice, to get a third measurement 
as a tie-breaker. Unfortunately, we could not do so due to the limitations of our protocols 
and the concern for aging of clinical samples over time (and we were not able to rerun all 
of the samples).  
 
Because our data provide a quantitative measurement (CT ratio), we averaged the two 
runs to obtain a consensus value of the CT ratio. When we do this (using dPCR values as 
an example), we find that three samples (#28, #29, #43) returned average CT ratios (1.48, 
1.07, 1.48) that were in agreement with the gold standard (S, R, S). For a fourth sample 
(#36), the average CT ratio (1.09) was also discordant with the gold standard (S) and we 
recorded it as an error in our analysis for both dPCR and dLAMP (see Table S1).  
 
Isolate maintenance and exposure experiments.  
 
For all experiments involving isolates (Fig. 2), isolates were maintained and antibiotic 
exposure carried out as described in previous work (26). All E. coli isolates were 
maintained on solid or liquid BHI media (BD), all Lactobacillus jensenii isolates were 
maintained on solid or liquid MRS media (BD).  
 
Intermediate samples  
 
In this manuscript, we focus on categorical agreement of our binary susceptibility 
determination (susceptible or resistant). We chose to design our study this way and to 
exclude intermediate samples for the following reasons: 
 
The current gold-standard antibiotic susceptibility testing method is broth dilution. This 
method, used every day in central clinical laboratories, is only accurate to +/one dilution 
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step. For example, E. coli with an initially determined ciprofloxacin MIC of 2.0 µg/mL 
might have an MIC of 1, 2, or 4 µg/mL if tested again using the same gold-standard 
method. According to the CLSI standards used in the US, 1.0 µg/mL is considered 
“susceptible”, while 2 µg/mL is considered “intermediate” and 4.0 µg/mL is considered 
resistant. This is well-known in the clinical microbiology community. In fact, the CLSI 
manual (59) states that one of the roles of the intermediate category is to include a buffer 
zone which should prevent small, uncontrollable, technical factors from causing major 
discrepancies in interpretation. Furthermore, when gold standard broth dilution vs gold 
standard inhibition zone diameter is compared, intermediate samples do not show 
consistent results (see Fig. 4 of (60); of the five samples tested with intermediate MICs 
(as determined by the goldstandard), the inhibition zone method called one of them 
resistant, two intermediate, and two susceptible (60)).  
 
A further issue is the discrepancy of the meaning “resistant and susceptible” around these 
concentrations. For example, using EUCAST standards, susceptible isolates are those 
with ciprofloxacin MIC of 0.25 µg/mL and below, while intermediate isolates have MIC 
of 0.5 µg/mL and resistant isolates are 1.0 µg/mL and above.  
 
We chose to exclude samples with MICs of 0.5, 1.0, and 2.0 µg/mL to ensure that the 
gold standard method would not frequently switch between a susceptible and resistant 
call if repeated.  
 
Importantly, this approach is still applicable to “real world” samples and does not 
correspond to only looking at extremes of MIC. Excluding these samples only eliminates 
a small percentage of E. coli samples based on epidemiological data [see “Ciproflaxin / 
Escherichia coli international MIC distribution” reference database (62)], with the caveat 
that these distributions may change at different times in different locations. For example: 
a broader range of antibiotic concentrations is tested when generating epidemiological 
data than is tested in clinical microbiology laboratories. The cut-off MIC for defining 
resistant and susceptible organisms is different between the epidemiological and clinical 
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microbiological data. Epidemiological cut-off is defined relative to the wild-type 
susceptibility whereas the clinical cut-off is defined relative to clinically relevant 
susceptibility. These data should not be used to infer the rates of resistance in a particular 
geographical location at a particular time (62).  
 
For nitrofurantoin (nit), MIC of >=128 is considered resistant and MIC of <= 32 is 
considered susceptible. Similarly, we chose to exclude the minimal possible number of 
samples with MICs that might switch between a susceptible or resistant call when 
repeated. For this reason, we excluded samples with MICs of 32 and 64 µg/mL.  
 
Therefore, it should not be surprising that when validating a new AST method with 
clinical samples, it is common to challenge the method only against susceptible and 
resistant samples that are above or below the MIC breakpoints, while avoiding 
intermediate samples (34, 35, 61).  
 
To test whether intermediate or near-intermediate samples provide any unexpected 
results, we did run a small separate study of 8 clinical isolates (2 operators with 4 isolates 
each) with intermediate and near-intermediate MICs using dPCR readout. We exposed 
these isolates with (1.0 µg/mL ciprofloxacin) and without antibiotics for 15 min and 
measured the nucleic acid concentrations with dPCR. Isolates with MIC of 1.0 µg/mL are 
clustering very close to the threshold and slightly below, while isolates with MIC of 0.5 
µg/mL are comfortably above the threshold and would be read as susceptible (fig. S3).  
 
Theoretical analysis of phenotypic AST  
 
To explore the tradeoffs among antibiotic exposure time, the growth rate of the bacteria 
in question, and the required resolution of the measurement method, we developed a 
simple model to inform optimal AST methods when DNA replication is used as the 
differentiating marker between susceptible and resistant bacteria. We assumed that i) a 
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[mol/L], has a DNA doubling time of tdouble [min] when incubated in media for tinc 
[min], ii) an antibioticsusceptible bacteria sample incubated in media with antibiotics 
does not grow at all, and iii) antibiotic-resistant bacteria grow at the same rate with and 
without antibiotics.  
 
Under these assumptions, the ratio of the NA concentrations of a control sample 
(Ccontrol) compared to an antibiotic-treated sample (CABX)—the control–treated ratio 
(CT ratio)—after a certain time of antibiotic exposure (tinc) would be:  
 𝐶𝑇	𝑟𝑎𝑡𝑖𝑜 = 𝐶-LY0.LZ(𝑡/Y-)𝐶[\](𝑡/Y-) = 𝐶= ∙ 20nca/0obBpeq𝐶= = 20nca/0obBpeq  
 
Plotting CT ratio as a function of tinc and tdouble yields Fig. 1B. Typically, qPCR is 
capable of resolving 2-fold differences in concentration, whereas digital PCR (dPCR) can 
resolve as low as 1.2-fold differences in concentration (41). Due to the higher resolving 
power of dPCR, phenotypic AST can be performed with shorter antibiotic exposure times 
than if qPCR was used as the measurement method.  
 
Experimental details for LAMP primer design, optimization, and specificity. 
  
LAMP primer optimization experiments (Fig. 3A, steps 1–2) were performed on a Roche 
LightCyler 96 using the SYBR Green I channel for readout, 6 µL reaction volumes, and 
the following concentrations of reagents: 20 mM Tris-HCl pH 8.8, 50 mM KCl, 10 mM 
(NH4)2SO4, 0.1% Tween-20, 1.4 mM dNTPs, 2 µM Syto-9, 400 U/mL Bst 2.0 (New 
England Biolabs), ~700 copies/µL E. coli gDNA, and 8 mM MgSO4. All samples were 
run across a temperature gradient spanning 60 – 72 ̊C.  
 
The experiments optimizing magnesium concentration (Fig. 3A, step 3) were performed 
using the same protocol as above with the following concentrations of reagents: 20 mM 
Tris-HCl pH 8.8, 150 mM KCl, 10 mM (NH4)2SO4, 0.1% Tween-20, 1.4 mM dNTPs, 2 
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µM Syto-9, 360 U/mL Bst 3.0 (New England Biolabs), ~700 copies/µL E. coli gDNA, 
and variable concentrations of MgSO4 (Fig. 3A). All samples were run across a 
temperature gradient spanning 60–74 ̊C.  
 
Primer concentrations were kept constant in all experiments: 1.6 µM FIP/BIP, 0.2 µM 
FOP/BOP, and 0.4 µM loopF/loopB (when included). The final selected primer set was 
as follows: GGCGTTAAGTTGCAGGGTAT (FOP), TCACGAGGCGCTACCTAA 
(BOP), CGGTTCGGTCCTCCAGTTAGTGTTTTCCCGAAACCCGGTGATCT (FIP), 
TAGCGGATGACTTGTGGCTGGTTTTTCGGGGAGAACCAGCTATC (BIP), 
ACCTTCAACCTGCCCATG (LoopF), GTGAAAGGCCAATCAAACC (LoopB).  
 
Identification and specificity experiments were performed using the same concentration 
of reagents as the experiments to optimize MgSO4 concentration, but were run with 5 
mM MgSO4. Although 6 mM MgSO4 yielded the fastest TTP, 5 mM MgSO4 was used 
in subsequent experiments in order to minimize the risk of background amplification. We 
have not observed background amplification with the primers described here, but other 
primer sets are sensitive to MgSO4 concentration. The optimal TTP using 5 mM MgSO4 
was only 12 s slower than when using 6 mM MgSO4.  
 
BLAST was used to evaluate primer specificity against the families Enterobacteriaciae, 
Staphylococcaceae, and Enterococcaceae. The specificity of the LAMP primers targeting 
the E. coli 23S rDNA gene was tested against human genomic DNA (Hs gDNA), Lj 
gDNA, urine from healthy donors, and water (Fig. 3A,B). Hs gDNA was tested at 0.002, 
0.02, and 0.2 ng/µL final reaction concentration as measured using a NanoDrop 2000c 
(Thermo Fisher Scientific). Lj gDNA was tested at final reaction concentrations of 0.16, 
0.8, and 1.6 ng/µL, as measured using a NanoDrop 2000c. Urine from healthy donors 
was run at 10% final reaction volume. Real-time LAMP amplification was performed 
using a range of concentrations of E. coli gDNA (Ec gDNA) prepared from clinical UTI 
urine samples and quantified using droplet digital PCR (Fig. 3C).  
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Rapid digital LAMP (dLAMP)  
 
Clinical urine samples were treated with and without 1 µg/mL cip or 16 µg/mL nit for 15 
min and nucleic acids extracted as described above. The dLAMP mix consisted of 20 
mM Tris-HCl pH 8.8, 150 mM KCl, 10 mM (NH4)2SO4, 0.1% Tween-20, 1.4 mM 
dNTPs, 1X EvaGreen (Biotium), 360 U/mL Bst 3.0, 1X RNase Cocktail (ThermoFisher), 
5 mM MgSO4, and 1 mg/mL BSA prepared in NF-H2O. Aliquots of NA extractions 
composed 10% or 20% of the final volume in the dLAMP mix. Two aliquots of dLAMP 
mix containing equal volumes of NA extractions from the control and treated samples 
were simultaneously loaded into two separate SlipChip devices. The top piece of each 
SlipChip was moved relative to the bottom piece, which partitioned the solution into 
1,280 3-nL compartments (lab made glass SlipChips) or 5,376 2.4-nL compartments 
(injection-molded plastic SlipChips) (see Supplementary Materials). When using the 
injection-molded plastic SlipChips, the treated chip was loaded 30 s after the control 
chip. The SlipChips were then placed onto the thermal cycler of a digital real-time 
imaging instrument and incubated at 72 °C for 20 min (56). Amplification time was 
recorded starting from when the thermal cycler reached 72 °C.  
 
Images were taken every 20 s and the fluorescent intensity was measured for each 
compartment (Fig. 4A/F) with LabView software as described in (56). Wells that showed 
liquid movement or bubbles were excluded from analysis. If there was a spatial 
amplification gradient (i.e., positives in one area of the chip appeared before other areas), 
then the experiment was excluded. The concentration of the target was calculated using 
Poisson statistics and was based on the number of “positive” compartments that exceeded 
the fluorescence intensity threshold, for time points where 13 or more compartments 
were positive. The concentration of the control and treated samples was calculated in 
real-time, along with a P value representing the probability that the ratio of 
concentrations being greater than 1.10 was a result of random chance (Fig. 4C/H). If P < 
0.05, we can be reasonably certain that the bacteria are susceptible to the antibiotic. If the 
P-value remains > 0.05, we can be reasonably certain that the bacteria are resistant to the 
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antibiotic. The CT ratio was calculated and plotted for each 20 s interval in Fig. 4 D/I 
for one susceptible sample and one resistant sample. For Fig. 6C, the CT ratio at 6.7 min 
was calculated and plotted for all 54 dAST experiments.  
 
In some cases, the TTP distribution (Fig. 4 B/G) of one chip was delayed relative to the 
other chip. If this happened, the TTP maximums were aligned to normalize the data 
before concentrations and CT ratios calculated. 
 
 
 
Fig. 3-S1. Resolution of digital devices. The resolution of digital quantification depends 
on the number and volume of compartments. Simulations were performed with the 
methods described in (45). A) For a fixed sample size, and fixed input concentration of 
106 cop/mL relevant to UTIs, increasing the number of compartments (and reducing the 
volume of each compartment accordingly) beyond 1,000 does not improve resolution in a 
useful way. B) For fixed compartment volume, and fixed input concentration of 106 
copy/mL relevant to UTIs, the resolution improves with increasing number of 
compartments, although this increase requires a larger input of sample and amplification 
reagents. C) Dependence of resolution on the number of multiplexed measurements made 
for a constant number of total wells. For example, while 10,000 of 1 nL compartments 
provide 1.08 resolution, 2,000 of 1 nL compartments provide 1.16 resolution each, 
enabling a 4- plex dAST (1 control and 4 ABX treated samples) to be performed. 
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Fig. 3-S2. Real-time dLAMP DNA quantification of a UTI sample with nit treatment. 
High-resolution single- molecule nucleic acid amplification was performed using ultrafast 
digital LAMP (dLAMP) for digital antimicrobial susceptibility test (dAST) of clinical UTI 
urine samples with antibiotic-susceptible (A–E) and antibiotic-resistant (F–J) E. coli. 
Aliquots of a clinical UTI sample were treated with and without 16 µg/mL nitrofurantoin. 
After 15 min, DNA was extracted and quantified with digital LAMP on SlipChips. The 
protocols followed and materials used are described in Materials and Methods, “Digital 
AST (dAST) using clinical UTI samples” and Supplementary Materials Section 5. (A,F) 
Real-time fluorescence amplification traces (only 200 of 1,280 traces shown for clarity). 
NFU = normalized fluorescence units; dotted line = positive threshold; when the 
normalized fluorescence intensity of a compartment crosses the threshold, that 
compartment is counted as positive. (B,G) Time-to-positive (TTP) distribution was 
determined by counting the number of compartments that crossed the positive threshold at 
each time point. (C,H) Detected concentrations of the target dAST marker in control and 
antibiotic-treated samples for successive image cycles. Grey lines represent 95% 
confidence intervals. Note these curves are not the amplification curves shown in A and F. 
(D,I) Detected control–treated (CT) ratios over time. Dashed line indicates susceptibility 
threshold. (E,J) Comparison of CT ratios for droplet digital PCR (dPCR) after 2 h and 
dLAMP (after 6.7 min of amplification). 
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Fig. 3-S3. The dAST method tested with isolates with near-intermediate MICs. The digital 
AST (dAST) method was tested with clinical isolates from urinary tract infections(UTIs) 
using a 15 min treatment of 1 µg/mL ciprofloxacin. Eight isolates with three near-
intermediate MICs were analyzed with the dAST method (two operators with four isolates 
each). Control–treated (CT) ratios were calculated from dPCR 23S DNA concentration 
measurements. 
 
 
Fig. 3-S4. Reproducibility of the dAST method with clinical urine samples. Three 
ciprofloxacin-susceptible samples (#37, #38, #45 from table S1) were analyzed with the 
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dAST method in triplicate and control–treated (CT) ratios were calculated from DNA 
concentration measurements using digital droplet PCR.  
 
Table 3-S1. Concentration of clinical urine samples. Pathogen-specific 23S DNA 
concentration as determined by digital LAMP after 6.7 min of amplification time (Fig. 
4C/H). Taking into account the number of rDNA copies per E. coli chromosome, and the 
efficiency of dLAMP in counting DNA in 6.7 min, the concentration of full genomes is ~6 
times lower than the number reported in this table. CFU/mL was determined by plate 
counting at the UCLA Clinical Microbiology Laboratory. 
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Table 3-S2. Clinical samples used in this study. Clinical urinary tract infection (UTI) 
urine samples tested for ciprofloxacin (cip) or nitrofurantoin (nit) susceptibility testing by 
gold-standard broth microdilution and by digital AST (dAST). Nucleic acids were 
quantified with both digital PCR (dPCR) and digital LAMP (dLAMP). Sample reruns 
(indicated by a “(2)”) were performed several hours later on the same day when the 
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control- treated ratio was discordant with the gold-standard AST call (CT ratio > 1.10 for 
a resistant sample or < 1.10 for a susceptible sample). S = antibiotic-susceptible; R = 
antibiotic-resistant; *major error; **very major error. 
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Table 3-S3. Rapid phenotypic AST literature summary showing the state of the art. 
Phenotypic antibiotic susceptibility tests using clinical samples, blood culture, contrived 
samples, clinical isolates, or reference strains with reported total assay time less than 3.5 
hrs (210 min). References are sorted by sample type and then by combined time of all 
steps. NR = not reported. Literature from 1997–2017. 
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atime does not include washing and centrifugation steps 
bdetailed times of each step not reported, listed time is median time reported for all samples  
cdoes not include time of overnight blood culture growth 
dtotal time of all steps reported as “less than 30 min.” 
etime does not include washing steps 
fwashing, imaging, and agarose embedding time not included 
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greported as “clinical samples” in the abstract, but methods clearly state that all work was 
performed with clinical isolates: “We tested 189 clinical isolates...Before testing, each 
isolate was subcultured on cation-adjusted MHA for 20-24 hours”  
hdoes not include time of FACS measurement  
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Chapter IV 
 
RNA Markers Enable Phenotypic Test of Antibiotic Susceptibility in 
Neisseria gonorrhoeae After 10 Minutes of Ciprofloxacin Exposure3 
 
Abstract 
 
Rapid antimicrobial susceptibility testing (AST) is urgently needed for informing 
treatment decisions and preventing the spread of antimicrobial resistance resulting from 
the misuse and overuse of antibiotics. To date, no phenotypic AST exists that can be 
performed within a single patient visit (30 min) directly from clinical samples. We show 
that AST results can be obtained by using digital nucleic acid quantification to measure 
the phenotypic response of Escherichia coli present within clinical urine samples exposed 
to an antibiotic for 15 min. We performed this rapid AST using our ultrafast (~7 min) 
digital real-time loop-mediated isothermal amplification (dLAMP) assay [area under the 
curve (AUC), 0.96] and compared the results to a commercial (~2 hours) digital 
polymerase chain reaction assay (AUC, 0.98). The rapid dLAMP assay can be used with 
SlipChip microfluidic devices to determine the phenotypic antibiotic susceptibility of E. 
coli directly from clinical urine samples in less than 30 min. With further development 
for additional pathogens, antibiotics, and sample types, rapid digital AST (dAST) could 
enable rapid clinical decisionmaking, improve management of infectious diseases, and 
facilitate antimicrobial stewardship. 
 
Introduction 
 
Neisseria gonorrhoeae is the second most common sexually transmitted bacterial 
infection in the United States, with about 460,000 cases reported in 2016, an 18.5% rise 
                                               
3This chapter was first published in Scientific Reports with authorship belonging to Tamineh Kazaei, Jacob 
T. Barlow, Nathan G. Schoepp, and Rustem F. Ismagilov. 
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since 2015Prevention 1. Worldwide, it is estimated that about 78 million new N. 
gonorrhoeae infections occur annually2. N. gonorrhoeae infections can lead to heart and 
nervous system infections, infertility, ectopic pregnancies, newborn blindness, and 
increased risk for other sexually transmitted infections, including HIV3. The CDC has 
identified N. gonorrhoeae as one of the three most urgent drug-resistant bacterial threats3. 
N. gonorrhoeae has developed resistance to all of the most commonly used antibiotics 
(including penicillins, sulfonamides, tetracyclines, and fluoroquinolones) leaving only 
one last effective class of antibiotics: cephalosporins. However, there have even been 
worldwide reported cases of decreased susceptibility to the cephalosporin ceftriaxone4-8, 
and therefore an imminent threat of widespread untreatable N. gonorrhoeae. An 
important factor leading to the widespread development of antibiotic resistance is the 
liberal use and misuse of antibiotics. Critically needed is a rapid antibiotic susceptibility 
test (AST) that can guide treatment at the point-of-care — both to provide correct 
treatment and to facilitate antibiotic stewardship.  
 
The gold standard for determining N. gonorrhoeae susceptibility to antibiotics is the 
culture-based agar dilution test, which is unacceptably slow (1–2 days). More rapid 
genotypic approaches, involving detection of gene mutations, are available for a subset of 
antibiotics in N. gonorrhoeae9,10, but such approaches are inherently limiting, as they 
require knowledge of the mechanisms of resistance. Moreover, N. gonorrhoeae is 
naturally competent for transformation, and can take up gonococcal DNA from the 
environment and recombine it with its own genome, resulting in frequent gene 
mutations11,12. Given the high rate at which new resistance emerges, relying solely on 
genotypic methods is not an acceptable long-term solution. Phenotypic methods 
involving growth measurements have enabled faster ASTs that are independent of 
resistance mechanisms13-16. However, such growth-based methods are challenging for N. 
gonorrhoeae, which is slow-growing and fastidious17. Another phenotypic approach for 
antibiotic susceptibility testing is quantification of nucleic acids18,19. We have previously 
demonstrated a rapid (30 min) phenotypic AST using quantification of DNA replication 
by digital PCR (dPCR) to assess the antibiotic susceptibility of Escherichia coli in 
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clinical urine samples20. However, AST methods that quantify changes in DNA 
replication require a longer antibiotic-exposure step for slow-growing pathogens such as 
N. gonorrhoeae, which has a doubling time of about 60 min21, compared with the 20 min 
doubling time of E. coli22.  
 
A complementary approach to DNA quantification is measuring the pathogen’s RNA 
response to antibiotic exposure. Transcriptional responses are among the earliest cellular 
changes upon exposure to antibiotics23, far before phenotypic changes in growth can be 
observed. Quantifying changes in RNA signatures is therefore a particularly appealing 
approach for slow-growing organisms. RNA has previously been used to differentiate 
antibiotic susceptibility and resistance in organisms where the transcriptional response is 
well characterized24,25. More recently, RNA sequencing (RNA-Seq) has been used to 
measure the transcriptome response of Klebsiella pneumoniae and Acinetobacter 
baumanii to antibiotic exposure25. Although the N. gonorrhoeae transcriptome has been 
previously sequenced26,27, to our knowledge, no one has characterized the transcriptome 
response of N. gonorrhoeae to antibiotic exposure. Unlike most bacteria, N. gonorrhoeae 
lacks the classic transcriptional SOS response to DNA damage whereby DNA repair is 
induced and the cell cycle is arrested28,29. The SOS response promotes survival to certain 
antibiotic classes, such as the fluoroquinolones, which act by directly inhibiting DNA 
synthesis30. The recA or recA-like proteins are essential for the induction of the SOS 
response28. However, neither recA transcripts nor recA protein levels increase in N. 
gonorrhoeae upon exposure to DNA damaging agents31,32.  
 
In this work, we explore the transcriptome response of N. gonorrhoeae upon exposure to 
ciprofloxacin. Ciprofloxacin is a fluoroquinolone and functions by inhibiting the enzymes 
topoisomerase II (DNA gyrase) and topoisomerase IV, thereby inhibiting cell division33. 
Ciprofloxacin was chosen in this study to gain insight into transcriptional changes that 
occur upon DNA damage in an organism lacking the classic SOS response. Here, we 
address the following questions: (1) How does the transcriptome of N. gonorrhoeae 
respond to ciprofloxacin exposure? (2) What is the shortest antibiotic exposure time at 
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which we can still observe significant changes (>4-fold) in RNA expression? (3) 
Which transcripts provide the largest and most abundant fold-changes per cell, which is 
an important consideration for clinical samples that have low numbers of pathogens? (4) 
Will candidate markers respond consistently across a large pool of isolates with wide 
genetic variability? 
 
Results 
 
We used RNA-seq to study the transcriptome response of susceptible and resistant 
isolates of N. gonorrhoeae after 5, 10, and 15 min of ciprofloxacin exposure (Fig. 1). 
Each clinical isolate was initially split into two tubes, where one tube was exposed to the 
antibiotic (+) and the other served as the control with no antibiotic exposure (-). Samples 
were collected for RNA-seq prior to antibiotic exposure and every 5 min for 15 min. We 
calculated the fold change in gene expression between the control and treated samples – 
defined as the control:treated ratio (C:T ratio); genes that demonstrated significant fold-
change differences between the susceptible and resistant isolates were identified as 
differentially expressed. To account for biological variability, three pairs of susceptible 
and resistant isolates were used in this study. Candidate markers were selected from the 
pool of differentially expressed genes and were validated using droplet dPCR (see 
Methods). 
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Figure 4-1. The work flow for selection and validation of RNA markers for phenotypic 
measurements of antibiotic susceptibility and resistance. Susceptible and resistant isolates 
of Neisseria gonorrhoeae are exposed to antibiotics (ABX) for 5, 10, and 15 min. 
Samples are collected for RNA sequencing at time zero and every 5 min thereafter. 
Genes demonstrating fold changes in expression (control:treated ratio (C:T ratio)) greater 
than the threshold of significance (gray line) are identified as differentially expressed 
(blue: downregulated and orange: upregulated). Candidate markers are selected from the 
pool of differentially expressed genes and validated by digital PCR. 
 
Temporal shifts in global gene expression upon antibiotic exposure  
 
We observed global shifts in RNA expression in susceptible isolates in as early as 5 min 
after antibiotic exposure (Fig. 2a). The distribution of fold changes in gene expression 
levels (C:T ratios) indicated global shifts toward negative log2 fold-change values 
(downregulation). The magnitude of fold change at which most genes were distributed 
was approximately 2-fold. The tail of the distribution illustrates that a few genes 
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responded to antibiotic exposure with changes as large as 6-fold within 5 min. 
Increasing the antibiotic exposure time further shifted the distribution to larger negative 
log2 fold-change values. The transcriptional response in resistant isolates was tightly 
distributed around a fold-change value of 1 at every time point, indicating that the 
transcriptome of the resistant isolates did not respond significantly to antibiotic exposure 
(Fig. 2a).  
 
To identify genes that were differentially expressed between control and treated samples, 
we defined a threshold of significance (Fig. 2b). The threshold of significance took into 
account technical variability and was calculated from the C:T ratios at t = 0 min of all 
biological replicates that were sequenced (three susceptible and three resistant isolates). 
For each of the six gene expression datasets (one for each isolate), we plotted the  
-log2(C:T ratio) against the -log2(expression) for all genes and fit a negative exponential 
curve to the outer edge of each plot. We then averaged the curves from all six datasets 
and added a 90% confidence interval to the average curve by assuming a Gaussian fit for 
the error distribution, which we define as our threshold of significance. Genes with a  
-log2(C:T ratio) value above or below the upper and lower thresholds were identified as 
differentially expressed. Downregulated genes (fold changes below the significance 
threshold) appeared as early as 5 min after antibiotic exposure (blue dots, Fig. 2b). Two 
upregulated genes (fold changes above the significance threshold) appeared after 10 min 
of exposure (orange dots, Fig. 2b). 
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Figure 4-2. Temporal shifts in global gene expression upon ciprofloxacin exposure in 
Neisseria gonorrhoeae. (a) The distribution of −log2(C:T ratios) for a susceptible isolate 
(Sus) and resistant isolate (Res) at 0, 5, 10, and 15 min. (b) The fold change in gene 
expression between control and treated samples (C:T ratio) versus expression in the 
control sample at 0, 5, 10, and 15 min for one susceptible isolate and one resistant isolate. 
Genes with C:T ratios above or below the significance threshold are identified as 
differentially expressed (blue: downregulated; orange: upregulated). Thresholds for 
statistical significance of fold change (gray lines) are determined by fitting a negative 
exponential curve (with 90% confidence interval) to the outer edge of the −log2 C:T 
ratios measured at time zero (see Methods). 
 
Selection of candidate markers that are consistent in response and abundant 
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RNA expression in response to antibiotics can be heterogeneous among different isolates 
of the same species34; thus, it is important to select candidate markers from differentially 
expressed genes that respond consistently across isolates of N. gonorrhoeae. To identify 
these candidate markers, we exposed three different pairs of susceptible isolates 
(minimum inhibitory concentrations (MICs) <= 0.015mg/mL) and resistant isolates 
(MICs 2.0 mg/mL, 4.0mg/mL, and 16.0mg/mL) to ciprofloxacin for 15 min and extracted 
RNA for sequencing (see workflow in Fig. 1). We found 181, 41, and 410 differentially 
expressed genes in susceptible isolates 1, 2, and 3, respectively (Fig. 3a). Among the 
differentially expressed genes, 38 genes responded consistently across the three pairs of 
susceptible and resistant isolates (i.e. responses overlapped in all three susceptible 
isolates, whereas all three resistant isolates were non-responsive) (Supplementary Table 
S1 online). These genes spanned a variety of biochemical functions in the cell. We 
selected six candidate transcript markers for further analysis based on the following 
criteria: (1) high fold change; (2) high expression levels (>75 transcripts per million, 
TPM); and (3) representative of different biochemical pathways. The selected candidate 
markers were: porB (membrane protein), rpmB (ribosomal protein), tig (molecular 
chaperone), yebC (transcriptional regulator), pilB (pilus assembly ATPase), and cysK 
(cysteine synthase). The candidate marker with the highest abundance and largest fold 
change upon antibiotic exposure was porB, which is a membrane channel forming protein 
and the site of antibiotic influx into the cell35.  
 
A high level of gene expression was one of our criteria for selection of candidate markers 
from the sequencing data. High expression of candidate markers is not only important for 
sensitivity and limits of detection, but is particularly important for clinical samples with 
low numbers of pathogen cells. One of the advantages of RNA compared with DNA as a 
nucleic acid marker is its natural abundance in the cell. Because the gene expression 
values obtained from sequencing are relative values, our next step was to quantify the 
absolute copies per cell for the candidate markers. In our quantification approach we 
plated clinical isolate samples after 15 min of ciprofloxacin exposure to obtain cell 
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numbers in colony forming units (CFU/mL). We designed primers for the candidate 
markers (see Methods and Supplementary Table S2) and measured their absolute 
concentration using dPCR. The concentrations were converted to per cell values using the 
cell counts from plating (Fig. 3b). Additionally, we used the RNA sequencing data to 
obtain transcriptome-wide estimates of transcript copies per cell. In the sequencing 
approach, we added external RNA control consortium (ERCC) spike-ins to the lysis 
buffer step of the extraction protocol in order to capture any loss of RNA throughout the 
extraction steps. By linear regression we captured the relationship between ERCC copies 
added to the samples and ERCC quantified by sequencing. Using the linear regression, 
we converted gene expression values from RNA sequencing (in TPM) to approximate 
copy numbers per cell (see Methods). The transcript copies per cell estimated for the 
candidate markers using the sequencing approach were within the same order of 
magnitude as the absolute copies per cell measured by digital PCR (Fig. 3b). 
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Figure 4-3. Selection of candidate RNA markers for phenotypic antibiotic susceptibility 
testing in Neisseria gonorrhoeae and measurements of candidate marker abundances per 
cell (a) Genes that are differentially expressed (light blue) across three pairs of resistant 
and susceptible clinical isolates are identified as candidate markers (dark blue). Six 
candidate markers that span different biological functions were selected for validation 
(red). (b) Copies/cell values for the candidate markers are determined from RNA 
sequencing (red) and dPCR (gray) (see Methods). Data is shown for one pair of 
susceptible (S2) and resistant (R2) isolates at 15 min of ciprofloxacin exposure. 
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Validation of candidate markers by dPCR 
 
We next asked how the relative changes observed through RNA-seq compare with direct 
gene expression measurements by dPCR. We designed dPCR assays for candidate 
markers, which involved measuring the absolute expression of the candidate marker in 
both control and treated samples, and calculating the C:T ratio. In this assay, the 16S 
rRNA was also measured and used to normalize the C:T ratio of the candidate markers. 
In the three susceptible isolates that were sequenced we found that rRNA consistently 
showed the smallest fold change (<1.06) in response to ciprofloxacin compared with all 
other genes in N. gonorrhoeae. Therefore, to account for experimental variations in the 
antibiotic exposure and RNA extraction steps between control and treated samples, we 
used the 16S rRNA as an intracellular control for normalizing the C:T ratios (see 
Methods). We found that the C:T ratios measured by the dPCR assay agreed with the C:T 
ratios obtained through sequencing (Fig. 4), confirming that both approaches accurately 
capture the transcriptional response to antibiotic exposure.  
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Figure 4-4. Validation of the RNA sequencing approach using digital PCR (dPCR) with 
six candidate markers. Control:treated ratios (C:T ratios) determined by RNA sequencing 
(red) were validated against C:T ratios measured by dPCR (gray). The dPCR C:T ratios 
were normalized using ribosomal RNA (rRNA) by dividing the C:T ratio of the candidate 
marker by the C:T ratio of 16S rRNA. This normalization step is not required for 
sequencing data because the values are normalized by sequencing depth (see Methods). 
Markers were validated using two susceptible (S1 and S2) and two resistant (R1 and R2) 
isolates at 15 min of ciprofloxacin exposure. 
 
Validation of RNA markers across CDC isolates 
 
Finally, we asked whether candidate markers respond consistently across a large pool of 
isolates with genetic variability. We chose the two candidate markers with the highest 
abundances and fold changes (porB and rpmB) to determine the susceptibility of 49 
clinical isolates, with a wide range of MIC values (Supplementary Table S3 online), from 
the N. gonorrhoeae panel of the Centers for Disease Control (CDC) Antimicrobial 
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Resistance Isolate Bank. The MIC values were representative of the population-wide 
distribution values reported by the European Committee on Antimicrobial Susceptibility 
Testing36. We exposed each clinical isolate to ciprofloxacin for 10 min and measured the 
fold change in expression of the two candidate markers between the control and treated 
sample using dPCR (Fig. 5). Both markers correctly classified all 49 CDC isolates, based 
on Clinical and Laboratory Standards Institute (CLSI) breakpoint values, as 9 susceptible 
and 40 resistant strains. 
 
 
Figure 4-5. Antibiotic susceptibility testing of 49 clinical isolates using (a) porB, and (b) 
rpmB as RNA AST markers. Antibiotic susceptibility of 49 clinical isolates (9 susceptible 
and 40 resistant) from the Neisseria gonorrhoeae panel of the CDC Antimicrobial 
Resistance Isolate Bank was determined using the “normalized” C:T ratios (C:T ratio of 
marker/C:T ratio of 16S rRNA). Clinical isolates were exposed to ciprofloxacin for 10 
min and the concentration of RNA markers was measured by digital PCR. 
 
Discussion 
 
In this work, we demonstrate that antibiotic-responsive transcripts can be used as suitable 
markers for a rapid phenotypic AST in N. gonorrhoeae. 
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When characterizing the global transcriptional response of N. gonorrhoeae to antibiotic 
exposure, we observed a significant change in response in as early as 5 min. The nature 
of the response was a global downregulation in transcript levels. Among the candidate 
markers, all exhibited downregulation in response to ciprofloxacin. We specifically 
looked at gyrA and parC, which are known genotypic markers of resistance to 
ciprofloxacin, and differential expression was not observed. We also looked at the recA 
transcript because recA is one of the prominent genes in the SOS response, and as 
expected, because N. gonorrhoeae does not have a true SOS system28,29, we did not find 
recA levels to increase. Whereas recA is a specific cellular response to overcome DNA 
damage, the global downregulation that we observed suggests a general shift away from 
growth and cell proliferation. Among the 38 candidate markers, 15 were ribosomal 
proteins (including one of the top markers, rpmB), which play a prominent role in 
assembly and function of the ribosomes and are essential for cell growth. Mutations in 
ribosomal proteins have been reported to confer resistance to different classes of 
antibiotics37. Another top marker identified in this study was porB, which is a membrane 
channel forming protein (porin) responsible for uptake of small nutrients and the site of 
antibiotic influx into the cell. The expression of porins is highly regulated in response to 
environmental stimuli38. Reducing permeability to decrease intracellular antibiotic 
concentration is a known mechanism for bacteria to confer antibiotic resistance37. The 
downregulation of porB observed in this study can be attributed to a halt in growth 
processes caused by ciprofloxacin damage and possibly an attempt to reduce influx of 
antibiotic.  
 
A key aim of this study was to identify RNA markers that would yield a measurable 
response after only a short antibiotic exposure (<15 min) to ensure this approach can fit 
within the required timescale for a rapid AST. It is possible that longer exposure times 
could provide additional insight into the biological response of N. gonorrhoeae to 
ciprofloxacin, but this was not the focus of our study. Furthermore, the short exposure 
times potentially introduce a bias in selection of transcripts present at low abundances. 
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For transcripts present at high abundance to display the same fold change as low 
abundance transcripts, a substantially higher number of mRNA molecules must be 
transcribed, which would require longer timescales. As an example, a 4-fold change from 
1 to 4 transcripts requires 3 additional mRNA to be produced, whereas a 4-fold change 
from 20 to 80 requires 60 mRNA to be transcribed. This bias also holds true in 
downregulation, where mRNA continues to be transcribed in the control samples, 
whereas transcript levels drop in treated samples due to degradation of RNA, and/or a 
reduction in the rate of transcription. 
 
We identified candidate markers with consistent differential expression across three sets 
of susceptible and resistant pairs. Among the candidate markers, one of our criteria for 
selection was transcript abundance, which is of particular importance in clinical samples 
with low cell numbers. Furthermore, marker abundance affects measurement sensitivity 
and limits of detection, as has been previously demonstrated in AST methods based on 
quantification of DNA replication20. To measure the abundance of the candidate markers, 
we used both dPCR measurements and ERCC spike-ins for RNA sequencing to obtain 
approximate RNA copies/cell. Both methods yielded results within the same order of 
magnitude. To our knowledge this is the first quantitative measurement of RNA 
abundance per cell in N. gonorrhoeae.  
 
We separately validated the performance of the two most abundant candidate markers, 
porB and rpmB, with 49 clinical isolates. Both markers were consistent in their ability to 
correctly determine susceptibility or resistance of all 49 clinical isolates. porB 
demonstrated C:T ratios between 2.5 to 7 and rpmB demonstrated C:T ratios between 2 
and 6 after 10 min of antibiotic exposure in the nine susceptible clinical isolates. The 
large fold changes highlight the significance of using RNA response as an AST marker 
compared with quantification of DNA replication. Our previous work using dPCR 
quantification of DNA replication demonstrated C:T ratios between 1.2 and 2.4 for 15 
min of antibiotic exposure in E. coli20, which has a doubling time approximately 3 times 
shorter than N. gonorrhoeae.  
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We performed an alignment search of porB against other prokaryotes and found it to be 
specific to the Neisseria genus. AST markers should be specific to the pathogen of 
interest because additional bacterial species are likely to be present in clinical samples. 
Additional experiments with mixtures of bacteria would be required to further confirm 
the specificity of the markers identified in this study. We additionally measured the 16s 
rRNA to normalize C:T ratios, which inherently enables pathogen identification as well. 
A combination of identification and susceptibility testing in a single integrated platform 
is important for correct and rapid diagnosis.  
 
This paper demonstrates that RNA markers can be used to determine antibiotic 
susceptibility of N. gonorrhoeae after short antibiotic exposure times, a requirement for a 
rapid phenotypic AST. N. gonorrhoeae is a fastidious slow-growing organism, presenting 
challenges to growth-based AST methods. Additional work will be needed to yield a 
clinic-ready, rapid RNA-based AST for N. gonorrhoeae. Additional background matrices 
of clinical samples, both urine and swab samples, that could possibly affect speed and 
sensitivity of an AST, must be further evaluated. Digital isothermal chemistries, such as 
digital loop-mediated isothermal amplification (dLAMP) should be considered to speed 
up quantification times relevant to point-of-care settings20. Follow-up studies should also 
examine the transcriptional response of N. gonorrhoeae to other classes of antibiotics and 
identify responsive RNA markers for class-specific antibiotics. Overall, as a first step, the 
work described here demonstrates the promise for a phenotypic RNA-based approach for 
a rapid AST of N. gonorrhoeae at the point-of-care, which is critically needed for disease 
management, surveillance, and antibiotic stewardship. 
 
Methods 
 
Antibiotic exposure for RNA sequencing 
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Antibiotic susceptible and resistant clinical isolates were obtained from the University 
of California, Los Angeles, Clinical Microbiology Laboratory. Isolates were plated from 
glycerol stocks onto Chocolate Agar plates and grown in static incubation overnight (37 
°C, 5% CO2). Cells were re-suspended in Hardy Fastidious Broth (HFB) and incubated 
for 45 min (37 °C, 5% CO2) with shaking (800 rpm) to an OD600 between 1 and 5. 
Cultures were diluted (5X) into HFB. Each isolate culture was split into “treated” and 
“control” tubes. Ciprofloxacin was added to the “treated” tubes (final concentration of 0.5 
µg/mL) and water was added to the “control” tubes; cultures were incubated (static; 37 
°C, 5% CO2) for 15 min. During incubation, samples were collected for RNA sequencing 
at 5, 10, and 15 min (300 µL aliquot of sample was mixed into 600 µL of Qiagen RNA 
Protect Reagent (Qiagen, Hilden, Germany) for immediate RNA stabilization). In 
addition, a sample was collected for RNA sequencing immediately before ciprofloxacin 
was added. To quantify CFU, the sample at t = 15 min was serially diluted (10x), plated 
on a Chocolate Agar plate, and incubated overnight (37 °C, 5% CO2). 
 
Antibiotic exposure for clinical isolates 
 
Antibiotic susceptible and resistant clinical isolates were obtained from the N. 
gonorrhoeae panel of the CDC Antimicrobial Resistance Isolate Bank. Isolates were 
plated from glycerol stocks onto Chocolate Agar plates and grown in static incubation 
overnight (37 °C, 5% CO2). Cells were re-suspended in pre-warmed HFB + 5 mM 
sodium bicarbonate and incubated for 30 min (37 °C, 5% CO2) with shaking (800 rpm) to 
an OD600 between 1 and 5. Cultures were diluted (100X) into HFB + 5 mM sodium 
bicarbonate. Each isolate culture was split into treated (0.5 µg/mL final concentration of 
ciprofloxacin) and control (water instead of antibiotic) samples. Samples were incubated 
at 37 °C for 10 min on a static hot plate. A 90 µL aliquot of each sample was placed into 
180 µL of Qiagen RNA Protect Reagent for immediate RNA stabilization. A 5 µL aliquot 
of each sample was plated onto a Chocolate Agar plate and incubated overnight (37 °C, 
5% CO2) as a control for the exposure experiments. If the expected growth phenotypes 
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(i.e. resistant = growth; susceptible = no growth) were not observed for any single 
sample in the plating control, the exposure experiment was repeated for the set of 
samples. From the 50 total isolates available from the N. gonorrhoeae panel of the CDC 
Antimicrobial Resistance Isolate Bank, 49 were used in this study. One isolate was 
excluded from this study because we suspected that it had been contaminated; we did not 
detect porB primer amplification using qPCR.  
 
RNA sequencing and analysis 
 
RNA was extracted using the Enzymatic Lysis of Bacteria protocol of the Qiagen 
RNeasy Mini Kit and processed according to the manufacturer’s protocol. DNA digestion 
was performed during extraction using the Qiagen RNase-Free DNase Set. The quality of 
extracted RNA was measured using an Agilent 2200 TapeStation (Agilent, Santa Clara, 
CA, USA). Extracted RNA samples were prepared for sequencing using the NEBNext 
Ultra RNA Library Prep Kit for Illumina (New England Biolabs, Ipswitch, MA, USA) 
and the NEBNExt Multiplex Oligos for Illumina. Libraries were sequenced at 50 single 
base pair reads and a sequencing depth of 10 million reads on an Illumina HiSeq 2500 
System (Illumina, San Diego, CA, USA) at the Millard and Muriel Jacobs Genetics and 
Genomics Laboratory, California Institute of Technology. Raw reads from the sequenced 
libraries were subjected to quality control to filter out low-quality reads and trim the 
adaptor sequences using Trimmomatic (version 0.35). The reads were aligned to the FA 
1090 strain of N. gonorrhoeae (NCBI Reference Sequence: NC_002946.2) using 
Bowtie2 (version 2.2.5) and quantified using the Subread package (version 1.5.0-p1). A 
pseudocount of 1 was added to the gene quantification; gene expression was defined in 
transcripts per million (TPM).  
 
Marker selection 
 
For each gene, we defined the C:T ratio as the gene expression (TPM) in the control 
sample divided by the gene expression (in TPM) in the treated sample. We plotted the -
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log2(C:T) against the -log2(expression in TPM) for all genes. To identify genes that 
were differentially expressed between control and treated samples, we defined a threshold 
of significance. The threshold of significance was calculated from the C:T ratios at t = 0 
min for the biological replicates that were sequenced (three susceptible and three resistant 
isolates). For each of the six gene expression datasets (one for each isolate), we fit a 
negative exponential curve to the outer edge of each plot and then averaged the curves 
from all six datasets. Finally, we added a 90% confidence interval to the average curve by 
assuming a Gaussian fit for the error distribution, which is our threshold of significance. 
Genes with a -log2(C:T) value above or below the upper and lower thresholds were 
identified as differentially expressed. Genes that were differentially expressed 
consistently (either always above or always below the thresholds) among the three 
susceptible isolates and were not differentially expressed among the three resistant 
isolates were defined as candidate markers.  
 
Copies/cell measurements from sequencing 
 
To measure copies per cell using sequencing data, we added 2uL of (1/1000 dilution) 
ERCC RNA Spike-In Mix (Thermo Fisher Scientific, Waltham, MA, USA) to the lysis 
buffer in the RNeasy Mini Kit to each individual sample. We calculated the number of 
copies of each ERCC transcript in the sample, by accounting for dilution and multiplying 
by Avogadro's number (manufacturer’s concentrations were reported in attomoles/µL). 
We plotted the relationship between log2(ERCC copies added) against log2(gene 
expression in TPM) and performed a linear regression in the region of linearity. We used 
the linear regression to convert TPM values to total RNA copies in each sample. Finally, 
using the CFU measured for each sample from plating (described in the “Antibiotic 
exposure for RNA sequencing” section), the total RNA copies were converted to copies 
per cell.  
 
Validation with droplet digital PCR (dPCR) 
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Primers were designed for candidate markers using Primer-BLAST39 and primer 
alignments were verified using SnapGene. Expression of candidate markers was 
quantified using the Bio-Rad QX200 droplet dPCR system (Bio-Rad Laboratories, 
Hercules, CA, USA). The concentration of the components in the dPCR mix used in this 
study were as follows: 1× EvaGreen Droplet Generation Mix (Bio-Rad), 150U/mL 
WarmStart RTx Reverse Transcriptase, 800U/mL RiboGaurd RNase Inhibitor, 500 nM 
forward primer, and 500 nM reverse primer. The RNA extraction comprised 5% of the 
final volume in the dPCR mix. The remaining volume was nuclease-free water. For each 
isolate, candidate marker expression was quantified in the control and treated samples 
and the fold-change difference (C:T ratio) was calculated. To account for potential 
differences between the control and treated samples that could arise from experimental 
variability and extraction efficiency, we used ribosomal RNA (rRNA) as an internal 
control because from our sequencing data, we found that rRNA was not affected by 
antibiotic exposure in the time frame of this study. To normalize by rRNA, we quantified 
the 16S rRNA in the control and treated samples by dPCR and calculated an rRNA C:T 
ratio. We then divided the C:T ratio of each marker by the rRNA C:T ratio. All dPCR 
C:T ratios reported in this paper are the normalized C:T ratios. 
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Chapter V 
 
Differential DNA Accessibility to Polymerase Enables 30-minute 
Phenotypic β-lactam Antibiotic Susceptibility Testing of Carbapenem-
resistant Enterobacteriaceae4 
 
Abstract 
 
The rise in carbapenem-resistant Enterobacteriaceae (CRE) infections has created a 
global health emergency, underlining the critical need to develop faster diagnostics to 
treat swiftly and correctly. Although rapid pathogen-identification tests are being 
developed, gold-standard antibiotic susceptibility testing (AST) remains unacceptably 
slow (1–2 days). Here, we develop the pol-aAST (polymerase-accessibility AST), a new 
phenotypic approach for β-lactams, the major antibiotic class for Gram-negative 
infections. The pol-aAST quantifies differences in accessibility of nucleic acids to 
polymerase during amplification after brief antibiotic exposure, yielding the fastest 
nucleic-acid-based phenotypic AST ever demonstrated for β-lactams. We test the three 
pathogens causing CRE infections using ceftriaxone, ertapenem, and meropenem, and 
show 100% agreement with gold-standard AST. Importantly, pol-aAST correctly 
categorized resistant isolates undetectable by current genotypic methods (negative for β-
lactamase genes or lacking predictive genotypes). To illustrate clinical potential, we show 
that the pol-aAST can be performed in 30 min sample-to-answer using contrived urine 
samples. 
 
Introduction 
 
                                               
4This chapter was submitted for publication with authorship belonging to Nathan G. Schoepp, Eric J. Liaw, 
Emily S. Savela, and Rustem F. Ismagilov. 
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The evolution and global spread of carbapenem-resistant Enterobacteriaceae (CRE) 
threatens to disrupt modern healthcare systems, which rely heavily on b-lactams 
(especially carbapenems, the last-resort treatments) to control bacterial infections.3-5 
Mortality rates for CRE infections are as high as 30–49%6-8, and thus the global 
emergence and spread of CRE infections represents a public health emergency.9-11 The 
CDC places CRE in its highest (“urgent”) category of antimicrobial-resistant pathogen 
threats10, 13 and the World Health Organization (WHO) labels CRE as a critical-priority 
pathogen9. Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp. compose the 
majority of CRE infections, and are the most commonly monitored Enterobacteriaceae10, 
14-16. 
 
To halt the further spread of CRE, patients need to be treated swiftly and correctly at the 
point of care (POC); however there is no fast and general method for determining 
antibiotic susceptibility17-19. The current clinical workflow for treatment of bacterial 
infections consists of an identification (ID) step followed by an antibiotic susceptibility 
test (AST). Although progress is being made to develop faster ID tests20-22 and a rapid 20-
min ID test is on the horizon23-25, the gold-standard for AST remains a culture-based 
workflow using broth or agar dilution that requires 1–2 days and is thus far too slow26-27. 
Because AST results are so delayed, health care providers usually treat empirically, 
leading to inappropriate prescriptions and even life-threatening outcomes,28 and the 
further spread of resistance. To improve treatment and promote antibiotic stewardship, 
healthcare providers need a rapid phenotypic AST29-31.  
 
ASTs are either genotypic or phenotypic. Genotypic tests predict resistance by measuring 
the presence of genes known to be involved in resistance. Genotypic tests can be fast32, 
but often have limited clinical utility because they target defined mechanisms of 
resistance. For example, rapid genotypic methods to detect Gram-negative b-lactamase 
genes have been developed33-36, but these tests only detect one of the many known b-
lactamase classes, and still require 30–40 min (estimated from described methods). 
Similarly, the commercial Cepheid Xpert® Carba-R assay, which detects five b-
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lactamase gene families, and was shown to detect 50% of resistant isolates and took 
88 min37. Moreover, although Carba-R is FDA-approved, its utility in treatment scenarios 
is limited (i.e., negative results are not actionable) so when prescribing antibiotics, it must 
be used in conjunction with a phenotypic AST38-39. Rapid methods for measuring the 
activity of specific b-lactamases also exist40-44. However, these tests only detect one 
mechanism of resistance, and sample-to-answer times have not been reported.  
 
Phenotypic ASTs are ideal because they measure susceptibility directly by exposing the 
sample to antibiotics (ABX) and measuring the target organism’s response. The gold-
standard AST (broth microdilution26-27) is a phenotypic test. Most phenotypic tests 
require the growth of viable organisms isolated from patient samples, a process that 
requires days and is thus too slow for the POC. Innovative, faster phenotypic tests for b-
lactams were developed based on in situ nucleic-acid staining or fluorescence 
measurements45-47, flow cytometry48, microscopy49-50, and mass spectrometry51. 
However, majority of the currently proposed methods still require 60–180 min ABX-
exposure steps in addition to the time needed to perform the assay, and no method has 
emerged that requires short (~15 min) ABX exposure, short (~15 min) assay time, and 
does not require excessively complex or delicate instrumentation so the method can be 
deployed at the POC. 
 
Rapid phenotypic methods based on quantification of nucleic acids (NAs) have shown 
great promise for a rapid POC AST due to the speed, specificity, and robustness of NA 
detection52-56.  There is an additional advantage to using NA quantification as a readout 
of the bacterial response to antibiotic: because rapid pathogen identification (ID) from 
clinical samples is commonly performed via NA analysis, therefore it would likely be 
easier to integrate NA-based phenotypic AST into a combined ID/AST workflow 
performed from the same clinical sample.  For ABX that directly or indirectly impact NA 
replication on short time scales, we have demonstrated that the quantification of DNA57-58 
or RNA59 can be used to rapidly (30 min) and reliably determine susceptibility to 
nitrofurantoin and/or ciprofloxacin. Subsequent efforts have targeted the b-lactam class 
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(the most widely prescribed class of ABX3-4) using these methods60. However, 
because b-lactams do not directly impact NA replication on short time scales, this direct 
translation of the existing NA-based technique required a two-hour antibiotic exposure, 
which is not sufficiently rapid for POC. For a POC AST to impact management of CRE 
infections, it must (i) determine susceptibility to b-lactams, including carbapenems; (ii) it 
must be rapid (< 30 min sample-to- answer)61-62; and (iii) it must be phenotypic (agnostic 
to resistance mechanism)29, 63.  As discussed below, rapid pathogen ID technologies are 
becoming available and therefore pathogen ID is not the focus of this work.   
 
Here, we hypothesized that a new NA-based approach could be used to develop a rapid 
phenotypic AST for multiple b-lactams. Knowing that susceptible bacteria have 
compromised cell walls as a result of exposure to b-lactams; we predicted that more NAs 
would be released from susceptible cells than from resistant bacteria, thus yielding faster 
amplification. Rather than measuring how total NA concentration is impacted by ABX 
exposure (as in previous NA-based ASTs), we hypothesized that we could measure the 
accessibility of NAs to polymerase following a short ABX exposure. To validate the 
method, termed pol-aAST (polymerase-accessibility AST), we perform 70 ASTs using 
clinical isolates of three major CRE pathogens exposed to each of three commonly 
prescribed b-lactams for Gram-negative infections: ceftriaxone (CRO), ertapenem (ETP), 
and meropenem (MEM). To further demonstrate clinical relevance (i.e., POC timescales), 
we perform timed sample-to-answer experiments using contrived urine samples to ensure 
the whole assay can be performed in < 30 min. 
 
Results 
 
The pol-aAST relies on differential accessibility of nucleic acids to polymerases as a 
result of ABX exposure. In this manuscript, we define differential accessibility to 
polymerase as a difference in the measured rate of amplification between control and 
ABX-treated samples. In the first step of pol-aAST, a single sample is split into control 
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and treated aliquots of equal volume, and the treated aliquot is exposed to a b-lactam. 
ABX-exposure is a critical step in any phenotypic AST because phenotypic tests measure 
the response of bacteria to ABX. If the bacteria in the sample are resistant, we 
hypothesized that no differences in NA amplification will be observed between control 
and treated aliquots. If the bacteria are susceptible, we hypothesized that ABX treatment 
would lead to a compromised peptidoglycan cell wall (Fig. 1a) and partial release of NAs 
(Fig. 1b). We hypothesized that both the compromised cell wall and partial release of 
NAs would increase the accessibility of NAs to polymerase in a treated ABX-susceptible 
aliquot. In the second step of pol-aAST, control and treated aliquots are exposed to 
polymerase in amplification conditions (Fig. 1c) and the rate of amplification is 
measured.  
 
 
Fig. 5-1. Overview of pol-aAST shown for susceptible (S) and resistant (R) samples 
exposed to b-lactams. (a) Treated aliquots are exposed to a b-lactam. In susceptible 
samples, b-lactams compromise cell wall integrity. (b) Nucleic acids (NAs) are released 
from compromised cells, increasing NA accessibility to polymerase. (c) Released NAs in 
the susceptible treated aliquot amplify faster than NAs from intact cells in the control 
aliquot (not shown), resulting in a difference in time-to-positive. No difference in 
amplification between control and treated aliquots is observed in resistant samples. (d) 
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Time-to-positive difference (TTPD) between control and treated aliquots is used to 
assess susceptibility. 
 
To successfully differentiate susceptible and resistant samples, ideal amplification 
conditions must i) not fully lyse cells, ii) enhance alterations (damage) to the cell wall 
caused by exposure to b-lactams, and iii) increase NA release only from ABX-damaged 
cells. The rate of amplification is dependent on the concentration of polymerase-
accessible NA. In susceptible samples, more NAs are released in treated aliquot, leading 
to faster amplification in susceptible treated aliquots (Fig. 1d) relative to control. 
Resistant samples are not affected by the ABX, so control and treated aliquots have 
similar NA release and amplification rate. Amplification rate in an isothermal 
amplification reaction is quantified by measuring the time-to-positive (TTP), the time it 
takes the reaction fluorescence to reach a predetermined threshold. We found that using 
pol-aAST, isolates susceptible to the b-lactam being tested show increased accessibility 
of NAs to polymerase, manifesting in an earlier TTP relative to the control. The TTPs of 
any two samples, such as the control and treated aliquots, can be compared to generate a 
TTP difference value (TTPD), which can then be used to determine susceptibility by 
comparing to a susceptibility threshold. Here we use the DNA polymerase Bst 3.0 under 
loop-mediated isothermal amplification (LAMP) conditions. 
 
We hypothesized that the chemical environment in which amplification occurs would 
significantly impact the result of pol-aAST, and that for pol-aAST to differentiate 
susceptible and resistant samples, amplification conditions should not be fully lysing. To 
test this, we performed pol-aAST using LAMP, and quantitative PCR (qPCR) (Fig. 2). 
LAMP is performed at a single temperature (70 °C), which we hypothesized would not 
be fully lysing, whereas qPCR is a thermocycled amplification technique reaching a 
maximum temperature of 95 °C, which we hypothesized would be fully lysing. Indeed, 
we observed that pol-aAST was successful in differentiating susceptible and resistant 
isolates when performed using LAMP, but not when performed using qPCR (Fig. 2). We 
tested qPCR with a total of two susceptible and two resistant isolates, none of which 
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showed a statistically significant difference in Cq between control and treated 
samples. When using LAMP, detectable differences were observed between control and 
treated aliquots when using isolates susceptible to the target b-lactam (TTPD = 1.02 
min). These differences confirm that choice of amplification chemistry is critical to the 
success of pol-aAST. 
 
 
Fig. 5-2. Polymerase-accessibility AST requires non-lytic amplification conditions. (a–b) 
Thermal profiles of LAMP and PCR. (c–d) LAMP and PCR amplification curves for a 
susceptible isolate exposed to ertapenem (ETP). A difference in time-to-positive (TTP) 
for control and treated aliquots is observed for susceptible isolates when quantifying 
nucleic acids using LAMP, but not PCR. 
 
To investigate the mechanism of pol-aAST, we performed experiments to separate free 
NAs from NAs contained within structurally intact cells or associated with cell debris. 
Susceptible and resistant clinical isolates were exposed to b-lactams for 15 min, then 
filtered through 0.2 µM filters to remove cells from free NAs. NAs in the sample and 
eluate were then quantified using droplet digital PCR (ddPCR). We observed that 
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following exposure to b-lactams, susceptible isolates treated with b-lactams released a 
significantly larger percentage of DNA than resistant samples (Fig. 3). The amount of 
DNA released depended on the ABX being tested. Exposure to meropenem resulted in an 
average of 21% of DNA being released from susceptible isolates, with a slightly smaller 
average percent (15%) released as a result of exposure to ertapenem. Interestingly, 
susceptible samples only released an average of 6% of DNA when exposed to CRO, 
demonstrating that NA release is dependent on choice of ABX and not, e.g., a universal 
stress response. These results also demonstrate that the magnitude of the effect of a b-
lactam on cell wall integrity can be measured and is different depending on the ABX 
used, even on short exposure time scales. 
 
 
Fig. 5-3. Percentage of DNA released following antibiotic exposure. Two susceptible (S) 
and two resistant (R) E. coli isolates were exposed to no antibiotic (control), ceftriaxone 
(CRO), ertapenem (ETP), or meropenem (MEM) for 15 min before filtering to separate 
intact cells from extracellular DNA. Experiments were performed in triplicate for all 
isolate/antibiotic combinations. 
 
  
126 
To validate the pol-aAST method, we performed 70 ASTs using 12 clinical isolates of 
Escherichia coli (Ec), 8 clinical isolates of Klebsiella pneumoniae (Kp), and 5 clinical 
isolates of two species of Enterobacter (Ebs) and the b-lactams CRO, ETP, and MEM. 
The set included isolates from each genus that were susceptible and isolates that were 
resistant to each of the three antibiotics. In addition to isolates obtained from the UCLA 
Clinical Microbiology Laboratory (see Methods in SI), those tested included Ec and Kp 
isolates from the Centers for Disease Control (CDC) Enterobacteriaceae Carbapenem 
Breakpoint panel12, as well as all available Enterobacter spp. isolates from the same 
panel. All samples were amplified using quantitative LAMP and categorical agreement 
was compared to gold-standard broth microdilution AST. Two approaches for 
determining susceptibility were investigated in all pol-aASTs performed. 
 
The first approach we investigated was to compare the difference in TTP values of the 
control and treated aliquots in each pol-aAST. This difference was defined as TTPDCT 
(Fig. 4a). Using this method, we obtained 100% categorical agreement with gold-
standard AST for all antibiotics tested with Ec (Fig. 4b), Kp (Fig. 4c), and Ebs (Fig. 4d) 
isolates. The values of TTPDCT were well-separated between susceptible and resistant 
isolates in all CRE-ABX combinations. Note that the threshold values separating TTPDCT 
of susceptible and resistant isolates depend on the antibiotic used (e.g. CRO gives a 
smaller response and therefore requires a lower threshold), as well as the pathogen tested 
(e.g. K. pneumoniae gives stronger response and requires a higher threshold).  The area 
under the curve (AUC) of the receiver operating characteristic (ROC) curve was 1.00 for 
all isolates and antibiotics tested. There were no errors relative to gold-standard AST 
when determining susceptibility by TTPDCT. 
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Fig. 5-4. Validation of the pol-aAST method using control (ctrl) and antibiotic-treated 
(+ABX) aliquots. (a) Example calculation of time-to-positive difference (TTPD) between 
control and treated aliquots (TTPDCT). The TTP (in minutes) of the control and treated 
aliquots are used to calculate TTPDCT. (b–d) The pol-aAST results using Escherichia coli 
(b), Klebsiella pneumoniae (c), and Enterobacter spp. (d) isolates exposed to ceftriaxone 
(CRO), ertapenem (ETP), and meropenem (MEM). Red points represent isolates with 
either no detectable carbapenemase genes (Ec and Kp isolates) according to a published 
genotypic assay1 and commercial assay,2 or no predictive genotype (Ebs isolates) 
according to the whole genome sequencing by the CDC.12 S/R thresholds (dashed lines) 
were set halfway between the lowest susceptible (S) and the highest resistant (R) 
TTPDCT values. 
 
The second approach we investigated was to compare the difference in the TTP of a fully 
lysed control aliquot and the antibiotic-treated aliquot in each pol-aAST. The fully lysed 
control aliquot was created by extracting NA from an aliquot of the ABX-treated sample 
using a single-step, LAMP-compatible extraction buffer. This difference was defined as 
TTPDLT (Fig. 5a). It is important to note that TTPDLT only requires the antibiotic-treated 
sample from the exposure step, meaning the original sample does not have to be split 
prior to exposure. Again, the thresholds were defined individually for each antibiotic and 
pathogen. Using this method, we obtained 100% categorical agreement with gold-
standard AST for all antibiotics tested with Ec (Fig. 5b) and Kp (Fig. 5c) isolates. When 
testing Ebs (Fig. 5d) isolates, we observed a single error in which an isolate classified as 
CRO-resistant was called as susceptible, resulting in an overall categorical agreement of 
92%. Because of this error, the AUC for Ebs isolates tested with CRO was 0.75. Aside 
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from this error, susceptible and resistant isolates were well separated in all cases, with 
AUC = 1.000 for all antibiotics tested with Ec and Kp. Although we observed a single 
error, using the TTPDLT metric still gave excellent agreement with gold-standard AST 
and required no splitting of the sample prior to exposure. 
 
 
Fig. 5-5. Validation of the pol-aAST method using lysed control (lc) and antibiotic-
treated (+ABX) aliquots. (a) Example calculation of time-to-positive difference (TTPD) 
between the lysed-control and antibiotic-treated aliquots (TTPDLT). The TTP (in minutes) 
in the lysed-control and antibiotic-treated aliquots are used to calculate TTPDLT (b) pol-
aAST results using Escherichia coli isolates exposed to CRO, ETP, and MEM. (c) pol-
aAST results using Klebsiella pneumonia isolates exposed to CRO, ETP, and MEM. (d) 
pol-aAST results using Enterobacter spp. isolates exposed to CRO, ETP, and MEM. For 
Ec and Kp isolates, 100% categorical agreement was obtained compared to gold-standard 
broth microdilution AST. For Ebs isolates, 92% categorical agreement was obtained. Red 
points represent isolates with either no detectable carbapenemase genes (Ec and Kp 
isolates) according to a published genotypic assay1 and commercial assay,2 or no 
predictive genotype (Ebs isolates) according to the CDC12. S/R thresholds (dashed lines) 
were set halfway between the lowest susceptible (S) and the highest resistant (R) TTPDLT 
values. 
 
To demonstrate one of the major differences between pol-aAST, a phenotypic method, 
and existing genotypic methods, we challenged the assay with five previously 
characterized isolates that had either i) no detectable b-lactamase genes or ii) lacked any 
genotypic signature predictive of b-lactam resistance. We tested two Ec and two Kp 
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isolates with no detectable b-lactamase genes as measured by both a published 
genotypic assay designed to screen for six b-lactamase gene families1, as well as the 
Cepheid Xpert® Carba-R test (a commercial, FDA-approved genotypic assay designed to 
screen for five b-lactamase gene families).2  These four isolates did not test positive in 
either assay because they lack the genes these assays screen for, despite being resistant 
(as determined by gold-standard broth microdilution). These four tested isolates were 
resistant to CRO and ETP, and one isolate from each genus was also resistant to MEM. 
Additionally, we tested a single resistant Ebs isolate from the CDC Enterobacteriaceae 
Carbapenem Breakpoint Panel (AR-Bank #0007). Whole genome sequencing of this 
isolate (performed by the CDC) revealed no known resistance markers12, meaning the 
mechanism of resistance was uncharacterized. The pol-aAST performed excellently in all 
cases, and all 5 isolates were correctly categorized as resistant (Figs. 4, 5, red points). 
 
To investigate the sample-to-answer time of the pol-aAST, we performed timed 
experiments using contrived urine samples (Fig. 6). Sample-to-answer time is a critical 
metric for any assay designed to be used at the point of care (POC), but is often not 
reported at all, even for methods claiming to be rapid. In timed experiments, we i) 
reduced the exposure time from 15 to 14 min to ensure all handling could be performed 
during the 15 min aliquoted for exposure, and ii) used an automated data-analysis 
spreadsheet to provide a susceptibility call as soon as the LAMP reactions reached a pre-
determined threshold (indicating successful amplification). At the start of pol-aAST, a 
timer was started which ran for the duration of the experiment and was stopped once a 
susceptibility call had been made. The susceptibility of four isolates to ETP was tested 
simultaneously (Fig. 6a). The pol-aAST consists of only three simple handling steps (Fig. 
6b-d), which allowed us to perform pol-aAST in a total time of just 29.5 min, with results 
in agreement with gold-standard AST (Fig. 6e). 
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Fig. 5-6. Timed sample-to-answer pol-aAST using contrived urine samples spiked with 
either E. coli (Ec) or Klebsiella pneumoniae (Kp). (a) Due to the minimal sample 
handling throughout pol-aAST, all four contrived urine samples were run in parallel. (b) 
Urine samples were split into control and antibiotic-treated aliquots and incubated at 37 
°C for 15 min. A timer was started immediately after sample splitting. (c) All samples 
were added to pre-made LAMP mix and run in triplicate. (d) Samples were amplified 
using LAMP and the fluorescence of reactions was monitored in real-time. Once total 
fluorescence passed a pre-determined threshold (indicating successful amplification), 
reactions were stopped and TTP values ported into an automated data-analysis 
spreadsheet. The timer was stopped as soon as the spreadsheet gave susceptibility calls. 
(e) Comparison of susceptibility calls with gold-standard AST categorization. Total assay 
time was 29.5 min. 
 
Discussion 
 
The pol-aAST method enables rapid, organism-specific measurement of susceptibility to 
b-lactams—the most important class of ABX for Gram-negative infections—thus 
providing the critically missing piece needed to develop a POC AST for this global health 
threat. The genera of isolates and the b-lactams used in this proof-of-concept study were 
intentionally chosen to broadly validate the pol-aAST: E. coli (Ec), K. pneumoniae (Kp), 
and the Enterobacter species E. aerogenes and E. cloacae (collectively Ebs), are 
responsible for the majority of CRE infections globally10, 14-16 (in some areas of the U.S. 
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Kp  is responsible for up to 90% of CRE infections7). It is for this reason that Ec, Kp, 
and Ebs together make up the majority of isolates in the CDC’s Enterobacteriaceae 
Carbapenem Breakpoint panel, a collection of isolates designed specifically to challenge 
carbapenem-susceptibility tests in Enterobacteriaceae12.  CRO, used broadly for a variety 
of infections because of its broad coverage and tolerability, was chosen as a 
representative third-generation cephalosporin. Similarly, ETP and MEM were chosen as 
clinically representative carbapenems64. 
 
The pol-aAST has two important requirements: i) amplification conditions that are not 
fully lytic and ii) release of NAs only from cells that are susceptible to the b-lactam to 
which they are exposed. If cells fully lyse, as they do in PCR, there is no difference in 
amplification between control and treated aliquots in susceptible isolates (Fig. 2). It is 
only under partial-lysis conditions, as in LAMP, that cell integrity is preserved long 
enough to yield a substantial TTP difference. In partial-lysis conditions, most NAs are 
still protected inside cells in the control aliquot, whereas a significant portion of NAs are 
released and start amplifying immediately in the treated aliquot. We know from previous 
work58 that the speed of an optimized bulk LAMP reaction makes it is difficult to linearly 
correlate TTP and NA concentration, unless very sensitive real-time measurements are 
made. Based on the magnitude of the differences in TTP observed here and the results 
measuring NA release (Fig. 3), we suspect that both the state of NA (inside intact cells 
vs. inside or outside damaged cells) and the differences in concentration of free NA 
contribute to the TTP differences observed. Cell-wall defects and damage are also likely 
to increase the penetration of amplification reagents into DNA trapped inside the remains 
of susceptible treated cells especially under the elevated temperature of the amplification 
reaction. We chose LAMP because we have shown previously that it is a rapid and 
specific isothermal amplification chemistry58. However, other non-lytic isothermal 
amplification chemistries could also be investigated. Additionally, DNA release (Fig. 3) 
could be measured to determine susceptibility using PCR if combined with a filtration 
step; we have not evaluated the pros and cons of this approach in this paper. 
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To demonstrate the flexibility of the pol-aAST method and the simplicity of the 
workflow, we investigated two approaches for determining susceptibility. The first, 
measuring TTPDCT, gave 100% categorical agreement and uses a standard ABX-
exposure step wherein one aliquot serves as the control and the other aliquot is exposed 
to an ABX. The second, measuring TTPDLT, differs in that only a single aliquot of the 
original sample is used during the ABX-exposure step. After exposure, this aliquot is 
compared with a fully lysed control aliquot, which could be extracted at any point during 
the assay. Using only a single aliquot of the original sample during exposure reduces the 
challenges of fluid handling and metering, which will be valuable when developing fully-
integrated devices. When using a control and treated aliquot, both aliquots must have 
precisely equal volumes, and the heating required during exposure must be performed on 
both aliquots. Using a single aliquot means only one solution would need to incubated 
which i) reduces the complexity of temperature control and ii) reduces fluid handling 
complexity. Both methods showed excellent categorical agreement with gold-standard 
broth microdilution, and the choice of approach will be dictated by future device 
architecture. 
 
To illustrate the generality of the method, we evaluated pol-aAST using isolates that 
tested negative for b-lactamase genes and isolates that lack a predictive genotype (e.g., no 
b-lactamase production, no modified porins, no modified penicillin-binding proteins), 
based on  published and commercial genotypic assays,1 and CDC classification based on 
the ResFinder database65 respectively. The ABX-susceptibility of isolates lacking beta-
lactamases cannot be detected by current, FDA-approved genotypic methods, yet bacteria 
that do not produce beta-lactamases can comprise 11–71% of CRE infections.6, 66-67 
Using pol-aAST, (which, like all phenotypic ASTs is agnostic to the mechanism of 
resistance), all five of these isolates were correctly categorized as resistant. 
 
Sample-to-answer time directly reflects the speed of diagnostics in practice, and is a 
major factor in how likely a diagnostic is to be adopted. In general, the shorter the 
sample-to-answer time, the more valuable the test is, and the more feasible for use at the 
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POC. With urine as the contrived sample matrix, pol-aAST was able to be completed 
in < 30 min. This time scale is on par both with suggested time-frames for rapid POC 
diagnostics61-62, and measured times of patient visits68. Additionally, because urine 
involves relatively simple sample-handling steps, we were able to perform four ASTs in 
parallel. The ability to run several samples in parallel demonstrates the potential to 
multiplex with isolates and antibiotics, which will be important for the next steps, 
including the design of integrated devices. 
 
The pol-aAST method is the first demonstration of a rapid NA-based phenotypic AST for 
b-lactams and CREs. As with any academic report of an innovative diagnostic 
technology development, this work has limitations in the breadth of its scope and level of 
technological maturity. The following work would further extend the clinical 
applicability of this study, and will be necessary for translation into a system suitable for 
regulatory approval and clinical use.  First, this proof-of-concept used contrived urine 
samples (clinical isolates of pathogens spiked into healthy urine) because they are easier 
to obtain and reduce the cost and complexity of running experiments at the early, proof-
of-concept stage. Although contrived samples are accepted by the FDA as a part of 
regulatory clinical studies and submissions69, the pol-aAST needs to be further evaluated 
with fresh clinical urine samples from patients. Urine is a relevant matrix for a CRE 
diagnostic because of the large number of hospital-acquired infections that involve 
catheters or other long-term indwelling medical devices14, where CRE infections cause 
major problems. Second, to expand the scope of this approach, other sample types such 
as blood and blood cultures should be tested (in combination with appropriate pathogen-
isolation and pathogen-enrichment technologies). Third, only categorical (S/R) agreement 
with the gold-standard method was tested here. While in the majority of cases a rapid 
categorical AST is clinically actionable, testing samples with a range of minimum 
inhibitory concentrations (MIC), including those with intermediate resistance, would 
further broaden the scope of the method.  Fourth, we have not tested pol-aAST against 
heteroresistant samples. However, these are more common in Gram-positive organisms70 
and are not common in Gram-negative organisms. Fifth, the pol-aAST chemistry should 
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be integrated with microfluidic devices so the AST can be performed directly on 
clinical samples with minimal user intervention. Sixth, the performance of these 
integrated devices will need to be evaluated in pre-clinical and clinical studies.  
 
We emphasize that the specific pol-aAST described in this paper, just like other 
innovative rapid ASTs,58, 71-74 is not intended to be the sole test to guide treatment.  Even 
though pol-aAST is based on detection of pathogen-specific nucleic acids and can 
therefore provide pathogen ID, we anticipate that in a clinical workflow pol-aAST would 
be performed after a separate rapid pathogen ID step.20-21, 23   Furthermore, pol-aAST 
would likely be combined with rapid AST for other antibiotics, such as fluoroquinolones 
that can be used to treat CRE infections.  AST methods that rely on similar underlying 
chemistries are more likely to be successfully integrated together. Isothermal 
amplification of pathogen-specific nucleic acids appears to be a promising approach for 
AST and we have already shown how rapid fluoroquinolone AST can be performed in 30 
min using digital LAMP.58  Upon integration with these complementary methods and 
translation to a distributable diagnostic, the pol-aAST will enable: i) improved antibiotic 
stewardship by reducing empiric use of carbapenems for Enterobacteriaceae, ii) improved 
patient outcomes by detecting CRE infections for which carbapenems would be 
ineffective, and iii) more cost-effective surveillance of CRE outbreaks.  
 
We envision that exploratory and mechanistic research inspired by pol-aAST will lead to 
a new generation of AST diagnostics. Additional mechanistic studies, such as those 
involving visualizing bacterial response to antibiotics75-76, would clarify the effects of 
different ABX on the responses measured in pol-aAST for different pathogens. To 
evaluate whether pol-aAST can be broadened beyond CREs and b-lactams, these studies 
would include organisms with cell envelopes that differ from Enterobacteriaceae (e.g., 
Gram-positives), and other antimicrobials that affect the cell envelope, such as 
antimicrobial peptides77 or vancomycin. It would also be desirable to evaluate pol-aAST 
with more amplification chemistries, including modified LAMP assays78-79 and other 
isothermal chemistries80-82 that are actively being developed. Ultimately, this new 
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generation of AST diagnostics will be integrated with the rapid ID methods being 
developed20-21, 23 and with future rapid NA-based AST methods for additional ABX and 
pathogens. For example, we have developed the nuc-aAST83, which measures 
accessibility of DNA to nucleases and was used to perform a rapid test of antibiotic 
susceptibility on the fastidious organism Neisseria gonorrhoeae.  In contrast to the pol-
aAST, the nuc-aAST enhances antibiotic-induced damage using surfactants after the 
ABX exposure step, and performs full cell lysis. Ultimately, to address the broad 
diversity of antibiotic-resistant pathogens, it is clear that integrated, multiplexed POC 
devices that incorporate multiple rapid phenotypic AST methods are needed. Innovative 
methods based on antibiotic-induced accessibility of nucleic acids to enzymes are 
promising for generating such ASTs for multiple antibiotics and pathogens in an 
approach that is intrinsically compatible with other rapid AST methods58 and with rapid 
pathogen ID.20-21, 24-25 
 
Materials and Methods 
 
Isolates, growth conditions, and antibiotic exposure conditions. 
 
We obtained 25 de-identified clinical isolates from the UCLA Clinical Microbiology 
Laboratory (CML) and the CDC’s Enterobacteriaceae Carbapenem Breakpoint panel12. In 
the case of isolates obtained from the UCLA CML, MICs were determined as described 
previously57. Genotypic testing of the two Ec and two Kp isolates selected for their lack 
of known b-lactamase genes was performed by UCLA CML using a previously published 
assay1 and separately at the Keck School of Medicine of USC using the FDA-approved 
Cepheid Xpert® Carba-R test. Whole genome sequencing of the single Ebs isolate 
selected for its lack of known resistance genes was performed by the CDC12. All isolates 
were stored as glycerol stocks at -80 °C. Glycerol stocks were streaked onto Trypticase 
Soy Agar with 5% sheep’s blood (Becton Dickinson, Franklin Lakes, NJ, USA) and 
grown overnight at 37 °C or resuspended directly in liquid media. Prior to experiments, a 
small clump of cells was resuspended from plates or glycerol stocks in 2 mL Brain Heart 
  
136 
Infusion Broth (BHI, Becton Dickinson) at 37 °C + 5% CO2 with 500 rpm shaking for 
2 to 4 h until visibly turbid. OD600 of the cultures was then measured, and working 
cultures prepared at an OD600 of 0.01–0.07 and grown for 50 – 145 min at 37 °C + 5% 
CO2 with 500 rpm. Working cultures were then diluted 10X into control and treated 
aliquots for antibiotic exposure. For validation experiments, antibiotic exposure was 
performed in 100 µL volumes consisting of 80 µL Mueller Hinton II Broth (Becton 
Dickinson), 5 µL nuclease-free H2O (NF-H2O), 5 µL 20X antibiotic stock solution, and 
10 µL of working culture. In control aliquots, antibiotic stock solution was replaced with 
NF-H2O. For filtration experiments, antibiotic exposure was performed in 100 µL 
volumes consisting of 65 µL Mueller Hinton II Broth (Becton Dickinson), 21 µL 
nuclease-free H2O (NF-H2O), 4 µL 25X antibiotic stock solution, and 10 µL of working 
culture. In control aliquots, antibiotic stock solution was replaced with NF-H2O. 
 
Antibiotic stocks. 
 
Ceftriaxone disodium salt hemi(heptahydrate) (Sigma, St. Louis, MO, USA), ertapenem 
sodium salt (Research Products International, VENDOR), and meropenem trihydrate 
(TCI, Portland, OR, USA) were used to create antibiotic stock solutions. All antibiotic 
stock solutions were prepared at 1.0 mg/mL antibiotic in nuclease-free H2O (NF-H2O) 
based on manufacturer reported purity, aliquoted, and stored at -80 °C. Aliquots were 
only thawed and used once on the days of experiments. 
 
Comparison of amplification methods. 
 
In order to compare amplification using LAMP and PCR, E. coli isolates were exposed to 
0.5 µg/mL ertapenem for 15 min. Samples were then transferred directly into either PCR 
or LAMP mix on ice. Amplification was started immediately. Quantitative PCR (qPCR) 
was performed on a Roche LightCycler 96 using SsoFast EvaGreen Supermix (BioRad, 
Hercules, CA, USA). 10 µL reactions were used. 10% of the final reaction volume was 
template. Published primers were used84 at a final concentration of 500 nM. Cycling 
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conditions consisted of 3.0 min at 95 °C, followed by 35 cycles of 95 °C for 10 sec, 
60 °C for 10 sec, and 72 °C for 15 sec. Fluorescence was measured using the SYBR 
Green channel after each 72 °C extension step. LAMP was performed on a BioRad 
CFX96 using the following conditions: 10 µL reaction volume containing 1X Isothermal 
Reaction Buffer II (NEB), 5 mM MgSO4 (NEB), 1.4 mM dNTPs (NEB), 320 U/mL Bst 
3.0 (NEB), and 2 µM Syto-9 (Thermo Fisher). 10% of the reaction volume was template. 
Primer sequences and concentrations have been described previously58. Cycling 
conditions consisted of 2.0 min at 12 °C (while lid was heating), followed by 120 cycles 
of 70 °C for 10 sec. Fluorescence was measured using the SYBR Green channel every 10 
sec (after each cycle). 
 
Filtration experiments.  
 
Filtration experiments were performed using E. coli isolates exposed to 0.5 µg/mL 
ertapenem for 15 min. Immediately following exposure, cultures were passed through 
0.22 µm, 1.5 mL cellulose acetate centrifuge tube filters (Corning Costar Spin-X, 
Corning, NY) by adding 50 µL of sample to the filter and centrifuging for 4 minutes at 
1000 rcf. DNA was extracted from both the feed and filtrate using QuickExtract DNA 
Extraction Solution (Lucigen, Middleton, WI, USA). Samples were diluted 10X into 
extraction buffer and extracted according to manufacturer instructions. The concentration 
of the single copy E. coli uidA gene was then quantified in the feed and filtrate 
extractions. The percentage of E. coli DNA in the filtrate was calculated as the filtrate 
concentration divided by the feed concentration. Droplet digital PCR (ddPCR) was 
performed using QX200 ddPCR Supermix for EvaGreen (BioRad). 10% of the final 
reaction volume was template. Published primers targeting the uidA gene in E. coli were 
used85 at a final concentration of 500 nM. Cycling conditions consisted of 5.0 min at 95 
°C, followed by 40 cycles of 95 °C for 30 sec, 60 °C for 30 sec, and 72 °C for 30 sec., 
with final dye stabilization steps of 4 °C for 5.0 min followed by 90 °C for 5.0 min. 
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pol-aAST validation.  
 
For pol-aAST validation experiments, E. coli and Enterobacter spp. isolates were 
exposed to either 2.0 µg/mL ceftriaxone (CRO), 0.5 µg/mL ertapenem (ETP), or 1.0 
µg/mL meropenem (MEM). K. pneumoniae isolates were exposed to either 2.0 µg/mL 
CRO, 1.0 µg/mL ETP, or 1.0 µg/mL MEM. Some isolates were run multiple times on 
different days. If this was the case, the average TTPDCT and TTPDLT are reported for that 
isolate. All isolates were exposed to ABXs for 15 min in 100 µL reaction volumes in 200 
µL PCR tube strips. After 15 minutes of ABX exposure, 10 µL of samples were 
transferred as template to LAMP reaction mix (as described above) on ice. Amplification 
was immediately started. 
 
Timed sample-to-answer using contrived urine samples.  
 
Timed sample to answer experiments were performed in the same fashion as pol-aAST 
validation experiments, except with the following modifications. Following initial growth 
and measurement of OD, isolates were resuspended in fresh, never-frozen, pooled human 
urine from healthy donors (Lee BioSciences). Additionally, a timer was started as soon as 
samples were added to the ABX exposure conditions. Escherichia coli (Ec) and 
Klebsiella pneumoniae (Kp) isolates were exposed to 0.5 and 1.0 µg/mL ETP 
(respectively) for 13 min. 13 min was chosen to ensure all handling steps could be 
completed within the first 15 min of the assay. Amplification was performed until all 
reactions reached a fluorescence value of 1000 relative fluorescent units (RFU) or 
greater. Amplification was then stopped, and TTP values copied into a spreadsheet pre-
populated with formulas to automatically output susceptibility calls. The timer was 
stopped once a susceptibility call had been determined. 
 
Statistical analysis.  
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All percent release values (Fig. 3) and TTPD values (Fig. 4–6) were calculated using 
Microsoft Excel. Data were plotted using GraphPad Prism 8.0 software. 
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Chapter VI 
 
Surfactant-enhanced DNA accessibility to nuclease accelerates phenotypic 
β-lactam antibiotic susceptibility testing of N. gonorrhoeae5 
 
Abstract 
 
Rapid, phenotypic antimicrobial susceptibility testing (AST) for Neisseria gonorrhoeae 
(Ng) is critically needed to counter widespread antibiotic resistance. However, rapid 
phenotypic AST for Ng is challenged by the pathogen’s slow doubling time and the lack 
of methods to quickly quantify its response to β-lactams (the largest antibiotic class used 
to treat Ng). Here, we devise an innovative approach for performing a rapid phenotypic 
AST that measures DNA accessibility to exogenous nucleases after exposure to β-
lactams. We show that DNA in antibiotic-susceptible cells has increased accessibility, 
and that a judiciously chosen surfactant enhanced this effect. We validated our method, 
termed nuc-aAST (nuclease-accessibility AST) using penicillin, cefixime, and 
ceftriaxone and showed 100% categorical agreement with gold-standard AST after just 
15-30 min of antibiotic exposure. This proof-of-concept provides a pathway toward 
developing a critically needed phenotypic AST for Ng and these innovations can be 
leveraged to develop ASTs for additional global-health threats. 
 
Introduction 
 
Gonorrhea, caused by Neisseria gonorrhoeae (Ng), is the second most common notifiable 
sexually transmitted infection (STI) in the U.S.(1) and the third most common STI 
globally, affecting 78,000,000 people each year worldwide(2). Untreated Ng infections 
can lead to pelvic inflammatory disease, infertility, ectopic pregnancy, and neonatal 
                                               
5This chapter was submitted for publication with authorship belonging to Nathan G. Schoepp, Emily S. 
Savela, Justin C. Rolando, Olusegun O. Soge, and Rustem F. Ismagilov. 
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blindness(3), and have a significant financial burden on healthcare systems(4). 
Antibiotic resistance in Ng emerged quickly and continues to spread unchecked because 
there is no rapid antibiotic susceptibility test (AST) to guide treatment. Lacking a rapid 
AST, clinicians are limited to making empiric prescriptions as recommended by the 
Centers for Disease Control and Prevention (CDC)(5) or World Health Organization 
(WHO)(6). When resistance to a particular ABX exceeds 5%, treatment guidelines are 
updated and the recommended treatment protocol is escalated to the next line of ABX(7, 
8). As a result, Ng strains continue to evolve resistance, including to the last-line (dual 
treatment with azithromycin/ceftriaxone)(9-11). The global prevalence and spread of 
resistant Ng infections has led the CDC to place Ng in its highest (“urgent”) category of 
antimicrobial-resistant pathogen threats(12) and the WHO to label Ng as a high-priority 
pathogen(13). Despite the threat of untreatable Ng(14) and an international call for rapid 
diagnostics(15-17), no phenotypic AST currently exists that can be performed rapidly 
enough for the point of care (POC). 
 
Successful and timely treatment of Ng infections while providing antibiotic stewardship 
requires two sequential steps to be performed at the POC. First, an identification (ID) test 
is run on the patient’s sample (typically urine or swab) to confirm that the patient is 
infected with Ng. Then, an AST must be run on the sample to determine whether the 
infecting strain of Ng is susceptible to the available ABX, so that the correct treatment 
can be prescribed. Substantial efforts (both academic(18-20) and commercial(21, 22)) are 
making great progress toward shortening the time required to identify Ng infections. 
However, there is no published path toward development of a rapid phenotypic AST for 
Ng, especially for beta-lactam antibiotics. Thus, even with swift diagnosis of an Ng 
infection, prescription of the correct antibiotics at the POC will remain bottlenecked by 
the lack of a rapid AST.  
 
AST methods are either genotypic or phenotypic. Genotypic methods predict resistance 
by screening for the presence of known resistance genes, whereas phenotypic methods 
determine susceptibly and resistance by directly measuring an organism’s response to an 
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antibiotic. Rapid genotypic methods exist for select antibiotic classes such as 
quinolones(23, 24), but the diverse mechanisms of resistance present in Ng would require 
highly multiplexed assays for most other antibiotic classes(25, 26), including β-
lactams(27, 28), which are the largest class of ABX for Ng. For example, hundreds of β-
lactamase genes are known(29), and new resistance genes continue to emerge, making it 
challenging to design a comprehensive genotypic AST, even for a single organism. Only 
phenotypic AST methods provide the ability to directly detect resistance, and 
susceptibility, regardless of the antibiotic’s mechanism of action. The current gold-
standard AST for Ng is agar dilution, a phenotypic method that takes many days and is 
only performed in a small number of reference laboratories(30). Efforts have been made 
to shorten the total assay time of culture-based techniques(31-33), but these methods still 
rely on multiple cell divisions and thus require many hours due to the slow doubling time 
(~60 min) of Ng. 
 
A phenotypic AST usable at the POC would be paradigm-shifting for Ng(34) because it 
would provide the correct timely treatment of infections, significantly reduce disease 
burden, and improve global surveillance efforts(35-37). Until a POC diagnostic is 
developed for Ng, empiric prescribing of the last-line dual antibiotic therapy of 
azithromycin/ceftriaxone will likely continue, as it has in the U.S. over the last five 
years(38). Likewise, if informed antibiotic prescriptions cannot be made, resistance will 
continue to spread, at which point no currently available ABXs will be recommended for 
treatment of Ng. Importantly, a rapid, phenotypic AST would greatly increase treatment 
options because if clinicians know which ABX will be efficacious for each infection, they 
can once again treat with ABX that are not prescribed in the current (empiric-based) 
system because of the risk of resistance. For example, even though cefixime (CFM) is no 
longer used as a first-line therapy for Ng, up to 95% of infections in the U.S. are still 
susceptible to CFM(1, 39). Similarly, up to 77% of Ng infections are susceptible to 
TET(1).  Therefore, having a POC AST would enable clinicians to once again safely 
prescribe CFM and other antibiotics(40). Several recent cases of Ng infections resistant to 
azithromycin(41, 42), or the currently recommended combination of 
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ceftriaxone/azithromycin(9, 11) were detected after treatment was administered, 
highlighting the critical need for faster diagnostics. 
 
For an Ng AST to inform treatment decisions at the POC, the total assay time to 
determine phenotypic susceptibility must be greatly decreased(43-45). Quantification of 
pathogen-specific nucleic acid (NA) concentrations has shown major promise for the 
rapid determination of susceptibility phenotype(46-49). These methods rely on 
comparing the NA concentrations of control and antibiotic-treated samples, and thus 
work well for rapidly dividing organisms and for ABX that directly affect NA replication. 
NA-based phenotypic AST methods also benefit from the high sensitivity of NA 
amplification, and fast isothermal amplification techniques have led to short total assay 
times(46). For example, by measuring the concentration of E. coli DNA, we have shown 
that the antibiotic-exposure step for phenotypic AST can be shortened to 15 min(50). We 
also were able to achieve a phenotypic AST with a 10-min antibiotic exposure time in Ng 
by measuring changes in RNA concentration after exposure to ciprofloxacin, which 
directly inhibits DNA replication and downstream translation(51). However, for ABX 
that do not impact DNA replication, such as β-lactams, these NA-based AST techniques 
have proven difficult; the fastest published method for Ng still requires four hours of 
beta-lactam exposure(52). Importantly, of the ABX prescribed for Ng, only one, 
ciprofloxacin(51), has been demonstrated to be compatible with this existing NA-based 
approach.  
 
Here, we describe an innovation that enables a rapid, NA-based phenotypic AST for β-
lactams, the largest class of ABX used to treat Ng. We hypothesized that cell wall 
damage caused by exposure to β-lactams could be exploited to determine phenotypic 
susceptibility faster than cell division. Our method, termed nuc-aAST (nuclease-
accessibility AST), measures the accessibility of intracellular Ng DNA to exogenously 
added nucleases after a short antibiotic exposure. We also wished to test whether the total 
time of the assay could be further decreased by including an enhancement step, defined 
  
155 
as a condition that would lead to greater differences in DNA accessibility between 
resistant (R) and susceptible (S) samples.  
 
We chose to validate this proof-of-concept nuc-aAST using three β-lactams, penicillin 
(PEN), cefixime (CFM), and ceftriaxone (CRO), that represent first-line treatments at 
different points in the history of Ng treatment(6, 53). Additionally, CRO, in combination 
with azithromycin, is the current recommended (and last-line) treatment for Ng. 
Determining susceptibility to CRO is thus relevant not only for treatment, but for 
surveillance efforts. Urine was chosen as the matrix for contrived sample testing because 
it is one of the primary sample types used for Ng diagnosis, especially in males(5, 6). We 
chose to test only categorically S or R isolates, based on EUCAST breakpoints(54), 
because S and R isolates are more useful than intermediate isolates for gaining initial 
mechanistic insights into nuc-aAST, and because S and R are actionable calls in 
antibiotic-prescribing scenarios. Lastly, keeping in mind clinical utility, we timed each 
assay step to determine whether the nuc-aAST could yield a definitive susceptibility call 
within the time period of a patient’s visit, which is usually less than an hour(44, 45). 
 
Results 
 
Design and rationale of the nuc-aAST 
 
The nuc-aAST method measures differences in the accessibility of genomic DNA to an 
exogenous nuclease between control and treated samples following a short antibiotic 
(ABX) exposure. Like other NA-based AST methods, the nuc-aAST (Fig. 1) relies on 
measuring changes in the quantity of pathogen-specific NAs in response to a treatment 
with ABX; however, the nuc-aAST differs from existing NA-based ASTs in three 
aspects. First, in nuc-aAST, exposure of cells to β-lactams is performed in the presence of 
a DNase enzyme to degrade any DNase-accessible NAs (Fig. 1a). DNA is accessible to 
DNase if it is released from the cells upon cell lysis, or if the action of the antibiotic 
porates the cells and allows DNase to access the DNA. Second, in nuc-aAST, an 
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enhancement step is introduced to increase accessibility of DNA in cells that have 
damaged or compromised peptidoglycan caused by β-lactams; DNase is present and 
active during this enhancement step (Fig. 1b). Third, in nuc-aAST, lysis of the sample is 
performed only after DNase has degraded all accessible DNA (Fig. 1c). This lysis step 
also inactivates the DNase, so that the enzyme does not impact downstream 
quantification. Following inactivation of DNase and lysis, DNA remaining in the sample 
is quantified and the percentage of accessible DNA is used to determine susceptibility 
(Fig. 1d). The percentage of accessible DNA is quantified by subtracting the 
concentration of inaccessible DNA (DNA not digested) in the treated aliquot from the 
concentration of DNA in the control aliquot, and dividing this value by the concentration 
of DNA in the control. Measuring the percentage of accessible DNA is an NA-based 
metric that enables us to quantify the damage to the cellular envelope induced by ABX 
targeting cell wall biosynthesis.  
 
 
Fig. 6-1. The nuc-aAST workflow shown for a sample containing an antibiotic-
susceptible pathogen. (a) A sample is split into control and treated aliquots; the treated 
aliquot is exposed to antibiotics (ABX) in the presence of DNase and any extracellular 
DNA is digested. ABX compromise peptidoglycan (PG) of cells in the treated aliquot. (b) 
Accessibility to nucleases is enhanced by the addition of an enhancer, which disrupts the 
outer membrane (OM). Genomic DNA becomes accessible and is degraded in the treated 
aliquot. Intact peptidoglycan in control samples (or in treated but resistant samples) 
prevents degradation. (c) Nucleic acids (NAs) are extracted, and DNase is inactivated. (d) 
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Accessibility is quantified by measuring NA concentrations in the control and treated 
aliquots and dividing the amount of digested DNA by the amount in the control (to yield 
percentage accessibility). When the percentage accessibility is greater than the threshold 
(dashed line), the sample is categorized as susceptible. 
 
β-lactams should primarily affect peptidoglycan(55), and should not have a major impact 
on the outer membrane, which serves as a structural element in Gram-negative 
bacteria(56). Therefore, we expected the primary mechanism behind any increase in 
accessibility to be cell lysis as a result of exposure to β-lactams, leading to release of 
genomic DNA to the extracellular environment containing DNase. Additionally, we 
hypothesized that autolysis, which has been observed as an active stress response in 
Ng(57, 58), might accelerate changes in accessibility due to ABX exposure. We tested 
our hypotheses in a time-course experiment using two penicillin-susceptible (PEN-S) and 
two penicillin-resistant (PEN-R) Ng clinical isolates (Fig. 2). We observed a significant 
difference in the percentage accessibility between susceptible and resistant isolates after 
90 min of exposure. This is the shortest incubation time for an Ng AST with PEN to date, 
and faster than existing NA-based methods that rely on DNA replication(52). However, 
the ideal length of an exposure step for an AST used at the POC would be even shorter 
(15-30 min) to keep the entire workflow within the time period of a patient visit. Thus, 
we were compelled to further accelerate changes in accessibility of DNA to nuclease as a 
result of β-lactam exposure in susceptible samples. 
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Fig. 6-2. Percentage accessibility of DNA over time using the nuc-aAST without the 
addition of an enhancing step. Two penicillin-susceptible (PEN-S) and two penicillin-
resistant (PEN-R) Ng isolates were exposed to penicillin in the presence of DNase I. 
DNA from the control and PEN-treated aliquots was extracted and quantified using qPCR 
at multiple time points to calculate percentage accessibility. Error bars represent the 
standard deviation of the PCR triplicates. 
 
Enhancing changes in accessibility 
 
We next hypothesized that the differences in DNA accessibility that we observed 
between susceptible and resistant isolates exposed to β-lactams could be enhanced using 
conditions that would modify the permeability of the cell envelope. In Gram-negative 
organisms like Ng, the outer membrane (OM) presents the first, and major, permeability 
barrier to macromolecules (e.g. nucleases and other enzymes) entering or exiting the cell, 
typically allowing only small molecules with molecular weights < ~600 Da to pass 
through(59, 60). The peptidoglycan, in contrast to the OM, is a looser barrier that has 
been estimated to allow macromolecules up to 50 kDa to pass through(61-63). We thus 
suspected that if the OM could be compromised, damage to the peptidoglycan would 
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result in immediate, measurable changes in accessibility of genomic DNA to DNase, 
both by allowing DNase to enter and by allowing DNA fragments to exit.  Therefore, we 
hypothesized that we could compromise the OM using an “enhancer” to decrease total 
assay time. 
 
The ideal enhancer would i) increase DNA accessibility to DNase in cells that have a 
compromised cell wall as a result of ABX exposure, ii) result in minimal lysis of healthy 
cells, iii) have a consistent effect on all Ng isolates and iv) have no effect on downstream 
extraction and quantification of NAs. With these parameters in mind, we chose to test 
hypo-osmotic stress, stimulated autolysis, and four classes of surfactant as potential 
enhancers.  
 
Hypo-osmotic stress was chosen as a method to enhance lysis of cells with damaged or 
compromised cell walls because osmotic stress of varying degrees is known to increase 
release of intracellular contents in Gram-negative bacteria,(64-66) although it has never 
been used to enhance accessibility in the context of AST. We exposed cells to hypo-
osmotic conditions by diluting control and treated aliquots 20-fold in water with DNase I 
and 500 µM CaCl2, resulting in a ~244 mOsm/kg shift from the ABX exposure 
conditions. Autolysis was chosen as an enhancer with the rationale of leveraging an 
already existing stress response in Ng to enhance changes in accessibility. Autolysis is a 
natural stress response in Ng, and can be accelerated by incubation in high pH conditions 
(e.g. Tris, pH 8.5)(67, 68). We hypothesized that using autolysis as an enhancer might 
result in large changes in NA accessibility. Surfactants were chosen as potential 
enhancers as a targeted chemical means of disrupting the bacterial cell membrane. We 
chose a representative surfactant from each of the four major charge-based classes of 
surfactants to investigate whether surfactant charge might lead to variability in their 
effectiveness due to natural variations in the OM of Ng. We tested the anionic surfactant 
sodium dodecyl sulfate (SDS), the cationic surfactant benzalkonium chloride (BAC), the 
non-ionic surfactant TERGITOL NP (TNP), and the zwitterionic surfactant 3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). Each of these 
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surfactant classes, with the exception of zwitterionic surfactants, have been well-
studied for their ability to compromise the integrity of the cell envelope(69), but none 
have been used in the context of AST, or to change DNA accessibility on such short time 
scales. We chose to include the less well-studied zwitterionic surfactant CHAPS based on 
the diverse interactions of zwitterionic solutes with the bacterial cell envelope(70). 
 
We tested each potential enhancer with respect to i) the degree of lysis caused by 
incubation with the enhancer alone, ii) the ability to differentiate PEN-S and PEN-R 
isolates using an enhancement step after exposure to PEN, and iii) the ability to 
differentiate CRO-S and CRO-R isolates using an enhancement step after exposure to 
CRO. We chose to use PEN and CRO because we expected that the degree of change in 
NA accessibility as a result of enhancement would depend on the type of β-lactam used 
during exposure. CRO and PEN bind and inhibit a different profile of penicillin-binding 
proteins(40, 71) and have different rates of killing(72), which we expected would lead to 
different effects depending on the enhancer. Each enhancer was tested using multiple 
isolates susceptible or resistant to either PEN or CRO. All enhancers were tested using a 
5-min enhancement step after 15 min of ABX exposure. Antibiotic-exposure and 
enhancement steps were performed separately to decouple their effects on the Ng isolates. 
 
Enhancers were first tested for the degree of lysis caused by a 5-min incubation with the 
enhancer alone (Fig. 3a-f). If the enhancement step lyses the majority of cells even 
without antibiotic exposure, then accessibility will increase in both control and treated 
aliquots, and any effect of the antibiotic will be diminished. We observed an average of < 
50% lysis when testing all potential enhancers except BAC (Fig. 3d), which showed an 
average of 94% lysis across all eight isolates tested. We next measured the percentage 
accessibility when using each enhancer after a 15 min exposure to PEN. We evaluated 
the ability to differentiate PEN-S and PEN-R isolates based on the average percentage 
accessibility in S isolates (which we want to be large), the average percentage 
accessibility in R isolates (which we want to be small), and the magnitude of separation 
between those two values. Based on these criteria, Tris (Fig. 3h), TNP (Fig. 3k), and 
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CHAPS (Fig. 3l) were the most promising enhancers for differentiating PEN-S and 
PEN-R isolates after 15 min of exposure. However, we observed differences in 
accessibility in response to CRO compared with PEN depending on the enhancer used 
(Fig. 3m-r). Among CRO-S isolates, enhancement with TNP or CHAPS resulted in the 
largest average changes in accessibility. We were unable to observe consistently large 
changes in the seven tested CRO-S isolates using the other two ionic surfactants, SDS 
(Fig. 3i,o) and BAC (Fig. 3j,p), regardless of the ABX treatment. Following these tests, 
we chose CHAPS as the enhancer to use for validation of the nuc-aAST because it 
resulted in low percentage lysis, large increases in DNA accessibility for PEN-S and 
CRO-S isolates following exposure, and only small increases in the DNA accessibility of 
PEN-R and CRO-R isolates. 
 
 
Fig. 6-3. Selection of enhancers. Six enhancers were tested for percentage of cell lysis 
due to enhancer alone (prior to antibiotic [ABX] exposure) (a-f), enhancement after 
exposure to penicillin (PEN) (g-l), and enhancement after exposure to ceftriaxone (CRO) 
(m-r). Each point represents the average of all biological replicates run for that condition. 
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Checkmarks indicate enhancers that met our criteria for inclusion in the nuc-aAST; 
X’s indicate enhancers that did not meet our criteria. 
 
Validation using clinical isolates 
 
To validate the nuc-aAST we performed 34 ASTs (with multiple biological replicates 
each) using 13 clinical isolates of Ng exposed individually to PEN, CFM, or CRO for 15 
min. We then compared the categorical susceptibility determined using the nuc-aAST to 
the susceptibility determined using gold-standard agar dilution (Fig. 4a-c). Receiver 
operating characteristic (ROC) plots(73) (not shown) were created so that the area under 
the curve (AUC) could be calculated for each β-lactam tested. After 15 min of exposure 
we obtained an AUC of 1.000 (PEN), 0.955 (CFM), and 1.000 (CRO). The AUC is 
determined by scanning a threshold through the ROC plot and measuring the sensitivity 
and specificity at each theoretical threshold value. This scanning allows one to select the 
threshold that would differentiate susceptible and resistant organisms with the maximum 
sensitivity and specificity within the given dataset. For example, an AUC of 1.000 
indicates there was a threshold value that perfectly separated susceptible (S) and resistant 
(R) categories. However, AUC measurements do not consider the experimental noise or 
the magnitude of separation between S and R samples and should be applied with care to 
datasets with limited number of measurements, such as ours.  For example, in the case of 
CFM, the difference between the two CFM-R isolates and the CFM-S isolates with the 
lowest responses (open circles in Fig. 4b) was small after 15 min of exposure, so setting 
the susceptibility threshold between them would be impractical. The same is true of 
setting a threshold between the single CRO-R isolate that was available to us and two 
CRO-S isolates with the lowest responses. We therefore set the thresholds for both these 
ABX at a more conservative 18% even though this threshold generates some errors (Fig. 
4b,c; open circles) in the CFM and CRO measurements after 15 min of ABX exposure.  
 
We then hypothesized that the differences observed in the magnitude of the response of 
the susceptible isolates after 15 min of exposure to each antibiotic, including the errors 
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observed when testing CFM and CRO (open points, Fig. 4b,c) could be the result of 
differences in how fast each β-lactam affects Ng(72). For example, a possible explanation 
for differences among isolates in their response to ABX could be phylogenetic 
differences(74-76). If isolates differ in their response times, a longer exposure would 
result in larger average separation between S and R isolates and potentially better 
categorical agreement if the S isolates were less-responsive as a result of a delayed 
response to antibiotic. 
 
 
Figure 4. Validation of nuc-aAST using clinical isolates. (a-c) nuc-aAST results after 
15 min of exposure to (a) penicillin (PEN), (b) cefixime (CFM), and (c) ceftriaxone 
(CRO). (d-e) nuc-aAST results after exposure to (d) CFM and (e) CRO for 30 min. All 
points represent the average percentage accessibility of single clinical isolates run in (at 
least) biological triplicate. Open points represent isolates that took longer than 15 min to 
respond to the β-lactam being tested. The dashed line represents the susceptibility 
threshold, which was set at 18% accessibility. 
 
To test the hypothesis that there are inherent differences in isolate response time, we 
performed nuc-aAST using CFM and CRO with 30-min exposure times and, as predicted, 
we observed a larger average separation between S and R isolates and full categorical 
agreement with gold-standard agar dilution in all isolates. After 15 min of exposure to 
CFM and CRO, 73% and 83% of susceptible isolates, respectively, were classified as 
susceptible using nuc-aAST. After 30 min of exposure to CFM and CRO, 100% 
categorical agreement was obtained. 
 
Sum-of-steps total time using contrived urine samples 
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To make a more realistic measure of total assay time, we modified the extraction and 
quantification steps of the nuc-aAST. The exposure and enhancement steps were 
performed as described above, but NA quantification was performed using a rapid, chip-
based, digital loop-mediated isothermal amplification (dLAMP) method, as described 
previously(77). Additionally, we used a faster, single-step nucleic acid extraction method 
based on previous work(46). Both modifications made the workflow faster. Additionally, 
the high precision of digital quantification allowed us to make a susceptibility call as 
soon as there was a significant difference between the concentration of NAs in the control 
and treated aliquots. 
 
We measured total assay time based on the sum of the steps of the nuc-aAST using 
contrived urine samples. Contrived samples mimic clinical urine samples and allowed us 
to better evaluate how the assay would perform in a clinical setting than assays performed 
with isolates in media. Samples were created using two PEN-S and two PEN-R isolates; 
one of the two PEN-R isolates was positive for β-lactamase activity, which we included 
in order to have PEN-R isolates with different mechanisms of resistance. To perform the 
AST, samples were first split into control and treated aliquots, and incubated at 37 °C for 
15 min. Next the samples were transferred to the enhancement step, and incubated for 5 
min in the presence of CHAPS. Samples were then extracted as described above and 
dLAMP was performed in commercial chips(77). Images were obtained in real time 
using a custom imaging system(78). LAMP quantification was performed using an 
automated data-analysis workflow in MATLAB(77) in which images are automatically 
processed and positive wells counted based on a digitized mask created from the final 
image (Fig. 5b). NA concentrations were used to determine percentage accessibility as 
soon as the measured NA concentrations in the susceptible sample became significantly 
different between the control and treated chips. All samples were tested in a total time 
(measured as the sum-of-steps) of 30 min and agreed with gold-standard agar dilution 
(Fig. 5c). 
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Fig. 6-5. The nuc-aAST workflow with each step timed. (a) The nuc-aAST workflow 
showing the time required for each step. (b) 2x2 mm subsection of masks created from 
chips used for performing digital LAMP (dLAMP) on control and treated aliquots of 
susceptible and resistant samples; as an illustration, each mask shows ~625 wells (out of 
~20,000 total wells) after 10 min of amplification. Wells that showed amplification of Ng 
DNA appear black. (c) Percentage accessibility determined at earliest significance (<7 
minutes of amplification, see Methods) for two susceptible and two resistant samples run 
using dLAMP. Each step was timed individually and the sum-of-steps of the assay was 
30 min for PEN. 
 
Discussion 
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Here we described a new approach—nuc-aAST—to enable developing a critically needed 
rapid phenotypic AST for the globally-important pathogen Neisseria gonorrhoeae. We 
show that by measuring the change in the accessibility of DNA after 15 or 30 min β-
lactam exposure, the nuc-aAST yields a phenotypic susceptibility readout in less than 1 
hour, as opposed to the currently available methods which require hours to days. We 
further show that the nuc-aAST breaks the current speed limits for nucleic-acid-based 
phenotypic ASTs using β-lactams (which do not directly impact NAs) by using an 
innovative approach: coupling cell wall damage to NA readout. The nuc-aAST thus 
provides a new approach for designing rapid phenotypic ASTs with NA-based readouts 
for ABX that impact cell envelope integrity. Overall, we envision that leveraging the nuc-
aAST and combining it with other creative biological and chemical insights will result in 
similarly innovative approaches for other important antibiotic classes for Ng, such as 
protein-biosynthesis inhibitors like tetracycline and azithromycin. Existing NA-based 
approaches, such as those for ciprofloxacin(23, 51), can also be combined alongside the 
nuc-aAST. 
 
We found that phenotypic ASTs that use NA accessibility as a readout benefit from the 
use of a carefully chosen enhancer. Here, the enhancement step consisted of a surfactant 
(CHAPS) that enabled detection of cell wall damage faster than cell division. Without the 
enhancement step, the cell envelope remains intact longer, so measurements of 
accessibility approximate the timescale of cell division (Fig. 2), which, for fastidious 
organisms such as Ng, will be too slow for POC applications. The increase in DNA 
accessibility in S isolates will differ based on the combination of β-lactam used and 
enhancer, highlighting the importance of testing multiple β-lactams with the nuc-aAST. 
Of the surfactants tested as enhancers, the charge-neutral surfactants TNP and CHAPS 
gave better results than the ionic surfactants SDS and BAC, suggesting that charge may 
be an important factor when designing an effective enhancement step. We also anticipate 
organism-specific OM chemistry and general stress responses will play a role in 
determining which enhancers are optimal in other organisms. 
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We found that for PEN, susceptibility of Ng could be determined after just 15 min of 
exposure in all isolates tested (Fig. 4a). However, for CFM and CRO, a small number of 
S isolates did not respond after 15 min of exposure but responded after 30 min exposure 
(Fig. 4b-e). We hypothesize that CFM and CRO required a longer exposure than PEN 
because of their differences in binding kinetics and rates of killing(71, 72, 79). Despite 
these differences, an actionable susceptibility call (i.e. determining that an isolate is 
susceptible to a particular ABX and therefore can be treated with that ABX) could still be 
made for most isolates after 15 min of exposure (100% using PEN, 77% using CFM, and 
85% of cases using CRO). One approach to balance reducing assay time with minimizing 
errors is to perform two exposures in parallel for each ABX.  The first exposure would be 
analyzed after 15 minutes. If a response is obtained indicating that the pathogen is 
susceptible (which should be the case for the majority of patients), the second exposure 
would be discarded. If no response or if an equivocal response is obtained, then the 
second exposure (after 30 min total) would be analyzed to provide the definitive 
susceptibility call. With this approach, the test would provide the answer after 15 min of 
ABX exposure for the majority of patients, and only a few patients would be delayed by 
the additional 15 min of ABX exposure.  
 
Several limitations will need to be overcome in order to translate the nuc-aAST approach 
to an automated and distributable system. First, in this paper we used clinical isolates and 
contrived urine samples. Although contrived samples are a good proxy for clinical 
samples and are accepted by the U.S. Food and Drug Administration in certain cases(80), 
the nuc-aAST should be validated with fresh clinical samples. It remains to be tested 
whether the enhancer chemistry has to be modified to account for the presence of host-
derived cells and metabolites that might interfere with the assay.  Second, future work 
should test more Ng isolates with diverse phylogeny(74-76) as they are made available to 
researchers and characterized, as well as test isolates with intermediate resistance to PEN, 
CFM, and CRO. These efforts could also aim to establish a correlation in the magnitude 
of nuc-aAST response and minimum inhibitory concentration (MIC) of ABX, which 
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would provide even more detailed information at the POC. Third, in timing the sum-
of-steps, we did not include handling time; future work should include optimization of 
handling steps and timed sample-to-answer experiments. Finally, the nuc-aAST method 
will need to be translated to a POC device so that larger-scale clinical evaluations can be 
performed.  Devices for multiplexed digital quantification(81-83) have been 
demonstrated and would be useful in performing nuc-aAST for multiple ABX in parallel.    
 
We envision that nuc-aAST would be deployed in combination with two complementary 
technologies:  (i) the pathogen ID technologies that are being developed by others(18, 19, 
21, 22) to identify Ng-positive samples that require an AST, and (ii) rapid genotypic 
and/or phenotypic ASTs that rely on NA readouts for other ABX used in the treatment of 
Ng, including fluoroquinolones (ciprofloxacin)(23, 46, 75) and protein synthesis 
inhibitors (tetracycline and azithromycin)(75).  Assuming these two complementary 
technologies are developed and validated, further development of nuc-aAST would 
provide the last—and we would argue the most challenging—piece needed for a 
complete rapid ID/AST workflow for Ng based on NA readout.  We chose NA readout 
for the nuc-aAST for two reasons. First, NA readouts will enable easy integration with 
pathogen ID and other NA-based AST technologies. Second, NA readouts are organism-
specific(46), and therefore should be effective even for mixed microbial populations 
potentially present in clinical samples (e.g., Ng in the presence of commensals or other 
pathogens).   
 
Implementation of a rapid phenotypic AST would dramatically improve the antibiotic 
stewardship of Ng infections and therefore impact the health of people who are infected 
with Ng; currently, there are an estimated 78,000,000 global cases of Ng every year(2). 
Furthermore, the nuc-aAST approach provides a framework for developing additional 
accessibility-based AST chemistries for other pathogens that pose global health threats 
but have been challenging for current phenotypic AST methods. For example, we have 
shown that quantifying NA accessibility to polymerases can be used to rapidly determine 
ABX susceptibility in Enterobacteriacea(84). Overall, this work highlights the diagnostic 
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capabilities that can be attained by developing innovative NA-based assays for AST; 
further expansion and application of these approaches is critically needed to address the 
crisis posed by antibiotic-resistant bacteria. 
 
Materials and Methods 
 
Isolates and agar-dilution MIC testing. Isolates were provided by the University of 
Washington Neisseria Reference Laboratory. MICs were determined by agar dilution 
according to the Clinical and Laboratory Standards Institute (CLSI) guidelines(86). 
 
Reagents and culture media. BD BBL Chocolate II Agar prepared plated media (GC II 
Agar, with Hemoglobin and BD IsoVitaleX) was purchased from VWR International 
LLC (VWR, Radnor, PA, USA). Graver-Wade Medium (GWM) was prepared as 
described previously(87). Cation-adjusted Mueller Hinton II Broth (MHB) (BD, Franklin 
Lakes, NJ, USA) was prepared according to manufacturer instructions. All sodium 
bicarbonate (NaHCO3) (Sigma, St. Louis, MO, USA) and calcium chloride (CaCl2) 
(Fisher Scientific, Hampton, NH, USA) stocks were dissolved in nuclease-free water 
(NF-H2O) and sterilized using 0.2-µm filters. DNase I (2000 U/mL) was obtained from 
New England Biolabs (NEB, Ipswich, MA, USA). Normal urine from pooled human 
donors was purchased from Lee Biosolutions (Maryland Heights, MO, USA) and filtered 
through 0.2-µM filters before use. 
 
Antibiotic stocks were prepared and stored as single-use aliquots at -80 °C. Aliquots were 
thawed once and diluted in NF-H2O before use. PEN (1 mg/mL) was prepared from 
penicillin G sodium salt (Sigma, St. Louis, MO, USA) in NF-H2O. CRO (1 mg/mL) was 
prepared from ceftriaxone disodium salt hemi(heptahydrate) (Sigma) in NF-H2O. CFM (5 
mg/mL) was prepared from cefixime trihydrate (Sigma) in DMSO. 
 
Unless otherwise noted, enhancer stock solutions were prepared in NF-H2O and stored at 
room temperature. Tris buffer (500 mM; pH 8.5 at 37 °C) was prepared according to the 
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Sigma buffer reference tables(88) using 0.2-µm filter sterilized stocks of 1 M Tris-
HCl (Sigma) and 1 M Tris base (Fisher Scientific) prepared in milliQ H2O. TNP HLB 
13.1 (100 mM) was prepared by mixing 334 µL 100 mM Tergitol NP-9 (Sigma) + 666 
µL 100 mM Tergitol NP-10 (Sigma). CHAPS (200 mM) was prepared from CHAPS 
solid powder (Sigma). 0.1% sodium dodecyl sulfate (SDS) was prepared by diluting 10% 
SDS (Invitrogen, Carlsbad, CA, USA). BAC (10%) was prepared from benzalkonium 
chloride solid powder (MP Biomedicals, Santa Ana, CA, USA). 
 
Nucleic acid quantification. Quantitative PCR (qPCR) was performed using ssoFast 
EvaGreen Supermix (BioRad, Hercules, CA, USA) in 10 µL reactions with 500 nM 
primers targeting the Ng 16S gene(89). DNA template composed 10% of the reaction 
volume. Cycling conditions consisted of 3.0 min at 95 °C, followed by 35 cycles of 15 
sec at 95 °C, 15 sec at 62 °C, and 20 sec at 72 °C. All qPCR was performed on either a 
Roche LightCycler 96 or BioRad CFX96 instrument. The Cq values obtained from qPCR 
are used to compute the percentage accessibility and percentage lysis as described in the 
equations below. Any negative percentages were set to 0 for all analyses. 
 
(1)  (2)  
 
Droplet digital PCR (ddPCR) was performed using QX200 ddPCR Supermix for 
EvaGreen (BioRad, Hercules, CA, USA) with the same primers and primer 
concentrations used in qPCR. DNA template composed 10% of the reaction volume. 
Cycling conditions consisted of 5.0 min at 95 °C, followed by 40 cycles of 30 sec at 95 
°C, 30 sec at 60 °C, and 30 sec at 72 °C, followed by a droplet stabilization step of 4 °C 
for 5 min, and 95 °C for 5 min. Calculations of percentage accessibility and percentage 
lysis for ddPCR are given the equations below, where  represents template concentration 
in copies/µL. The template concentrations are used to compute percentage accessibility 
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and percentage lysis as described in the equations below. Any negative percentages 
were set to 0 for all analyses. 
 
(3)  (4)  
 
A dLAMP assay was performed using a previously published system(77). The dLAMP 
mix consisted of 1 µL NEB Isothermal Amplification Buffer (200 mM Tris-HCl, 20 mM 
MgSO4, 500 mM KCl, 100 mM (NH4)2SO4, 1% Tween 20, pH 8.8), 0.6 µL MgSO4, 0.5 
µL BSA (20 mg/mL), 0.4 µL Syto-9 (50 µM, prepared within two weeks of use), 1.4 µL 
dNTPs (10 mM each), 0.5 µL 20X primer mix, 0.4 µL NEB Bst 2.0 WarmStart, 0.2 µL 
Ambion RNase cocktail, 4.0 µL NF-H2O, and 1 µL of template. Primers were designed to 
target the Ng 16S gene, and screened as described previously(46). Primer sequences used 
are as follows, with the final concentration in the amplification mix in parentheses: 
GCGGTGGATGATGTGGATT (forward outer primer, 0.2 µM), 
CCGGCAGTCTCATTAGAGTG (backward outer primer, 0.2 µM), 
CTCCTCCGTCTCCGGAGGATTCaaaaCGATGCAACGCGAAGAAC (forward inner 
primer, 1.6 µM), TCGTCAGCTCGTGTCGTGAGATttttCCCAACCGAATGATGGCA 
(backward inner primer, 1.6 µM), CGCACATGTCAAAACCAGG (forward loop primer, 
0.4 µM), and GCAACGAGCGCAACCC (reverse loop primer, 0.4 µM). The following 
equation was used to compute percentage accessibility, where  represents the template 
NA concentration in copies/µL as measured by dLAMP. 
 (5)  
 
Ng culture preparation. Isolates were streaked from glycerol stocks stored at -80 °C 
onto BD BBL Chocolate II Agar plates and incubated overnight in a 37 °C incubator with 
5% CO2. Isolates were then passed onto fresh BD BBL Chocolate II Agar plates and 
grown for 4-7 h at 37 °C with 5% CO2. In all experiments, cells from plates passed 1-3 
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times were used. Several colonies were scraped and resuspended in 37 °C GWM to 
generate a working suspension. Optical density at 600 nm (OD600) was measured, and the 
working suspension was diluted to create a 2 mL working culture of OD600 0.05 in GWM 
in 15 mL polypropylene culture tubes. Cultures were incubated, with 500 rpm shaking, at 
37 °C + 5% CO2 for 3-5 h prior to ABX exposure. 
 
nuc-aAST time-course without enhancing step. Working cultures of Ng isolates were 
prepared as described in “Ng culture preparation.” Incubation at 37 °C was performed in 
100 µL reaction volumes in PCR tube strips on a BioRad C1000 Thermal Cycler. Treated 
samples consisted of 77.5 µL MHB, 2.5 µL NaHCO3 (200 mM), 5 µL DNase I (2 U/µL), 
5 µL PEN (20 µg/mL), and 10 µL working Ng isolate culture. PEN was replaced with 
NF-H2O in control samples. A 10 µL aliquot of each sample was extracted at 15, 30, 45, 
60, 90, and 120 min and diluted 10X in QuickExtract DNA Extraction Solution 
(Lucigen, Middleton, WI, USA), then heated for 6 min at 65 °C followed by 4 min at 98 
°C on a BioRad C1000 Thermal Cycler. All sample handling following antibiotic 
exposure was performed using a multichannel pipette; qPCR and calculation of % 
accessibility were performed as described above. 
 
Enhancer use. Working cultures of Ng isolates were prepared as described in “Ng 
culture preparation.” Initial exposure was performed by incubating 100 µL control and 
treated samples at 37 °C in PCR tube strips on a BioRad C1000 Thermal Cycler. Treated 
samples consisted of 75 µL MHB, 5 µL NaHCO3 (100 mM), 5 µL DNase I (2 U/µL), 5 
µL PEN or CRO (20 µg/mL), and 10 µL working Ng isolate culture. ABX were replaced 
with NF-H2O in control samples. After 15 min of incubation, samples were vortexed and 
quick-spun, and aliquots of all samples were transferred to the enhancement step as 
described below. After the enhancement step, 5 or 10 µL of all samples were extracted by 
diluting 10X in QuickExtract DNA Extraction Solution (Lucigen) and heating for 6 min 
at 65 °C followed by 4 min at 98 °C on a BioRad C1000 Thermal Cycler. All sample 
handling following ABX exposure was performed using a multichannel pipette; qPCR 
and calculation of % accessibility was performed as described above. 
  
173 
 
Osmotic and autolytic enhancing steps were performed in 100 µL volumes. The osmotic 
enhancing step consisted of 89.75 µL NF-H2O, 4.75 µL DNase I (2 U/uL), 0.5 µL CaCl2 
(100 mM, 0.2-µM filtered), and 5 µL initial exposure samples. The autolytic enhancing 
step consisted of 75 µL NF-H2O, 4.75 µL NaHCO3 (100 mM, 0.2-µM filtered), 10 µL 
Tris pH 8.5 (500 mM), 4.75 µL DNase I (2 U/uL), 0.5 µL CaCl2 (100 mM), and 5 µL of 
the sample exposed to antibiotic. 
 
All surfactant-enhancing steps were performed in 50 µL volumes with 25 of the 50 µL 
consisting of initial exposure samples. In the TNP enhancement step, the remaining 25 
µL consisted of 1.25 µL DNase I (2 U/uL), 1.25 µL NaHCO3 (100 mM), 20 µL MHB, 
and 2.5 µL TNP (100 mM). In the CHAPS enhancement step, the remaining 25 µL 
consisted of 1.25 µL DNase I (2 U/uL), 1.25 µL NaHCO3 (100 mM), 20 µL MHB, and 
2.5 µL CHAPS (200 mM). In the SDS and BAC enhancement steps, the remaining 25 µL 
consisted of 1.25 µL DNase I (2 U/uL), 1.25 µL NaHCO3 (100 mM), 17.5 µL MHB, and 
either 5 µL SDS (1% w/v) or BAC (1% w/v) respectively. 
 
Nuclease-accessibility AST validation. Working cultures were prepared, exposed to 
ABX, and enhancing steps performed as described for the CHAPS enhancement step in 
the “enhancer selection” section above. Extraction was performed as described above. 
Treated samples in the initial exposure step had a final concentration of 1.0 µg/mL PEN, 
CFM, or CRO. Samples were excluded if the percent lysis (equation 2) due to CHAPS 
was > 75%. Three to ten biological replicates were performed for each isolate-antibiotic 
combination. Biological replicates included separate antibiotic exposure, control 
exposure, and no-enhancer controls. 
 
Timed sum-of-steps. Working cultures of Ng isolates used in Fig. 4 were prepared as 
described in “Ng culture preparation” and 1.5 mL of the cultures were pelleted at 2500 g 
for 2.5 min and resuspended in 150 µL normal human urine (Lee Biosciences) pre-
warmed to 37 °C. Initial exposure was performed by incubating 100 µL control and 
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treated samples at 37 °C in PCR tube strips on a BioRad C1000 Thermal Cycler. 
Treated samples consisted of 65 µL MHB, 5 µL NaHCO3 (100 mM), 5 µL DNase I (2 
U/µL), 5 µL PEN (20 µg/mL), and 20 µL Ng isolate suspension in urine. NF-H2O was 
used in place of PEN in control samples. A CHAPS enhancing step was performed as 
described above. After the enhancement step, a 20 µL aliquot from each sample was 
extracted by diluting 5X in QuickExtract DNA Extraction Solution (Lucigen) and heated 
for 1 min at 65 °C followed by 1 min at 98 °C on a BioRad C1000 Thermal Cycler. All 
sample handling following ABX exposure was performed using a multichannel pipette. 
Amplification was then performed using qPCR, ddPCR, or dLAMP. Extractions were 
diluted 2.5X in NF-H2O before use in dLAMP. 
 
Osmolarity measurements. Osmolarity measurements were performed on a Model 3320 
Osmometer (Advanced Instruments Inc., Norwood, MA, USA). The instrument was 
calibrated with reference standards (Advanced Instruments) prior to experiments. 
Samples identical to the antibiotic-exposure condition (i.e., media, nuclease, etc.) and 
samples identical to the osmotic enhancing condition were prepared and measured. The 
volume that would normally be comprised of Ng culture was replaced with media. 
 
Statistical analysis. P-values for Fig. 2 were calculated using GraphPad Prism 8.0 
software from an unpaired, two-tailed t-test comparing the averages of the three 
replicates of each susceptible sample to each resistant sample. A significance value of 
0.02 was used for statistical significance. ROC plots used for setting susceptibility 
thresholds in Fig. 4 were created using GraphPad Prism 8.0 software. Sensitivity was 
defined as the proportion of gold-standard susceptible samples correctly identified as 
susceptible by the nuc-aAST. Specificity was defined as the proportion of gold-standard 
resistant samples correctly identified as resistant by the nuc-aAST. Statistical analyses for 
Fig. 5, (dLAMP measurements) were performed as published previously(46, 90). As in 
our previous publication(46), the control and treated concentrations are compared as a 
ratio for statistical analysis. 
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This concentration ratio is transformed into a percentage change for visualization 
purposes, but the ratio is assessed for statistical significance. Poisson statistics were used 
to calculate the confidence interval of the NA concentration for each measurement(90). 
The error in the concentration ratio, a term used in the calculation of percentage 
accessibility, is calculated with standard-error propagation methods: 
 (7)  
 
A one-tailed Z-test, assuming a normal distribution, is used to calculate p-values for 
digital NA concentrations. A threshold value for significance is set as a ratio of 1.22, 
corresponding to a percentage accessibility of 18%. 
 (8)  
 
A significance value of 0.05 was used for statistical significance. The p-values to 
determine significance in dLAMP experiments were computed using Microsoft Excel’s 
standard normal cumulative distribution function and Z-value. 
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Chapter VII 
 
Evaluating 3D printing to solve the sample-to-device interface for LRS and 
POC diagnostics: example of an interlock meter-mix device for metering 
and lysing clinical urine samples6 
 
Abstract 
 
This paper evaluates the potential of 3D printing, a semi-automated additive prototyping 
technology, as a means to design and prototype a sample-to-device interface, amenable to 
diagnostics in limited-resource settings, where speed, accuracy and user-friendly design 
are critical components. As a test case, we built and validated an interlock meter-mix 
device for accurately metering and lysing human urine samples for use in downstream 
nucleic acid amplification. Two plungers and a multivalve generated and controlled fluid 
flow through the device and demonstrate the utility of 3D printing to create leak-free 
seals. Device operation consists of three simple steps that must be performed 
sequentially, eliminating manual pipetting and vortexing to provide rapid (5 to 10 s) and 
accurate metering and mixing. Bretherton's prediction was applied, using the bond 
number to guide a design that prevents potentially biohazardous samples from leaking 
from the device. We employed multi-material 3D printing technology, which allows 
composites with rigid and elastomeric properties to be printed as a single part. To 
validate the meter-mix device with a clinically relevant sample, we used urine spiked 
with inactivated Chlamydia trachomatis and Neisseria gonorrhoeae. A downstream 
nucleic acid amplification by quantitative PCR (qPCR) confirmed there was no 
statistically significant difference between samples metered and mixed using the standard 
protocol and those prepared with the meter-mix device, showing the 3D-printed device 
                                               
6This chapter was first published in Lab on a Chip with authorship belonging to Erik Jue, Nathan G. 
Schoepp, Daan Witters, and Rustem F. Ismagilov. The original manuscript can be found at: 
http://dx.doi.org/10.1039/c6lc00292g. 
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could accurately meter, mix and dispense a human urine sample without loss of 
nucleic acids. Although there are some limitations to 3D printing capabilities (e.g. 
dimension limitations related to support material used in the printing process), the 
advantages of customizability, modularity and rapid prototyping illustrate the utility of 
3D printing for developing sample-to-device interfaces for diagnostics. 
 
Introduction 
 
We evaluate multi-material 3D printing for the design and prototyping of an interlock 
meter-mix device that meters and lyses human urine samples for a workflow compatible 
with limited-resource settings (LRS) and point of care (POC) diagnostic testing. 3D 
printing comprises a set of additive manufacturing techniques that allows the formation 
of complex 3D structures with minimal restrictions. The emerging technological 
capabilities of 3D printing bring exciting advancements in the fabrication of microand 
macrofluidic de vices, enabling architectures that would be difficult with conventional 
fabrication techniques such as soft lithography.1,2 A primary advantage of 3D printing is 
the ability to rapidly prototype and iterate new designs, without needing to tool expensive 
molds.3 3D printing reduces the design and prototyping time from weeks and months 
down to hours and days, making prototyping more cost-effective and therefore more 
accessible—particularly for research labs where needs may change frequently. Because 
3D printing is semi-automated, it minimizes assembly time, the requirements for labor, 
and reproducibility issues, therefore reducing many of the barriers that currently prevent 
some research labs from prototyping complex 3D parts.2 The customizable design files 
generated in computer-aided design (CAD) software can be easily modified in 
coordination with experiments. 3D printed materials also exhibit a wide range of 
properties, with varying levels of rigidity, surface roughness, optical clarity, and 
biocompatibility to fit a diverse range of device requirements.4 In combination, all of 
these advantages make 3D printing attractive for prototyping fluidic devices relevant to 
lab-on-a-chip and diagnostics fields.  
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The sample-to-device interface for diagnostics is a critical component of nucleic acid 
amplification testing (NAAT) in LRS, and remains an unsolved challenge.5,6 Many 
NAAT technologies are not amenable to LRS, because NAAT is an intrinsically 
multistep process involving sample metering, lysis, nucleic acid (NA) purification, 
amplification, and detection.7 To be useful in clinical practice in POC or LRS, the entire 
NAAT workflow should be fully automated, user-friendly (without training or pipetting 
steps to meet CLIA-waiver), rapid, equipment-free, sensitive, and specific. To equip a 
portable device with complete sample-in to answer-out functionality requires the 
appropriate consideration of all upstream and downstream processes. While many efforts 
have been taken to automate nucleic acid (NA) purification and amplification, sample 
metering must always be addressed because a user in LRS or at the POC cannot be asked 
to pipette accurately. Furthermore, combining sample transfer with the step in which the 
sample is mixed with the lysis buffer is attractive, because it has the advantage of 
minimizing the cost and complexity of an integrated diagnostic device, and could benefit 
such devices being developed in research labs, including our own.8–11 Precise metering is 
especially critical in NAAT testing of sexually transmitted diseases (STDs), such as 
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG).12 In 2013, there were 1 
401 906 and 333 004 reported cases of CT and NG, respectively, in the United States, 
with many more cases unreported and undiagnosed.13 The Centers for Disease Control 
and Prevention (CDC) estimates 20 million new STD infections per year in the US, 
accounting for $16 billion in health care costs.13 The CDC now recommends NAAT for 
CT/ NG diagnosis14 because these tests are sensitive, accurate and use non-invasive urine 
samples. Many of these tests need to be done under LRS or POC settings.  
 
Currently, there is no standardized way to deliver a known amount of sample mixed with 
lysis buffer to an LRS- or POC-compatible NAAT diagnostic device. A method for doing 
so is subject to the following constraints: (i) meter a precise volume of urine with <5% 
coefficient of variation (CV), (ii) mix urine with premeasured, preloaded lysis buffer at a 
specific ratio (as determined by the extraction chemistry), (iii) transfer the lysed urine 
without dripping potentially infectious solution, (iv) perform these operations quickly, in 
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a userfriendly, equipment-free manner that minimizes potential user errors, and (v) 
maintain the sensitivity and specificity of the overall assay (no loss of nucleic acids to 3D 
printed surfaces, contamination, or leachates).  
 
Here, we evaluate the capabilities of multi-material 3D printing to design and prototype a 
single-use disposable macrofluidic device that meets the above constraints. We also 
discuss the advantages and disadvantages of 3D printing as a research tool for device 
development. Multi-material printing, wherein different materials are combined into a 
single printed part, offer expanded capabilities, so we chose to spe cifically investigate 
multi-material 3D printing as a tool for building sample-to-device interfaces. We have 
previously demonstrated the utility of multi-material printing in the development of a 
pumping lid for interfacing with microfluidic devices,15 however the pumping lid we 
developed was only used to compress air, and did not contact fluids directly. Here, we 
expand on the ability to use multi-material printed parts to generate sealed fluid cavities 
through the development of a multivalve and plungers used within our device. 
 
Results and discussion 
 
Interlock design and meter-mix device operation  
 
To operate the meter-mix device (see ESI† video), the user performs three simple steps 1. 
insert urine suction tube into patient sample and pull urine plunger, 2. remove from 
patient sample and slide multivalve, and 3. push lysis buffer plunger to eject the mixed 
solution. The device can then be easily disposed of as biohazardous waste. Furthermore, 
the user of the device cannot accidentally perform these three operations out of order due 
to the presence of interlock features attached to the plungers. In the initial position, the 
urine plunger interlock blocks the sliding of the multivalve, and the multivalve blocks the 
movement of the lysis buffer plunger (Fig. 1A). When the user pulls up on the urine 
plunger, urine is aspirated through the suction tube, through the valve, and into the urine 
chamber. Pulling up on the urine plunger also releases the interlock that was blocking the 
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multivalve (Fig. 1B and C). The user then slides the multivalve, which disconnects the 
urine suction tube inlet while generating two new outlets to a static mixer, one outlet for 
urine and the other for lysis buffer which has been prestored on the device. By pre-storing 
the lysis buffer on device, we eliminate many manual pipetting steps and reduce user 
error.16 The sliding of the multivalve also creates openings for the urine plunger interlock 
and the lysis buffer plunger interlock (Fig. 1C). In the final step, the user pushes down on 
the lysis buffer plunger, which also pushes the urine plunger, ejecting both urine and lysis 
buffer through the static mixer (Fig. 1D). The total user operating time is between 5 and 
10 s.  
 
 
Fig. 7-1. Schematic overview of the design and operation of the 3D-printed interlock 
meter-mix device for metering and mixing a urine sample with lysis buffer. (A) The 
multivalve has five holes that are labeled accordingly. (B) Lysis buffer (blue) is 
preloaded into the lysis buffer chamber, where the topmost position of the lysis buffer 
plunger (left, grey) is pre-determined by stoppers (tan). The urine plunger interlock rod 
(right, beige) is posi- tioned within the multivalve, preventing the valve from sliding and 
simultaneously blocking the lysis buffer plunger interlock rod. The user pulls up on the 
urine plunger (C) until it contacts and is stopped by the lysis buffer plunger, aspirating 
urine and simultaneously removing the urine plunger interlock rod from the multivalve. 
The user slides the multivalve (D), closing off the urine suction tube, opening the lysis 
buffer and urine outlets to the mixer, and providing openings for both interlock rods. In 
the final step, the user pushes down on the lysis buffer plunger (E), ejecting urine and 
lysis buffer through a static mixer, wherein the solutions are well mixed before finally 
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being ejected from the tip of the mixer. Red blocks at the bottom of each panel show a 
top-down view of the multivalve. Black circles and rings indicate holes in the multivalve. 
Slashed circles indicate the presence of a feature that is blocked by the multivalve. 
Colored circles indicate the presence of an interlock rod or an open channel for the flow 
of a solution. 
 
The meter-mix device is composed of eight assembled parts: 1. main enclosure, 2. lysis 
buffer plunger, 3. urine plunger, 4. two plunger stoppers, 5. multivalve, 6. urine suction 
tube, 7. static mixer elements, and 8. static mixer case (Fig. 2). All parts were designed 
using 3D CAD software (Solidworks 2015 Education Edition) and fabricated using an 
Objet 260 multi-material 3D printer (Stratasys, Eden Prairie, MN, USA). We judiciously 
selected two semi-transparent photopolymer materials, Veroclear and TangoPlus, 
corresponding to a rigid plastic, analogous to polyIJmethyl methacrylate) (PMMA), and a 
soft, elastomeric material, analogous to rubber, respectively. By utilizing translucent 
materials, fluids are visible as they are transported among chambers of the device, 
providing visual feedback during operation. All of the parts were composed of Veroclear, 
providing a strong structure. The plunger heads, stoppers, and the multivalve were 
printed with a combination of Veroclear and TangoPlus, which enabled us to design 
sliding surfaces and generate seals. With the exception of the plunger stoppers, each part 
underwent between seven and 25 unique design iterations. In the Fig. 2 demonstration, 
which shows the entire device assembly and operation, 1150 µL 0.05% (v/v) sky blue 
Ateco dye (August Thomson Corp., Glencove, NY, USA) was preloaded into the lysis 
buffer chamber and 0.1% lemon yellow Ateco dye was manually loaded into the urine 
chamber. These two dye solutions were run through the device and combined to form a 
green mixed solution (Fig. 2D).  
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Fig. 7-2. Photographs of the device at different stages of operation. (A) In the initial 
position, blue dye representing lysis buffer is preloaded and the urine plunger is down. 
(B) In the second position, the urine plunger contacts the lysis buffer plunger and a 
specific volume of yellow dye representing urine is metered. (C) In the third position, the 
multivalve was slid 5 mm to the right, simultaneously closing and opening new 
connections. (D) In the final position, both plungers are down, dispensing a green 
solution out through the static mixer and into a 1.5 mL tube (inset). 
 
Designing and prototyping leak-proof connections  
 
To ensure reliable device operation, all of the seals on the device need to be hermetically 
sealed. We accomplish this using the capability of multi-material 3D printing to generate 
materials jointly composed of hard plastic (Veroclear) and soft rubber-like material 
(TangoPlus). We used multi-material printing for fabricating both plungers and the 
multivalve. The challenge with creating leak-proof connections is determining the 
appropriate dimensions, overlap, and the ratio of soft:hard material to create a strong 
leak-proof connection that is still easy to move by hand. We took advantage of the rapid 
prototyping capabilities of 3D printing to quickly converge on functional designs. For the 
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urine chamber, we found a good fit using an 8 mm diameter hole and an 8 mm 
diameter plunger head, where the inner diameter of the plunger head consisted of 7.2 mm 
Veroclear; the remaining diameter was filled with TangoPlus. For the lysis buffer 
chamber, we found good fit using an 11.31 mm diameter hole and an 11.31 mm diameter 
plunger head, where the inner diameter of the plunger head consisted of 10.18 mm 
Veroclear; the remaining diameter was filled with TangoPlus. These parameters made 
hermetically sealed connections capable of generating and holding a vacuum. We 
selected the dimensions of the chambers in the main enclosure to provide the desired air 
volumes and mixing ratios (see Accurate dispensing). To generate the multivalve seal, an 
open cavity was designed through the side of the main enclosure, with raised ridges 
around each hole for the inlets and outlets. The multivalve was 2.7 mm thick, with 0.54 
mm TangoPlus (20%) layered on the top and 0.54 mm on the bottom. At the points of 
contact between the multivalve and the inlet/outlet ridges, there was a 0.2 mm overlap 
where the ridge pushed into the TangoPlus layer (by 3D CAD design). To assist sealing 
and sliding, we applied silicone oil to lubricate all contact points at movable interfaces 
(plunger heads, chambers, and the multivalve).  
 
Plunger system and accurate metering  
 
To accurately meter urine, we designed a plunger system with predetermined start and 
stop positions. During device operation, the urine plunger is pulled up until it contacts the 
underside of the lysis buffer plunger. The volume displaced by the plunger was calculated 
in CAD software, providing an estimate for the volume of urine aspirated into the device. 
To precisely calibrate metering, the working design was iterated by testing prototypes of 
the device by aspirating deionized water, weighing the device, and modifying the height 
of the plunger stoppers to adjust the volume displaced by the plunger. To accurately 
meter lysis buffer, we use a pipettor to preload the meter-mix device. When the device is 
set to the initial configuration, lysis buffer is sealed on both sides by the lysis buffer 
plunger and multivalve. This is advantageous for a disposable LRS and POC device 
because the filling step can be performed during manufacturing and assembly. In this 
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way, the end-user does not need to consider handling of the lysis buffer during device 
operation.  
 
With diagnostic devices, it is important to minimize dead volumes to avoid wasting 
reagents, losing sample, or introducing a source of variability. One strength of 3D 
printing is that potential sources of dead volume can be identified and reduced during the 
design process. For the meter-mix device, we identified four potential sources of dead-
volume: urine lost in the suction tube, urine lost in the urine chamber, lysis buffer lost in 
the lysis buffer chamber, and mixed solution remaining in the static mixer. We recognize 
that patient urine is abundant, and that it is acceptable for the meter-mix device to overfill 
urine; however, the final volume of urine ejected from the device must be consistent 
between runs. To ensure accurate, consistent ejected volumes, the dead-volume of the 
urine suction tube was taken into account while modifying the positions of the plunger 
stoppers. It should be noted that dead-volume can be reduced by changing the design of 
the suction tube as required. For our meter-mix device, we were concerned with dead 
volumes of urine remaining in the urine chamber and the static mixer, which could 
contribute to differences in the volumes of urine ejected between runs. In particular, a 
user who sees liquids trapped in the static mixer may be inclined to shake the meter-mix 
device, introducing error which affects the accuracy of downstream quantitative 
processes. To remove this dead volume, we leave a pocket of air that sits above the lysis 
buffer within the lysis buffer chamber. After urine is aspirated into the device, we 
designed the system so that the heights of the pockets of air are roughly equal (the air 
initially residing in the suction tube is incorporated into the device during the aspiration 
step). These two pockets of air produce a blow-out volume of air which removes the dead 
volumes of urine and lysis buffer that would otherwise remain in the chambers and static 
mixers.  
 
We wanted to ensure that after urine is aspirated into the urine chamber, urine is unable 
to leak out through the tip of the urine suction tube. Bretherton previously examined this 
problem, and found the dimensionless bond number, Bo (which relates gravity to surface 
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tension), to be a guiding parameter.17 The bond number is related to the density 
difference between the liquid and air, the diameter of the tube, and the surface tension of 
the liquid. He predicted that for a vertical tube that is sealed at one end, a bubble 
contained within will not rise if Bo < 0.842.17 Thus, in our meter-mix device, if the bond 
number is low, and a bubble enters the urine suction tube, the bubble will be immobile, 
preventing solution from dripping out through the tip of the urine suction tube. 
Bretherton's prediction suggests that we want to minimize the bond number, which we 
can do simply by reducing the diameter of the 3D-printed urine suction tube. We would 
not, however, want to make the diameter so small that it generates a high resistance to 
flow, as this would generate a noticeable delay in the filling time and negatively affect 
the user experience. Tube diameter is constrained with our 3D printing methods because 
as tube diameter decreases, it becomes increasingly difficult to remove the support 
material and clean inside the tube. For our device, we limited our testing to >1.5 mm 
diameter sized suction tubes. At the millimeter scale, there was no noticeable delay 
between pulling up on the urine plunger and filling of the urine chamber.  
 
We tested the Bretherton prediction using 3D-printed parts. A simple plunger system was 
designed along with suction tubes of varying diameters. In multi-material 3D printing, the 
printing of support material can be avoided for some geometries and configurations. We 
printed straight suctions tubes in the vertical configuration, which does not print support 
within the suction tube and therefore does not require support cleaning. Although we can 
choose not to print some support pieces, one limitation of our multi-material printer is 
that it always prints support material for the bottom layer in contact with the 3D printer's 
build plate. When one side of the model is printed in contact with support and the other 
parts of the model are located on the exterior sides of the device, there may be minor 
differences between dimensions and surface roughness. For example, we found that when 
printing straight tubes upright, the diameter on the side of the tube in contact with the 3D 
printer's build plate was slightly smaller than the opposite opening. A discrepancy 
between parts of the model in contact with the build plate and parts that are open to the 
air is not an exclusively multimaterial 3D printing characteristic, but is common to many 
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types of 3D printers. Care was taken to always use the side of the tube in contact with 
the build plate for the connection to the body of the plunger system.  
 
Table 7-1. Bretherton’s prediction tested using 3D printed tubes of varying diameter 
 
 
To test the Bretherton prediction, we used the opposite side of the suction tube to aspirate 
solution into the tube. The suction tube was manually disturbed through tapping the tip in 
order to introduce bubbles, mimicking a real-world user experience where the user bumps 
the device. We found that there was general agreement between bond number and the 
Bretherton prediction (Table 1). Using water, for a bond number ≤ 0.416, no bubbles 
entered the device and no fluid dripped from the tip. For bond numbers between 0.544 
and 0.688, a bubble entered the tube releasing some drops, but the bubble did not rise and 
the liquid–air interface at the tip regained stability. Close to the Bretherton prediction at 
Bo = 0.850, bubbles entered the tube and both rise and no rise of the bubble were 
observed, which seemed to depend on the size of the bubble incorporated. Finally, for a 
large bond number (1.028), drops were released when the bubble initially entered the 
tube, the liquid–air interface at the tip regained stability, and we saw bubble rise as 
predicted by Bretherton. The experiment was repeated using ethanol, which has a lower 
surface tension than water, with similar results. We also observed that for very large bond 
numbers (Bo ≥ 2.155), once the ethanol–air interface at the tip was disturbed, a column of 
air entered the suction tube, spilling all of the solution out of the tip. Accounting for 
Bretherton's prediction, the limitations of cleaning support material, and for the pocket of 
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air for blow-out, we selected a suction tube diameter of 2.3 mm in the final design. 
The surface tension of urine from healthy patients ranges from 48–70 mN m−1.18 Using 
the low value of surface tension at 48 mN m−1, a density of 1.01, and a 2.3 mm diameter 
gives a Bo = 0.272.  
 
Accurate dispensing  
 
The flow rate of each solution is determined by the design of the device chambers, 
plungers, and outlets. We designed each chamber of the device to undergo the same 
driving pressures over the entire dispensing operation. We can accomplish this by 
matching the solution height, air pocket height, and plunger heights in both chambers. 
For example, a 2 : 1 volume ratio can be obtained by making the area of one chamber 
twice the area of the second chamber. The crosssectional area of the channels and outlet 
valves should also be maintained at the 2 : 1 ratio to obtain the flow resistance and 
corresponding volumetric flow rate. In our device, we designed the device with a 2:1 
volume ratio between lysis buffer and urine, but we were cognizant of the potential for 
flow irregularities near the beginning and end of the flow regime. If slight inaccuracies 
during filling cause urine to enter the static mixer prematurely or after all of the lysis 
buffer has gone through, this could leave some urine unmixed and unlysed. This could 
lead to inaccuracies during downstream quantification and unlysed bacteria are a 
biohazard. To address these concerns, we slightly overfilled the lysis buffer compartment 
leading to a final lysis buffer to urine volume ratio of 2.2 : 1.  
 
We evaluated the dispensing accuracy of our device using water, green dye, 
spectrophometer measurements, and a balance. To examine inter-device variability, we 
tested three different device prototypes each run in triplicate (Table 2). There was no 
significant difference among devices for aspiration volume (P = 0.46) or the volume 
expelled (P = 0.44). Sample aspiration was found to accurately meter ∼790 µL (<1% 
CV). As previously described, the blow-out volume of air is responsible for ejecting the 
final volumes of urine and lysis buffer remaining in the chambers and the static mixer. 
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We found that pushing the plunger down over the course of 1–2 s led to relatively 
little error in the final ejection volume (<2% CV). However, pushing the plunger down 
faster (in <1 s) pushed bubbles through the static mixer and greater volumes of liquid 
remained in the device, resulting in reduced ejection volumes (∼1350 µL). In real-world 
applications, it is important to minimize differences resulting from user operation. Future 
designs can address the issue of plunger speed affecting dead volume by reducing the 
diameter of the outlets to prevent bubbles from escaping before the fluid. The ratio of 
solution ejected from the lysis buffer chamber and the urine chamber was calculated by 
measuring the absorbance of the final ejected solution and comparing it to the green dye 
loaded into the lysis buffer chamber. We found that dispensed volumes out of the lysis 
buffer chamber and urine chamber were similar, with percent deviations of 2.5% and 
6.7%.  
 
Table 7-2. Evaluation of metering and dispensing accuracy of the meter-mix device 
 
 
Static mixer design and mixing evaluation  
 
To simplify the user experience and eliminate mixing by pipetting or vortexing, we 
designed an on-device Kenics static mixer (KMS), a common mixer used for a variety of 
industrial applications.19 We had previously designed the flow rates of urine and lysis 
buffer to exit the outlets at a consistent flow rate. We predicted that a KMS mixer placed 
after the lysis buffer and urine outlets would be an efficient way to mix the two streams. 
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The static mixer is composed of alternating leftand right-hand 180° helical twists with 
90° offsets between elements. This immobile structure encased within a tube guides the 
flow of solutions from the center of the tube to the wall of the tube and from the wall to 
the center. Each element splits and recombines streams of flow, rapidly homogenizing the 
fluid, similar to mixing by chaotic advection in moving plugs.14,20,21 We designed a KMS 
static mixer com posed of eight elements, with a diameter of 5 mm, and a length : 
diameter ratio of 1.25 : 1. Limited by the requirements of removing support material from 
3D-printed parts, it was not feasible to print the entire mixer and tube enclosure as a 
single unit. Instead, we used a modular approach, printing the mixer elements and the 
mixer case as separate pieces. Both parts were printed in the upright configuration.  
 
When static mixer elements were printed with the glossy finish setting, only the topmost 
element was glossy and had different surface roughness and dimensions than the other 
elements (remaining parts had the matte finish because they were printed in contact with 
supporting material). To address this issue, we printed the static mixer elements with the 
matte finish (Fig. 3A). The static mixer elements and the static mixer case were cleaned 
separately and assembled carefully because the static mixer elements were very prone to 
breaking (Fig. 3B–D).  
 
To evaluate mixing quality, a starch iodine–thiosulfate decolorization was used. The 
decolorization reaction is a preferred method to evaluate mixing because any pockets of 
unmixed regions will be visible.22 The initial decolorization reaction occurs quickly in a 1 
: 1 iodine : thiosulfate ratio, although a secondary reaction leads to the reappearance of 
color so higher ratios of iodine : thiosulfate (e.g. 1 : 1.2 or 1 : 1.4) can be used.23–25 For 
the meter-mix device, we used a 1 : 1.05 ratio because the design enables rapid mixing 
within the timescale of the device operation. The starch iodine solution was loaded into 
the urine chamber through the suction tube, and the sodium thiosulfate was preloaded 
into the lysis buffer chamber. The device mixed the two solutions within the first three to 
four elements (Fig. 3G). As a control, to confirm that the loss of color is due to mixing 
and not an artifact of the chemical or optical properties of the 3D printed part, we also 
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show the static mixer element fully filled and while mixing with a solution that does 
not cause decolorization. We ran the meter-mix device with starch iodine indicator 
loaded into both chambers (Fig. 3E) and in a separate experiment with starch iodine 
loaded into the urine chamber and water loaded into the lysis buffer chamber (Fig. 3F).  
 
 
Fig. 7-3. Assembly of the static mixer (A–D) and a demonstration of its use in the meter-
mix device (E–G). (A) Freshly printed static mixer ele- ments before cleaning. (B) Static 
mixer elements after a 15 min cleaning step to remove support material. (C) Static mixer 
case. (D) As- sembled static mixer with elements inserted into case. (E) Iodine– starch 
indicator loaded into both chambers and ejected through the static mixer. (F) Iodine–
starch indicator mixing with water to show a di- lution. (G) Iodine–thiosulfate de-
colorization reaction demonstrating rapid mixing within the first few static mixer 
elements. 
 
Function and biocompatibility  
 
We evaluated the meter-mix device for compatibility with a routine nucleic acid 
extraction kit by comparing the metering and mixing steps performed by the device with 
standard approaches for metering and mixing (manual pipetting and vortexing). Two 
concerns are the potential for nucleic acids to bind to 3D printed surfaces, and the 
potential for compounds from 3D printed materials to leach into the solutions, both of 
which can negatively affect downstream analysis of nucleic acids. We preloaded the 
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device with 1150 µL lysis buffer and aspirated urine spiked with 104 cells per mL of 
either C. trachomatis (CT) or N. gonorrhoeae (NG) through the suction tube. The 
multivalve was slid and the plungers were pushed manually, ejecting the solutions 
through the static mixer and into a 2 mL polypropylene tube. An off-device sample was 
tested in parallel, with 1100 µL lysis buffer and 500 µL spiked urine (see Table 2) 
metered by a pipettor and the solution mixed by vortex. We also ran no-template controls 
containing clean urine for both on and off-device conditions. After mixing, all samples 
were processed in parallel according to the manufacturer's instructions using the QIAamp 
Viral RNA Mini kit (recommended for purification of bacterial DNA from urine). 
Following extraction, nucleic acid concentrations were compared using routine 
quantitative polymerase chain reaction (qPCR) with primers previously evaluated for the 
detection of C. trachomatis26 or N. gonorrhoeae.27 The threshold cycles for vortexed and 
device-mixed samples were not statistically different (Fig. 4), indicating that there was no 
significant loss of nucleic acids and or material leaching that inhibited downstream 
analysis. No-template negative controls showed no amplification after 35 cycles. 
 
 
Fig. 7-4. qPCR threshold cycles on DNA extracted from urine spiked with either 
inactivated Chlamydia trachomatis (CT) or Neisseria gonorrhoeae (NG). Sample 
metering and mixing with lysis buffer was performed with either the meter-mix device 
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(light green bars) or stan- dard pipette and vortex (dark green bars). The remainder of 
the extraction protocol was identical for both conditions. 
 
Experimental 
 
Meter-mix device cleaning and assembly  
 
Printed parts were cleaned using pipette tips or copper wire and rinsed with water. The 
urine plunger, lysis buffer plunger, multivalve, and both chambers of the main enclosure 
chambers were lubricated with viscous silicone oil (dimethylpolysiloxane 12500 cSt, 
Sigma Aldrich, St. Louis, MO, USA). To assemble, first the urine plunger was inserted 
into the urine chamber of the main enclosure followed by the lysis buffer plunger into the 
lysis buffer chamber. The two plunger stoppers were then inserted, locking the topmost 
position of the lysis buffer plunger. The multivalve was inserted into the main enclosure 
from the side, and pushed into its final position to preload 1150 µL lysis buffer through 
the outlet. The multivalve was then moved into its starting position, the urine plunger 
pushed to the bottom of the chamber, and the urine suction tube and static mixer were 
attached. For these joints, the outer diameter of the static mixer case (8 mm) and the outer 
diameter of the urine suction tube (4.5 mm) was sized exactly to the diameter of adapters 
on the main enclosure. After cleaning, a thin layer of support material remains at the 
junctions of the main enclosure. Because this support material is shed from the joints 
during device use, we used silicone oil to enhance the seal.  
 
Characterization of metering and dispensing  
 
To evaluate metering and dispensing, we loaded into the lysis buffer chamber 1150 µL 
0.5% (v/v) green food color dye (The Kroger Co., Cincinnati, OH, USA) diluted in 
deionized water. Deionized water was aspirated into the urine chamber through the urine 
suction tube, and mass measured to obtain the aspirated volume (using water density of 1 
g mL−1). The multivalve was pressed and the solution ejected into a pretared conical 
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tube to obtain the mass of the solution ejected from the device. The resulting solutions 
were well-mixed through vortexing. The original 0.5% (v/v) green dye and each resulting 
solution was diluted by 20×, loaded into a cuvette, and measured with a UV-vis 
spectrophotometer (Nanodrop 2000c, Thermo Scientific, Wilmington, DE, USA). 
Measurements were taken at the wavelength where the absorbance was maximal (630 
nm), and the ratio was used to determine the volume of solutions ejected from each 
chamber.  
 
Iodine–thiosulfate decolorization reaction  
 
Iodine, starch indicator, and sodium thiosulfate solutions were prepared according to the 
“Handbook of industrial mixing”.22 Briefly, 1150 µL sodium thiosulfate nonahydrate 
(0.5 mM, ThermoFisher Scientific, Waltham, MA, USA) was loaded into the the lysis 
buffer chamber. Starch indicator was prepared by adding 100 mg starch, soluble potato, 
powder (J.T. Baker, Center Valley, PA, U.S.) and 20 g potassium iodide to 10 mL 
deionized water. 50 µL of this starch solution was added to a 1 mL solution of iodine (1 
mM, Alfa Aesar, Ward Hill, MA, USA), coloring the solution dark bluishpurple. The 
final ratio of iodine:thiosulfate was 1:1.05. A video was taken using a Samsung Galaxy 
S4 camera, and frames extracted during device operation when the flow fully filled the 
static mixer (Fig. 3E–G).  
 
Qiagen extraction and qPCR experiment  
 
In order to test device compatibility with biological samples and ensure that downstream 
nucleic acid analysis was not negatively affected, we compared samples that were 
metered and mixed on-device against traditional vortex mixing using a commercial 
nucleic acid extraction kit (QIAamp Viral RNA Mini Kit, 52904). Lysis buffer was 
loaded with 2 ng µL−1 carrier DNA (salmon sperm DNA, Thermo Fisher AM9680). 
Non-infectious CT and NG samples were obtained from ZeptoMetrix Corp. (NATNG-
ERCM, NATCT(434)-ERCM, Buffalo, NY, USA). Quantitative PCR was performed on 
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a Roche LightCyler 96. PCR reactions consisted of 5 µL SsoFast EvaGreen Supermix 
(BioRad cat no. 1725200), 2.0 µL of template (extracted spiked urine), 0.5 µL of 20× 
primer stocks, and 2.5 µL nuclease-free water. The primers used26,27 were previously 
evaluated for the detection of either CT or NG. Final primer concentration in the reaction 
was 500 nM. Thermal cycling consisted of a 3 min initial denaturation step at 95 °C, 
followed by 40 cycles of20sat95°C,20sat62°C,and20sat72°C.Meltanalysis confirmed 
specific product for all reactions. 
 
Conclusions 
 
We showed that multi-material 3D printing can be used to prototype a disposable 
interlock meter-mix device that accurately meters urine and completely mixes it with 
lysis buffer in a format that meets the requirements for a downstream NAAT compatible 
with LRS and POC settings. The 3D-printed device accurately aspirated predetermined 
volumes into a urine chamber with a coefficient of variation of 0.8%. Urine and lysis 
buffer were dispensed through a KMS static mixer at a 2.2 : 1 mixing ratio. Printing with 
translucent materials enabled visual confirmation of fluid movement and showed that 
mixing occurred within the first few elements of the static mixer, with homogenization 
and lysis later verified by qPCR. Printing with multi-material 3D printer enabled us to 
use a combination of composites to create airtight seals that slide without leaking or 
losing vacuum pressure. Using a 3D printer also helped address the potential for sample 
drip ping, a biohazardous concern when working with bodily fluids and potentially 
dangerous solutions, as we were able to test Bretherton's prediction for bubble rising 
through several prototype iterations and identify optimal tube dimensions that ensured the 
sample did not drip.  
 
The 3D-printed device was designed to optimize the user's experience: operation is 
simple (three steps); interlock features protect against user error; neither pipetting nor 
vortexing are required; and the entire device operation is completed within 5 to 10 s (see 
ESI† video). We validated our device by lysing urine samples spiked with CT/NG and 
  
206 
performed downstream processes to quantify nucleic acids through qPCR. These 
results confirmed that the 3D-printing materials (Veroclear and TangoPlus) were 
biocompatible; we observed no loss of nucleic acids and devices performed equally well 
compared with the standard protocol of pipettor metering and vortex mixing in a 
polypropylene tube. Finally, we demonstrated that the performance of the meter-mix 
device matched the performance of standard laboratory protocols for metering and 
mixing, with a substantially shorter time period for device operation.  
 
The meter-mix device described here is not limited to mixing urine with lysis buffer. A 
common operation in biology, chemistry, and medicine is to mix two solutions of known 
volume. Due to the customizability of 3D printing and CAD design, it is easy to adapt the 
meter-mix device to different volumes or configurations. In some applications, it may be 
desirable to meter two different solutions at the time of use. In this example, the meter-
mix device could be reconfigured with an additional suction tube appended to the lysis 
buffer chamber. Given the versatility of the metermix device, it may be useful in a variety 
of applications such as sequencing, dilutions, or chemical syntheses. Because the meter-
mix device simplifies and accelerates workflow, protects against user error and provides 
a user-friendly experience, we foresee its future application in research labs and limited-
resource settings. For example, time-sensitive laboratory measurements may require 
metering and mixing on the timescale of single digit seconds rather than the tens of 
seconds required for pipetting. In commercial applications, an important advantage of a 
single-use disposable device is that it can be assembled and pre-loaded with lysis buffer 
before it is shipped, eliminating a pipetting step for the end user.  
 
Throughout the course of device development, the 3D printing workflow was a major 
advantage over analogous forms of prototyping, such as soft lithography. Prototyping 
with 3D printing was rapid, enabling us to design, test, redesign, and reprint a prototype 
in the period of a single day. For small parts that can be printed in less than a few hours, 
it is possible to iterate multiple designs in a single day. The ease with which parts can be 
modified after having developed the initial design allowed us to print multiple variations 
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of the meter-mix device at once and determine the optimal architecture of each part in 
a single experiment. This was useful for determining the diameter of the suction tube, 
setting the parameters for the static mixer, and adjusting the fit for the seals. Another 
advantage with 3D printing is that the 3D CAD models which are developed during the 
design stage can also be utilized and adapted for injection molding. This is important in 
commercial applications, where large quantities are required, because injection molding 
has higher start-up costs but lower costs per part than 3D printing. We also found 
modularity to be an important advantage with 3D printing. Parts can be built as separate 
components and later reassembled, reducing build time (which relies heavily on z-axis 
height). It is also easier, and less expensive, to validate and iterate with individual 
components than to redesign and reprint an entire device. Of course, the final cost of 
producing these devices using standard manufacturing methods (injection molding) will 
be even lower than prototyping costs.  
 
The greatest limitation we faced with multi-material 3D printing pertained to the support 
material. We faced three specific issues: (i) wherever support material is printed in 
contact with the model, the printer produces a matte finish with different surface 
characteristics and dimensions compared with the glossy finish of parts that do not 
contact the support material, (ii) it can be difficult to remove the support material for 
some geometries, so care needs to be taken during the design to account for cleaning, and 
(iii) removal of the support material takes time, requiring ∼45 min to clean all of the 
components for a single device. As new support material is developed, this limitation will 
diminish. For example, some companies have developed new dissolvable support 
materials that can be removed in a soak-and-rinse process; however, these processes are 
still diffusion-limited and may be difficult to implement when cleaning long, narrow 
channels relevant to microfluidic devices. Despite some limitations, we conclude that 3D 
printing is an attractive prototyping technology with great potential for solving the 
sample-to-device interface problem in diagnostics, especially in resource-limited settings. 
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Chapter VIII 
 
Flow-through capture and in situ amplification can enable rapid  
detection of a few single molecules of nucleic acids from several milliliters 
of solution7 
 
Abstract 
 
Detecting nucleic acids (NAs) at zeptomolar concentrations (few molecules per milliliter) 
currently requires expensive equipment and lengthy processing times to isolate and 
concentrate the NAs into a volume that is amenable to amplification processes, such as 
PCR or LAMP. Shortening the time required to concentrate NAs and integrating this 
procedure with amplification on-device would be invaluable to a number of analytical 
fields, including environmental monitoring and clinical diagnostics. Microfluidic point-
of-care (POC) devices have been designed to address these needs, but they are not able to 
detect NAs present in zeptomolar concentrations in short time frames because they 
require slow flow rates and/or they are unable to handle milliliter-scale volumes. In this 
paper, we theoretically and experimentally investigate a flow-through capture membrane 
that solves this problem by capturing NAs with high sensitivity in a short time period, 
followed by direct detection by amplification. Theoretical predictions guided the choice 
of physical parameters for a chitosan-coated nylon membrane; these predictions can also 
be applied generally to other capture situations with different requirements. The 
membrane is also compatible with in situ amplification, which, by eliminating an elution 
step enables high sensitivity and will facilitate integration of this method into sample-to-
answer detection devices. We tested a wide range of combinations of sample volumes 
and concentrations of DNA molecules using a capture membrane with 2 mm radius. We 
                                               
7This chapter was first published in Analytical Chemistry with authorship belonging to Travis S. Schlappi, 
Stephanie E. McCalla, Nathan G. Schoepp, and Rustem F. Ismagilov. The original manuscript can be found 
at: http://dx.doi.org/10.1021/acs.analchem.6b01485. 
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show that for nucleic acid detection, this approach can concentrate and detect as few 
as ~10 molecules of DNA with flow rates as high as 1 mL/min, handling samples as large 
as 50 mL. In a specific example, this method reliably concentrated and detected ~25 
molecules of DNA from 50 mL of sample. 
 
Introduction 
 
Detection of nucleic acids (NAs) at ultra-low concentrations (few molecules per milliliter 
of sample) in short time intervals is invaluable to a number of analytical fields, including 
environmental monitoring and clinical diagnostics1-6. Pathogens in aqueous 
environmental samples are frequently present at or below zeptomolar concentrations 
(~1000 microorganisms per liter), requiring laborious filtration and concentration 
procedures before detection is possible.7,8 In many clinical applications, including 
minimal residual diseases9 and latent Hepatitis C viral (HCV) or HIV infections, target 
NAs are also present at < 10 molecules/mL.10,11 Blood bank donations are typically 
pooled before screening, so targets may be diluted by several orders of magnitude before 
being screened for pathogens, generating a sample where ultra-sensitive detection is 
critical.12,13 Each of these examples requires the processing of large volumes (mLs) of 
extremely dilute samples, and therefore the ability to concentrate NAs on the order of 
1000X to reach PCR-suitable volumes (µLs). Additionally, the entire concentration 
process must be done within minutes and not rely on expensive equipment to be directly 
applicable to limited-resource settings (LRS) and at the point-of-care (POC).14,15 
 
Commercial systems for the purification and concentration of nucleic acids typically 
involve solid phase extraction (SPE), which uses chaotropic agents to control the 
absorption and release of NAs on silica.16,17 While this method is widely used, most 
available protocols require centralized laboratories for centrifuging samples or 
manipulating beads.18 NA precipitation19 methods are also commonly used to extract and 
concentrate NAs from clinical and environmental samples; however these methods are 
laborious and involve the use of hazardous reagents.20 These methods are challenging to 
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deploy for LRS, where instrumentation is limited, or for use at the POC, where 
diagnostics must be rapid and require minimal sample handling.18 To address these needs, 
several charge-based methods have been developed, which typically include a charged 
polymer matrix including chitosan, poly-L-lysine, and so on for NA capture (we are 
building on that work in this paper).21-25 To increase sensitivity, these and other systems 
concentrate NAs and then either elute before amplification21,22,24,25 or perform 
amplification in situ.23,26-29 Concentration factors up to 15X21,30 and limits-of-detection as 
sensitive as 104 copies/mL23 or 500 cells/mL26 have been reported. While these methods 
have clear advantages over traditional solid-phase extraction methods, processing time 
and lowest detectable concentration are still limited by their inability to handle large 
sample volumes (>1 mL)26-28,31 and/or their slow processing rates, which range from 
µL/min to µL/hr.18,21,22,24,32,33 Thus, current methods—whether commercialized or from 
literature—lack the required combination of sensitivity, speed, and ease of 
implementation, leaving a gap in the current NA detection workflow. 
 
We hypothesized that pressure-driven flow and capture in a porous matrix could facilitate 
the handling of large samples, while retaining many of the characteristics needed for both 
LRS and POC. Here, we analyze this approach theoretically and experimentally to 
determine a regime in which rapid, convection-driven capture is possible. Using a 
theoretical framework to predict capture efficiency as a function of flow-through 
conditions, we determined the parameters necessary for a detection matrix to capture a 
few nucleic acid molecules (<10) from several mLs of volume in short times (<10 
minutes). We tested our predictions experimentally with respect to capture efficiency, 
lowest detectable concentration, processing time, and total sample volume. Furthermore, 
we demonstrated that the capture matrix is compatible with direct amplification, 
eliminating the need for an elution step. The ability to amplify in situ makes this 
approach amenable to integration into sample-to-answer devices, and preserves the high 
concentration factors achieved during capture by preventing loss of target to the capture 
matrix during elution. 
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Experimental Section 
 
Capture Simulations. The fraction of nucleic acid molecules captured in a membrane 
pore compared to the amount flowed through (capture efficiency) was simulated at 
steady-state using the Transport of Diluted Species module of Comsol Multiphysics 
(version 4.4). A complete description of the model geometry, transport parameters, 
kinetics, boundary conditions, mesh, and calculations performed is included in 
Supporting Information. 
 
Chitosan Membrane Fabrication. A nylon membrane (LoProdyne LPNNG810S, Pall 
Corp., New York City, NY) was used as a porous matrix support. Two methods were 
employed for chitosan functionalization of the membrane, summarized below as “Method 
A” and “Method B.” 
 
Method A: The LoProdyne membrane has hydroxyl surface chemistry and was 
functionalized with N,N carbonyldiimidazole (CDI) in methylene chloride according to 
the manufacturer’s protocol (http://www.pall.com; Supporting Information S-VII). 
 
Chitosan oligosaccharide lactate (No. 523682, Sigma-Aldrich, St. Louis, MO) was 
purified by dissolving 1.2 g chitosan in 40 mL nuclease-free (NF) water, then precipitated 
by adding 3 mL 1M NaOH. This solution was mixed and filtered through Whatman paper 
#8 (12 cm). It was then rinsed with MilliQ water until the eluant was neutral. Washed 
chitosan was dried for 2 h under vacuum, then a rotary evaporator was used to remove 
residual moisture. 
 
The optimal pH at which to cross-link chitosan with CDI was determined to be pH 5.0. 
Based on the pKa of chitosan (pKa = 6.3), ~5% of the chitosan’s amines will be 
deprotonated and able to react. At pH > 5, a larger percentage of the chitosan amines will 
be deprotonated, resulting in a higher degree of crosslinking to the support surface, and 
fewer available amines to interact with nucleic acids. At a pH of 5.0, the chitosan 
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polymer should crosslink to the support at either one or two positions, leaving the 
bulk of the polymer free in solution. 
 
To prepare chitosan-coated supports, a 6 mg/mL solution of purified chitosan was 
prepared in 34 mM HCl.  This solution was vortexed for 10 min until the chitosan was 
fully dissolved, then sonicated to remove bubbles. The pH was then raised to 5.0 by 
addition of NaOH while vortexing. A CDI-functionalized LoProdyne membrane was then 
saturated with this chitosan solution. The membrane and chitosan solution were 
sandwiched between two glass slides, and pressed to remove excess chitosan solution. 
The wet membrane was blot-dried and placed in a desiccator to dry under vacuum for 
20–30 min. After drying, the membrane was placed in a 50 mL Falcon tube and rinsed 
with NF water. The water was poured out, 0.1 M HCl was added to quench any 
remaining CDI and remove non-crosslinked chitosan, and the membrane and HCl 
vortexed for 2 min. The HCl was poured out and the membrane was rinsed with NF water 
again. Next, the membrane was placed in a fresh Falcon tube, rinsed more with NF water, 
washed in NF water for 25 min while agitated, rinsed with NF water three more times, 
blot dried, then air dried in a desiccator. 
 
Method B: To prepare hydrogel coated membranes, a 0.5% (w/v) solution of chitosan 
(TCI OBR6I) was prepared in 150 mM HCl. A 25% (v/v) solution of glutaraldehyde was 
added to this solution to a final concentration of 4 mM. The solution was rapidly mixed, 
and added to the LoProdyne membrane in excess. The saturated membranes were then 
spun on a Laurel WS-400-6NNP/Lite spin coater at 500 rpm for 5 s with an acceleration 
setting of 410, followed by 15 s at 2000 rpm with an acceleration setting of 820. 
Membranes were allowed to crosslink for 2 h in air, washed 3 times with NF water, and 
dried under vacuum. 
 
Binding Capacity Measurements. 1000 ng of salmon sperm DNA (Invitrogen, Carlsbad 
CA) in 100 µL of 10 mM MES buffer (pH ~5) was sequentially flushed through a 
chitosan membrane (radius = 2 mm, fabricated with Method A) five times via a 
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syringe/luer lock system (Figure 4-S4). The inlet and eluate DNA concentration of 
each flush was measured with PicoGreen dye (Invitrogen); subtracting the eluate from the 
inlet and converting to mass of DNA yielded the plot in Figure 8-3. 
 
Capture and In Situ Amplification. λ-phage DNA stocks were quantified via digital 
PCR.34 This DNA was spiked into varying volumes of 10 mM MES buffer (pH ~5) to 
create concentrations ranging from 0.2 to 20 copies/mL (Table 4-S4). The solutions were 
flowed through chitosan-coated nylon membranes (radius = 2 mm) using syringes and 
luer locks (Figure 4-S4), followed twice by 100 µL MES buffer.  The membranes were 
then removed from the syringe/luer lock system, placed in an Ilumina EcoTM well plate, 
and 5–10 µL of PCR mix was added to each membrane. The well plate was inserted into 
an Ilumina EcoTM real time PCR system (EC-101-1001, Ilumina, San Diego, CA) and 
thermal cycled; correct λ-phage product was verified with a gel and melt curve analysis 
(Figure 4-S5). 
 
The PCR mixture used for amplification of λ-phage DNA on the chitosan-coated nylon 
membranes contained the following: 5 µL 2X SsoFast Evagreen SuperMix (BioRad, 
Hercules, CA), 1 µL of BSA (20 mg/mL), 2 µL of 10 ng/uL salmon sperm DNA 
(Invitrogen), 1 µL of 5 µM primers (SI-VI), and 1 µL of NF water. The PCR 
amplification was performed with an initial 95 °C step for 3 min and then followed by 40 
cycles of: (i) 20 s at 95 °C, (ii) 20 s at 62 °C, (iii) 15 s at 72 °C. 
 
Results and Discussion 
 
Theoretical Analysis. To predict a regime that would enable rapid flow-through capture 
of nucleic acids present at low concentrations, we developed a theoretical model that 
takes into account the convection, diffusion, and adsorption of nucleic acid molecules 
onto a capture agent layered within a porous matrix (Figure 8-1a and S-I). Although the 
structure of the nylon membrane is spongy and non-uniform, approximating the pores as 
cylinders is an appropriate simplification to estimate the transport processes and has been 
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done previously.35,36 The parameters governing capture dynamics in a cylindrical pore 
are superficial velocity U [m/s], pore radius Rp [m], membrane radius Rm [m], membrane 
thickness (or, equivalently, pore length) δm [m], diffusivity of nucleic acid molecules37 D 
[m2/s], association rate constant38 kon [m3/(mol·s)], surface concentration of the capture 
agent γ [mol/m2], and mass transfer coefficient kc [m/s]. Instead of analyzing every 
relevant parameter individually, we condensed them into two dimensionless numbers:39,40 
Damköhler (Da) and Péclet (Pe). Da characterizes the balance between adsorption rate 
and transport rate (Eq. 2) while Pe characterizes the balance between convection rate and 
diffusion rate (Eq. 2). 
 𝐷𝑎 =	 (yzL.{0/LY	.(0|0.(Yz{L.0	.(0| = }bc~}a , 𝑘- = 1.62 N $PTSW   (2) 
 𝑃𝑒 = 	 -LY)|-0/LY	.(0|y/Jz/LY	.(0| = $//P                                        (2) 
 
Da > 1 indicates that the rate of DNA binding to the capture agent is faster than the rate 
of DNA transport to the pore wall; Pe < 1 means the rate at which molecules diffuse to 
the pore wall is faster than the rate at which they are convected through the pore. To 
capture dilute nucleic acids from large volumes in short times, two conditions must be 
met: i) efficient capture (Da >> 1), and ii) fast flow rates (Q ~ 1 mL/min) while 
maintaining Pe < 1. 
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Figure 8-1. Theoretical model and numerical simulations for flow-through capture. a) A 
schematic drawing showing the process of capturing nucleic acids from a sample flowing 
through a porous membrane (which has been functionalized with a capture agent). b) 
Predictions for the percentage of molecules captured at the pore wall as a function of the 
Damköhler number (Da). c) Predictions for the percentage of molecules captured at the 
pore wall as a function of the Péclet number (Pe).  Pe is changed by varying the velocity 
(U), pore length (δm), or pore diameter (Rp); all result in a similar dependence of capture 
percentage on Pe. 
 
Capture efficiency is a factor of binding kinetics (time for the nucleic acid molecule to 
bind to the capture agent) and transport (time for the nucleic acid molecule to travel from 
the bulk solution to the pore wall coated with capture agent).  High capture efficiency 
occurs when the transport rate is slower than the binding reaction rate (i.e., Da >>1), 
which can occur with fast reactions or slow transport. Many passive capture processes—
such as wicking through a porous matrix or mixing with beads—rely on slow transport 
rates to achieve high Da.  These processes capture efficiently at small length scales in 
microliter volumes;21-23,33 however, for milliliter volumes and large length scales, passive 
capture processes would require impractical amounts of capture agent or time for Da to 
be greater than 1. A fast binding reaction with diffusion-limited kinetics would enable 
higher transport rates (and thus faster flow rates) without adversely affecting capture 
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efficiency. Electrostatic binding and silica adsorption in the presence of Ca2+ are 
examples of diffusion-limited chemical reactions41,42 that would maintain high Da 
without relying on slow transport rates to ensure efficient capture. Our simulations show 
that when a capture agent coated on a pore wall has fast binding kinetics, Da > 10 ensures 
> 95% capture of nucleic acids flowing through the pore (Figure 8-1b and S-I). To scale 
up efficient capture processes to larger volumes, the mass transport rate can be increased. 
One way to increase mass transport rate is actively forcing fluid through a porous 
matrix,43 which has been used for protein capture44 and is well established in membrane 
chromatography35,36. However, flow-through capture has not been analyzed theoretically 
nor tested experimentally for rapid capture and detection of zeptomolar nucleic acids.  
In general, high flow rates increase the transport rate, decrease Da, and thus reduce 
capture efficiency. However, the transport rate can be maintained below the adsorption 
rate (keeping Da >> 1) by manipulating other transport parameters, thus counteracting 
the high flow rate. These transport parameters can be analyzed together by simulating the 
capture efficiency as a function of Pe (S-I): simulations show that keeping Pe < 1 ensures 
> 90% capture efficiency (Figure 8-1c). To achieve a high convection rate and maintain 
Pe < 1, a relatively high diffusion rate is required, which ensures that the molecules don’t 
leave the pore before having a chance to diffuse to the wall and bind. To maintain this 
balance of a high convection rate with an even higher diffusion rate, the membrane 
radius, pore radius, and membrane thickness can be adjusted. Setting Pe < 1 in Eq. 2 
provides the following constraint on flow rate through the membrane (Q) as a function of 
δm, Rm, and Rp, where ϕ represents the porosity of the membrane (see S-II for derivation). 
 𝑄 < PP    (3) 
  
Plotting Eq. 3 at different membrane thicknesses explores the relationship of these 
parameters (Figure 8-2a); trends favoring Pe < 1 and flow rates > 1 mL/min are 
decreasing pore radius, increasing membrane radius, and increasing membrane thickness. 
Decreasing the pore size enables faster diffusion rates and lower Pe, but it also increases 
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the resistance to flow. Figure 8-2b considers this tradeoff, showing the pressure drop 
required for a sample to flow through the membrane at 1 mL/min at different membrane 
and pore radii.  The overlap of the green triangles (Pe < 1) with red color (ΔP < 1 atm) 
represents an ideal combination of parameters wherein Pe is low enough and a reasonable 
pressure drop is achieved to flow at 1 mL/min. 
 
 
Figure 8-2. Predictions of membrane radius, pore radius, and membrane thickness 
tradeoffs for achieving high flow rates while also maintaining reasonable pressure drop 
(ΔP) and a low Péclet number (Pe). a) Combinations of membrane radius, pore radius, 
and flow rate that maintain Pe < 1 for different membrane thicknesses. Any point below 
the surface curvature has Pe < 1.  b) The influence of membrane and pore radius on 
pressure drop with the flow rate through the membrane held constant at 1 mL/min. The 
overlap of the green triangle (Pe < 1) and red colored area represents efficient and rapid 
capture with a reasonable pressure drop (ΔP < 1 atm). The white area signifies a 
combination of membrane and pore radius that results in prohibitively large pressure 
drops (ΔP > 1 atm) necessary to achieve 1 mL/min. 
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Experimental Analysis. Based on these predictions, we chose an appropriate 
experimental system to evaluate the ability of a flow-through matrix to rapidly capture 
zeptomolar concentrations of nucleic acids. This matrix should be compatible with in situ 
amplification, so glass fiber, silica, and other common capture materials that inhibit 
amplification reactions were not considered.45,46 Nylon membranes do not prevent 
nucleic acid amplification and can be purchased in various pore sizes and thicknesses. 
The membrane thickness for a LoProdyne nylon membrane from Pall Corporation ranges 
from 127.0-190.5 µm (see Experimental Section); at this thickness, a membrane radius 
of 2 mm is flexible and easily placed in a well plate for nucleic acid amplification. For a 
membrane thickness of 160 µm, flow rate of 1 mL/min, and membrane radius of 2 mm, 
Eq. 3 predicts that pore radii less than 0.76 µm would maintain Pe < 1. Therefore, we 
chose LoProdyne membranes with a pore radius of 0.6 µm; coating the membrane pores 
with a capture agent makes the pore size even smaller, ensuring that we were well below 
the 0.76 µm requirement. As described, the capture agent must have diffusion-limited 
kinetics. Because electrostatic binding is very fast and can easily be used for nucleic acid 
capture utilizing a cationic polymer to attract the negatively charged phosphate backbone 
of DNA, we chose chitosan as the capture agent, which has previously been used for NA 
capture.21-25 Chitosan is an inexpensive biocompatible polymer with amine groups on its 
backbone that become positively-charged when the pH is below 6.3.22,47 We 
functionalized chitosan onto the nylon membrane as described in Experimental Section. 
To verify that functionalizing the membrane with chitosan does not reduce the pore size 
such that the pressure drop becomes untenable (Figure 8-2b), we measured the capture 
efficiency at different flow rates. This experiment showed that the chitosan-
functionalized nylon membrane captures > 90% of nucleic acids when solution is flowed 
through at 1 mL/min (see Figure 4-S2 of the Supporting Information). 
 
To test the predictions from our analysis, we  evaluated the capture efficiency as a 
function of Pe by flowing 500 ng/mL solutions of DNA through chitosan membranes at 
five different flow rates. Each flow rate was tested with three replicates and the capture 
efficiency along with one standard deviation is plotted in Figure 4-S2. These experiments 
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confirmed that the chitosan membranes capture efficiently over a range of Pe, with > 
90% capture of DNA when Pe < 1 (Figure 4-S2). We also measured the DNA binding 
capacity of chitosan-functionalized nylon membranes and found that they have a capacity 
of 1000 ng or more (Figure 4-3). This capacity is much greater than needed for our target 
application of zeptomolar concentrations (10-21 M ~ 0.6 fg/mL for a bacterial genome). 
However, researchers in other fields may find this matrix useful in capturing large 
amounts of genetic material for other applications. 
 
Figure 8-3. DNA binding capacity of chitosan-functionalized membranes fabricated with 
Method A. 
 
Next, we tested whether in situ amplification would be chemically compatible with the 
nylon membrane that had been functionalized with chitosan. We added serial dilutions of 
DNA to the membrane, then submerged in amplification mix and amplified DNA via 
PCR. The chitosan membrane was compatible with in situ PCR amplification down to ~2 
copies per reaction (Figure 4-S3a). We also tested the chitosan membrane compatibility 
with in situ LAMP and showed successful amplification at 20 copies per reaction (Figure 
4-S3b48). 
 
In this paper we did not study the location at which amplification occurs (i.e. whether 
amplification is initiated on the target molecules still attached to the surface of the 
membrane, or on the molecules released from the surface into the membrane pores, or on 
the molecules diffusing out of the pores). Further, we did not study the spatiotemporal 
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mechanism of propagation of amplification once it is initiated. Such studies could 
provide interesting information in subsequent research.  
 
The final step was to use chitosan’s charge-switch capability to couple rapid capture with 
direct amplification without eluting the nucleic acids. A sample flows through the 
chitosan-coated membrane at pH ~5 and the negatively-charged phosphate backbone of 
DNA will electrostatically bind to the positively-charged amine groups on the chitosan. 
Following capture of NAs, the addition of amplification mix at pH ~8 deprotonates the 
amine groups and releases the captured nucleic acids for amplification (Figure 8-4). 
 
 
Figure 8-4. Schematic of capture and in situ amplification. a) Nucleic acids in a solution 
with pH < 6.3 will electrostatically bind to the protonated chitosan pore wall. b) Addition 
of amplification mix (pH ~8) deprotonates the chitosan and releases nucleic acids. 
Thermal cycling amplifies DNA. 
 
We then tested this idea (combining rapid capture and in situ amplification via charge-
switch) at ultra-low concentrations (~1 copy/mL) and fast flow rates. Various amounts of 
λ DNA were spiked into volumes ranging from 1 to 50 mL with 100 ng or less 
background DNA (Table 4-S4); the solution was then flowed through a 2 mm radius 
chitosan-functionalized membrane at ~1 mL/min. After capture, the amplification was 
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performed in situ with small volumes of PCR reagents (5–10 µL), as opposed to the 
traditional method of eluting from a capture matrix and using larger volumes of PCR 
reagents. DNA product was detected after thermal cycling using EvaGreen dye (see SI-V 
for details). This methodology detected a DNA target at concentrations as low as 0.5 
copies/mL from as many as 50 mL (Figure 8-5b). Compiling data from replicate 
experiments run on different days, pre-concentration using the chitosan-functionalized 
membrane allowed detection down to 1 copy/mL over 85% of the time. Using any 
concentration above 10 copies/mL, detection results for the capture and amplification 
matrix were positive 100% of the time. No amplification was detected when flowing 
through buffer without DNA (see Figure 4-5a and Table 4-S4), ensuring that the λ DNA 
product detected is indeed from the sample flowed through the membrane and not 
contamination of the membrane, lab materials, or PCR reagents with λ-phage DNA. 
 
 
Figure 8-5. Nucleic acid detection via flow-through capture and in situ amplification on 
chitosan membranes. a) Percent of membranes that were positive for λ DNA product over 
different experiments on different days for varying concentrations (0.2–20 copies/mL). 
The volume flowed through ranged from 1 to 50 mL (Table 4-S4) and the flow rate was 
~1 mL/min. Each bin of the histogram has 6–26 samples for a total of 82 samples. b) 
Percent of membranes that were positive for λ DNA product over different experiments 
on different days. 50 mL solutions with 25 copies of target DNA and 10 or 100 ng 
background DNA were flowed through membranes at ~0.3 mL/min. The number of 
replicates are N = 10 for 100 ng and N = 9 for 10 ng. All error bars are 1 S.D. 
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We observed that the chitosan membrane performance appeared to decrease slightly as 
larger volumes were flowed through (e.g., >10 mL volumes were 77% positive (23 out of 
30 tests) and >20 mL volumes were 60% positive (9 out of 15 tests), see Table 4-S4). 
This decreased performance at higher volumes could be due to chitosan shedding off the 
membrane during flow or the fact that larger volumes have longer residence times and 
therefore more opportunity for the DNA molecule to release from its binding site and be 
flushed out of the membrane with the eluate. A thicker membrane with longer pores or a 
chitosan-functionalization method that more strongly attaches chitosan to the nylon 
membrane could potentially improve its performance at larger volumes; however, these 
parameters were not tested and are outside of the scope of this study. 
 
Our experiments have been using stringent conditions with high flow rate (~1 mL/min) 
and high level of added background DNA. For some applications, these conditions might 
be too stringent, and high sensitivity of detection may be more valuable. For example, 
drinking water samples do not always have the high level of background DNA we used. 
The presence of high levels of background DNA can affect capture efficiency of the 
target molecule during flow-through and can affect amplification efficiency during PCR. 
We therefore also tested detection of ultra-low concentrations of nucleic acids from large 
volumes with reduced background DNA at 10 ng and slower flow rates at 0.3 mL/min. 
We compared 50 mL solutions with 100 ng background DNA to 50 mL solutions with 10 
ng background DNA. These experiments showed that 25 copies in 50 mL could be 
consistently detected under these conditions (Figure 4-5b). We have not yet further 
investigated how the performance of this method depends on the interplay of flow rate, 
pore geometry, level of DNA background, and the details of fabrication of the chitosan 
coating.To test whether salts in solution could interfere with electrostatic binding and 
decrease the ability of chitosan membranes to capture and detect nucleic acids, we 
performed six preliminary experiments. The experiments were identical to those 
performed for Figure 4-5, but instead of using 10 mM MES buffer as the medium 
comprising nucleic acids, various salt solutions were used (see S-VIII for details): i) 
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Ringer’s solution (10 and 20 copies λ DNA in 1 mL), Ringer’s solution with 5 mM 
EDTA (10 and 20 copies λ DNA in 1 mL) and 5 mM EDTA alone (10 and 20 copies λ 
DNA in 1 mL). All six experiments resulted in positive amplification, indicating that the 
presence of salts does not disrupt capture of nucleic acids on the chitosan membrane nor 
their subsequent amplification. 
 
Conclusion 
 
We evaluated an approach for ultrasensitive detection of nucleic acids using chitosan as a 
charge-switch matrix that enables concentration factors up to 5000X (defined as the ratio 
of final detection volume to the starting sample volume, e.g., DNA from 50 mL of 
solution was detected in 10 µL of PCR mix) and subsequent in situ amplification. A 
theoretical model guided the parameters chosen for flow rate, membrane radius, and pore 
radius. Based on model predictions, membranes with specific pore and membrane radii 
were functionalized to capture low copy numbers of nucleic acids from large volumes in 
short times. Using this approach, we were able to capture zeptomolar concentrations of 
nucleic acids from up to 50 mL of solution at a flow rate of 1 mL/min with ΔP < 1 atm.  
In applications with different requirements for flow rate, pressure drop, or membrane 
size, this theory can be applied to guide choices of membrane parameters that meet those 
requirements. 
 
In addition, flowing through a matrix that is compatible with in situ amplification 
obviates the need for centrifugation or bead manipulation and simplifies the purification 
process by eliminating an elution step. Chitosan-functionalized nylon membranes are 
sturdy, flexible, and small enough to be incorporated into integrated devices for complete 
sample-to-answer diagnostics. In this study, we focused on the theory and the proof-of-
principle experiments using solutions of purified nucleic acids in clean matrixes. 
However, more complex matrices are encountered in many applications. Ultrasensitive 
measurements of viral, bacterial, and cancer-associated nucleic acids provide important 
diagnostic information to clinicians, but require the extraction and detection of NAs from 
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milliliters of plasma and in some cases cell lysis. Combining this approach with lysis 
buffers and/or sample pretreatment should be tested next to evaluate the efficacy of this 
methodology for detection from a variety of sample matrices, such as blood, plasma, 
urine, and water. Additional work on integration of this approach with isothermal 
amplification would enable rapid and ultra-sensitive nucleic acid measurements for point-
of-care and limited-resource settings. 
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Supporting Information 
 
Flow-through capture simulations 
 
The fraction of nucleic acid molecules captured in a membrane pore compared to the 
amount flowed through (capture efficiency) is a function of pore geometry, flow 
parameters, and adsorption kinetics (Figure 8-S6). The concentration of nucleic acids at 
any position in the pore, C(r, z), was simulated at steady-state using the Transport of 
Diluted Species module of Comsol Multiphysics (version 4.4) with the parameters listed 
in Table 4-S1. To generate the data for Figure 4-1b-c, a parametric sweep was performed 
with various values of kon·γ, U, Rp, and δm (Table 4-S2 and Table 4-S3). Then, the inlet 
flux (Jin = J|z = δm) and outlet flux (Jout = J|z = 0) were evaluated and used in Eq. S-3 to 
calculate capture efficiency. 
 𝐶𝑎𝑝𝑡𝑢𝑟𝑒	% = 1 − 𝐽LJ0𝐽/Y  (S-3) 
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Figure 8-S6. Schematic of flow-through simulation geometry.  Red represents the 
capture agent (γ) coated on the surface of the pore wall. 
 
Table 4-S1. Parameters used in the flow-through capture simulations. 
Parameter Description Value 
Rp Pore radius 0.56  – 17.78 µm 
δm Pore length (thickness of membrane) 0.316  – 3162 µm 
U Flow velocity 0.118 – 1000 mm/s 
D Diffusivity of nucleic acid molecule 10 µm2·s-1 
kon Nucleic acid binding rate constant 106 L·mol-1·s-1 
γ Surface concentration of capture agent 10-7 mol·m-2 
Cin Inlet concentration of nucleic acids 1 µM 
 
Table 4-S2. The product of kon·γ was varied to generate Capture % as a function of 
Damköhler number (Da) (Figure 4-1b).  Rp (1 µm), δm (100 µm),U (2 mm/s), D (10 
µm2·s-1), and Cin (1 µM) were held constant. 
 
kon·γ (m/s) kc (m/s) Da Jin (mol/s) Jout (mol/s) Capture % 
1.00E-07 1.62E-05 0.01 -3.92E-18 -3.88E-18 1.0 
2.15E-07 1.62E-05 0.01 -3.92E-18 -3.83E-18 2.1 
4.64E-07 1.62E-05 0.03 -3.92E-18 -3.74E-18 4.5 
1.00E-06 1.62E-05 0.06 -3.92E-18 -3.55E-18 9.3 
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2.15E-06 1.62E-05 0.13 -3.92E-18 -3.19E-18 18.5 
4.64E-06 1.62E-05 0.29 -3.92E-18 -2.58E-18 34.2 
1.00E-05 1.62E-05 0.62 -3.92E-18 -1.75E-18 55.2 
2.15E-05 1.62E-05 1.33 -3.92E-18 -9.77E-19 75.0 
4.64E-05 1.62E-05 2.87 -3.92E-18 -5.03E-19 87.2 
1.00E-04 1.62E-05 6.17 -3.92E-18 -2.94E-19 92.5 
2.15E-04 1.62E-05 13.3 -3.92E-18 -2.11E-19 94.6 
4.64E-04 1.62E-05 28.7 -3.92E-18 -1.78E-19 95.5 
1.00E-03 1.62E-05 61.7 -3.92E-18 -1.63E-19 95.8 
2.15E-03 1.62E-05 133 -3.92E-18 -1.57E-19 96.0 
 
Table 4-S3. U, δm, or Rp was varied to generate Capture % as a function of Péclet number 
(Pe) (Figure 4-1c).  Cin (1 µM), kon·γ (10-4 m/s), and D (10 µm2·s-1) were held constant. 
 
U (m/s) δm (µm) Rp (µm) Pe Jin (mol/s) Jout (mol/s) Capture % 
1.18E-04 100 1 0.12 -2.46E-19 -2.32E-36 100.0 
2.68E-04 100 1 0.27 -5.32E-19 -1.00E-26 100.0 
6.11E-04 100 1 0.61 -1.20E-18 -4.11E-22 100.0 
1.39E-03 100 1 1.39 -2.72E-18 -7.21E-20 97.4 
3.16E-03 100 1 3.16 -6.19E-18 -1.11E-18 82.0 
7.20E-03 100 1 7.20 -1.41E-17 -5.92E-18 58.0 
1.64E-02 100 1 16.4 -3.21E-17 -2.02E-17 37.0 
3.73E-02 100 1 37.3 -7.30E-17 -5.70E-17 22.0 
8.48E-02 100 1 84.8 -1.66E-16 -1.46E-16 12.3 
1.93E-01 100 1 193 -3.78E-16 -3.54E-16 6.5 
4.39E-01 100 1 439 -8.60E-16 -8.32E-16 3.2 
1.00E+00 100 1 1000 -1.96E-15 -1.93E-15 1.6 
2.00E-03 3162 1 0.06 -3.90E-18 8.30E-39 100.0 
2.00E-03 1000 1 0.20 -3.90E-18 -1.15E-28 100.0 
2.00E-03 316 1 0.63 -3.90E-18 -1.72E-21 100.0 
2.00E-03 100 1 2.00 -3.90E-18 -2.90E-19 92.6 
2.00E-03 31.6 1 6.32 -3.90E-18 -1.50E-18 61.5 
2.00E-03 10.0 1 20.0 -3.90E-18 -2.65E-18 32.1 
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2.00E-03 3.16 1 63.2 -3.90E-18 -3.30E-18 15.4 
2.00E-03 1.00 1 200 -3.90E-18 -3.65E-18 6.4 
2.00E-03 0.316 1 632 -3.90E-18 -3.80E-18 2.6 
2.00E-03 100 0.56 0.63 -1.23E-18 -1.60E-21 99.9 
2.00E-03 100 1.00 2.00 -3.90E-18 -2.90E-19 92.6 
2.00E-03 100 1.78 6.32 -1.23E-17 -4.20E-18 65.9 
2.00E-03 100 3.16 20.0 -3.90E-17 -2.30E-17 41.0 
2.00E-03 100 5.62 63.2 -1.23E-16 -9.40E-17 23.6 
2.00E-03 100 10.00 200 -3.90E-16 -3.40E-16 12.8 
2.00E-03 100 17.78 632 -1.23E-15 -1.15E-15 6.5 
 
Geometry: The model was assembled using a cylindrical geometry drawn in 2D axially 
symmetric space, with r as the radial component and z the axial component (Figure 4-S1).  
The radius of the cylinder (Rp) varied from 0.56 µm to 17.78 µm; the length of the 
cylinder (δm) varied from 0.316 µm to 3162 µm (Table 4-S3). 
 
Transport: In a porous matrix, fluid flow can be approximated with a uniform velocity 
(U) independent of radius1.  The flow velocity varied from 1.18·10-4 m/s to 1 m/s (Table 
4-S3).  The top boundary of the cylinder (z = δm) was an inlet and the bottom boundary (z 
= 0) was an outlet.  The diffusion coefficient used was for DNA2, 10-11 m2/s. 
 
Kinetics:  The binding rate between nucleic acids and the capture agent was assumed to 
be second order with respect to nucleic acid concentration and capture agent surface 
concentration. We assumed the surface concentration of capture agent (γ) was in excess 
(and therefore unchanging during the course of the adsorption reaction) and estimated it 
to be 10-7 mol/m2.  With a kinetic rate constant estimated from nucleic acid-cationic 
polymer kinetics3, the adsorption rate occurring at the pore wall is shown in Eq. S-4. 
 𝑅(yz = 𝑘LY ∙ 𝛾 ∙ 𝐶(𝑅{, 𝑧) (S-4) 
Normally, adsorption kinetics include both an on and off rate.  However, in this situation, 
we excluded the off rate from analysis because it was insignificant compared to the on 
rate (kon ~ 107 M-1s-1, koff ~ 10-3 s-1, reference 38 from the manuscript). 
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Boundary conditions:  The inlet concentration of nucleic acid molecules (Cin = 10-6 
mol/L) represents a normal nucleic acid concentration in human blood plasma4.  Axial 
symmetry was imposed at r = 0, and a flux boundary condition (Eq. S-5) was imposed at 
r = Rp to represent the adsorption of nucleic acid molecules to the surface of the pore 
wall. 
 𝑅(yz 	= 𝐷 𝜕𝐶(𝑟, 𝑧)𝜕𝑟 .  (S-5) 
Mesh and solver settings: The geometry was meshed using a Free Triangular mesh with a 
maximum element size of 0.0525 𝜇m.  The Direct Stationary Solver (PARDISO) was 
used with a nested dissection multithreaded preordering algorithm and an auto scheduling 
method. 
 
Equation 3 and Figure 4-2b 
 
The number of pores in a membrane (np) can be calculated from the porosity (ϕ) as in Eq. 
S-6. 
 𝜙 = 𝑛{𝜋𝑅{T𝜋𝑅T → 𝑛{ = 𝜙𝑅T𝑅{T  (S-6) 
The flow rate through the entire membrane (Q) is the flow rate through each pore (Qp) 
multiplied by the number of pores (Q = npQp).  Using Eq. S-6 for np and solving for Qp 
gives the following: 
 𝑄{ = 𝑄𝑅{T𝜙𝑅T  (S-7) 
Eq. S-8 results from plugging Eqn S-7 into the relationship between pore flow rate and 
flow velocity (Qp = UπRp2). 																							𝑈 = 𝑄{𝜋𝑅{T = 𝑄𝜋𝜙𝑅T  (S-8) 
Then, using Eq. S-8 in Eq. 2 and setting the condition that Pe < 1 yields Eq. S-9. 
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Solving Eq. S-9 for Q yields Eq. 3. ϕ = 0.6 and D = 10-11 m2/s were assumed for all 
calculations. 
 
To calculate the pressure drop as a function of pore radius (Rp) and membrane radius 
(Rm), Pouiselle flow was assumed (Eq. S-10).  Flow rate through the pore (Qp) was 
replaced with flow rate through the entire membrane (Q) using Eq. S-7.  Q (1 mL/min), µ 
(10-3 Pa·s), and ϕ (0.6) were held constant; Rp and Rm were varied from 1 to 3 µm and 1 
to 3 mm, respectively. The results, along with regimes of Pe < 1 calculated from Eq. 2, 
are plotted in Figure 4-2b. 
 Δ𝑃 = 8𝜇𝑄{𝛿𝜋𝑅{  = 8𝜇𝑄𝛿𝜋𝜙𝑅{T𝑅T  (S-10) 
 
DNA binding efficiency as a function of Pe 
 
100 ng of salmon sperm DNA (Invitrogen, CA) in 200 µL of 10 mM MES buffer (pH ~5) 
was flushed through a chitosan membrane with a radius of 2 mm at different flow rates 
via the syringe/luer lock system shown in Figure 8-S9. The inlet and eluate DNA 
concentration of each flush was measured with PicoGreen dye (Invitrogen, CA); 
converting to mass (mDNA), Eq. S-11 was then used to calculate the capture efficiency. 𝐶𝑎𝑝𝑡𝑢𝑟𝑒	% = V1 − 𝑚¢[,LJ0𝑚¢[,/Y X · 100 (S-11) 
Pe was calculated via Eq. 2 and the results are plotted in Figure 8-S7.  This agrees with 
theoretical predictions that Pe > 1 results in reduced capture.  Also, layering the nylon 
membrane with chitosan does not significantly hinder flow rate or require untenable 
pressure drops to achieve flow rates of ~ 1 mL/min and efficient capture. 
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Figure 8-S7. Capture efficiency depends on flow rate. 
We clarify that capture efficiencies > 90% are only possible when the capture agent is in 
excess of the target DNA molecule and Pe < 1, which is the case for 100 ng of input 
DNA (Figure 4-S2). On the other hand, the purpose of the experiments in Figure 4-3 was 
to measure the total binding capacity of the chitosan membrane (i.e., occupy all the 
cationic binding sites). To accomplish this, larger quantities of DNA (1000 ng) were 
flowed through the membrane and the capture efficiency was not expected to be high; in 
fact, with each successive load, it should decrease to 0% until all binding sites are 
occupied. Indeed, we observed that the capture efficiency in Figure 4-3 varied from 60% 
in the first run to 20% in the fifth run—by the time the fifth load of 1000 ng DNA was 
flowed through the membrane, there were fewer binding sites available and thus the 
recovery was much lower than the first load when all binding sites were available. 
 
Compatibility of chitosan membrane with in situ amplification 
 
To test the compatibility of chitosan membranes with in situ PCR amplification, 1 µL of 
varying concentrations of λ DNA was wetted into chitosan membrane with a radius of 2 
mm.  The membrane was then placed in a well plate and 10 µL PCR mix was added to 
the well. Replicates containing 10 µL PCR mix with the same amount of λ DNA and no 
membrane present were also included.  The well plate was inserted into an Ilumina EcoTM 
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real-time PCR System (EC-101-1001) and thermal cycled; correct λ-phage DNA 
product was verified with melt curve analysis.  The PCR mix and thermal cycling 
conditions used were the same as described in the Experimental Section.  Figure 8-S8a 
shows that chitosan membranes are compatible with in situ PCR amplification down to 
~2 copies/reaction. 
 
To test compatibility with in situ LAMP amplification, 20 copies of λ DNA were wetted 
into a chitosan membrane with a radius of 2 mm.  The membrane was then placed in a 
well plate and 10 µL LAMP mix was added to the well. Replicates containing 10 µL 
LAMP mix with 20 copies of λ DNA and no membrane present were also included as 
solution controls.  The well plate was inserted into an Ilumina EcoTM real-time PCR 
System and incubated for 40 min at 68 °C. Figure 8-S8b shows the real-time fluorescent 
traces representing DNA product. 
 
Figure 8-S8.  Compatibility of chitosan membranes with PCR and LAMP amplification. 
a) Dilutions of λ DNA were wetted onto chitosan membranes or placed into a well plate 
without a membrane; PCR mix was added and amplification was detected via melt curve 
analysis.  Six replicates were run at each dilution; the percent of replicates positive for λ 
DNA product is shown (n = 6).  b) 20 copies of λ DNA were wetted onto chitosan 
membranes within a well plate, or placed into a well plate without a membrane; LAMP 
mix was added and amplification was detected via real-time fluorescence.  Three 
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replicates were run for each sample; the fluorescent traces as a function of time are 
plotted. 
 
LAMP reagents were purchased from Eiken Chemical (Tokyo, Japan), product code 
LMP207.  The LAMP mixture used for amplification of λ-phage DNA contained the 
following: 5 µL Reaction Mixture, 0.4 µL of Enyzme Mixture, 0.5 µL of 20X LAMP 
primer mixture (Table 4-S6), 0.25 µL of Calcein (Fd), and 3.85 µL of nuclease-free 
water. 
 
Details of capture and in situ amplification (Figure 4-5) 
 
Figure 8-S9 is a schematic of the syringe/luer lock system used to flow mL-scale volumes 
through chitosan membranes with a radius of 2 mm. Syringes were purchased from BD 
(Franklin Lakes, NJ) and luer locks (Catalog #LC78-J1A) were purchased from Nordson 
Medical (Westlake, Ohio). Table 4-S4 shows all the quantities of λ DNA, volumes of 10 
mM MES buffer, and amounts of background DNA used to generate Figure 4-5. Salmon 
sperm DNA from Invitrogen (Carlsbad, CA) was used as “background DNA”. 
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Figure 8-S9.  Schematic of syringe/luer lock system used to flow mL-scale volumes 
through the chitosan membrane with a radius of 2 mm.  A chitosan membrane is placed 
in between two luer locks.  A syringe containing a nucleic acid sample is connected to the 
top luer lock and the plunger is compressed to flush the sample through the membrane.  
Then, the luer locks are disconnected from the syringe, and taken apart, and the 
membrane containing captured nucleic acids is placed in a PCR tube along with 
amplification mix for thermal cycling. 
 
Table 4-S4. Volumes of 10 mM MES (2-(N-morpholino)ethanesulfonic acid) buffer and 
final concentrations of λ DNA used for Figure 4-5a.  The two fabrication methods are 
described in the Experimental Section. 
 
Copies of 
λ DNA 
Volume of 10 
mM MES 
buffer (mL) 
λ DNA 
Concentration 
(cop/mL) 
Background 
DNA added to 
MES buffer (ng) 
Positive 
membranes 
Total 
membranes 
tested 
Fabrication 
Method 
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0 1 0 100 0 3 A 
0 3 0 100 0 3 B 
10 50 0.2 100 1 1 B 
10 50 0.2 100 1 4 A 
5 15 0.3 100 2 2 A 
10 30 0.3 100 1 2 A 
10 25 0.4 100 1 2 A 
5 10 0.5 100 2 2 A 
10 20 0.5 100 3 4 A 
25 50 0.5 100 1 1 B 
25 50 0.5 0 1 1 B 
9 10 0.9 10 6 6 B 
5 5 1.0 100 2 2 A 
10 10 1.0 100 1 2 A 
10 10 1.0 50 3 3 B 
9 5 1.8 0 6 6 B 
6 3 2.0 100 2 3 B 
10 5 2.0 50 2 3 B 
12 5 2.4 100 3 3 A 
10 4 2.5 100 2 2 A 
5 1 5.0 100 5 5 A 
10 2 5.0 100 4 4 A 
6 1 6.0 100 3 3 B 
10 1 10.0 100 3 4 A 
20 2 10.0 100 2 2 A 
10 1 10.0 0 2 3 B 
20 1 20.0 100 5 5 A 
20 1 20.0 0 3 3 B 
 
To detect λ DNA product after in situ amplification, two methods were used.  i) After 
thermal cycling the membrane with PCR mix in a well plate, an appropriate amount of 6x 
gel loading dye and TE buffer was added to each well and pipette mixed.  Then, 5 µL of 
this solution was removed from the well, placed in a 1.2% agarose gel, and run for 50 
min at 80V.  Samples with DNA product at the same length as the λ PCR amplicon (322 
base pairs) were considered positive.  An example of a gel image is shown in Figure 8-
S10a. ii) After thermal cycling, the PCR reaction mixture was transferred to an empty 
well and an appropriate amount of 20X Evagreen dye (Biotium) and 10X TE buffer was 
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added. A continuous melt curve was then obtained from 65–95 ˚C; samples with a 
peak around ~85 ˚C (the melting temperature of the λ PCR amplicon) were considered 
positive. (Figure 8-S10b). 
 
 
Figure 8-S10.  DNA detection after in situ amplification.  a) Varying concentrations of λ 
DNA in 10 mM MES buffer were flowed through chitosan membranes.  The membranes 
were then placed in a well plate and thermal cycled.  After thermal cycling, each sample 
was run on a gel. Lanes 1–2: 5 copies/mL; Lanes 3–4: 2.5 copies/mL; Lane 5: positive 
control (10 copies of λ DNA in PCR mix, no membrane); Lane 6: negative control (0 
copies of λ DNA in PCR mix, no membrane).  b) Dilutions of λ DNA were wetted onto 
chitosan membranes; PCR mix was added and melt curve fluorescent traces are plotted. 
Three replicates were run at each dilution. 
 
It is important to note that while Table 4-S4 includes experiments done on multiple 
batches of membranes over 8 months, it does not include all experiments that we 
performed with chitosan-coated nylon membranes. Using binding capacity measurements 
(described in Experimental Section) and DNA capture experiments (described in S-IV), 
we determined that there was batch-to-batch variation in the fabrication process.  
Therefore, only those batches with consistent performance were analyzed and other 
batches that did not meet our standards were excluded from analysis. 
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Table 4-S5 summarizes Table 4-S4 by binning the various experiments into concentration 
ranges and reporting a “% Positive membranes” along with the standard error. This data 
is then plotted in Figure 4-5a of the manuscript. 
 
Table 4-S5. Histogram of Table 4-S4 with concentration bins and standard error. 
Concentratio
n (cop/mL) 
positive total positive/total SE 
0 0 6 0.00 0.00 
0.2 - 0.5 5 10 0.50 0.16 
0.5 - 0.9 6 7 0.86 0.13 
0.9 -  2.0 22 25 0.88 0.06 
2.0 - 10.0 24 26 0.92 0.05 
10.0 - 20.0 8 8 1.00 0.00 
 
To reliably detect ultra-low concentrations of nucleic acids from large volumes, we 
reduced the background DNA amount to 10 ng and relaxed the constraint imposed on the 
experiments for Figure 4-5a that the solution be flowed through the membrane at 1 
mL/min. We instead flowed through at ~0.3 mL/min and compared 50 mL solutions with 
100 ng background DNA to 50 mL solutions with 10 ng background DNA. These 
experiments showed that 25 copies in 50 mL can be consistently detected when the flow 
rate and background DNA are reduced from the previous constraints of 1 mL/min and 
100 ng. The data is shown in  
Table 4-S6 below and summarized in the manuscript with Figure 4-5b. 
 
Table 4-S6. Volumes of 10 mM MES (2-(N-morpholino)ethanesulfonic acid) buffer and 
final concentrations of λ DNA used for Figure 4-5b. The two fabrication methods are 
described in the Experimental Section. 
Copies 
of λ 
DNA 
Volume of 10 
mM MES 
buffer (mL) 
λ DNA 
Concentra-
tion (cop/mL) 
Background DNA 
added to MES 
buffer (ng) 
Positive 
membr-
anes 
Total 
membr-
anes tested 
Fabrication 
Method 
25 50 0.5 100 6 10 B 
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25 50 0.5 10 9 9 B 
 
 
Primer sequences for 𝝀-phage DNA PCR amplification and 𝝀-phage DNA LAMP 
amplification 
 
A mixture of primers from Table 4-S7 was made at 5 µM each in nuclease-free water and 
used for the PCR amplification reactions described in this manuscript. 
 
Table 4-S7. Sequences for λ-phage DNA PCR primers. 
forward CGTTGCAGCAATATCTGGGC 
reverse TATTTTGCATCGAGCGCAGC 
 
A mixture of each primer from  
Table 4-S8 was made in nuclease-free water and used for the LAMP amplification 
reactions described in S-IV.  The concentration of each primer in the 20X mixture is also 
listed. 
 
Table 4-S8.  Sequences for λ-phage DNA LAMP primers5 and their concentration in the 
20X primer mix. 
Name Sequence Conc. 
FOP GGCTTGGCTCTGCTAACACGTT 4 µM 
BOP GGACGTTTGTAATGTCCGCTCC 4 µM 
FIP CAGCCAGCCGCAGCACGTTCGCTCATAGGAGATATGGTAGAGCCGC 32 µM 
BIP GAGAGAATTTGTACCACCTCCCACCGGGCACATAGCAGTCCTAGGGA
CAGT 
32 µM 
LOOPF CTGCATACGACGTGTCT 8 µM 
LOOPR ACCATCTATGACTGTACGCC 8 µM 
 
CDI functionalization of nylon membrane 
 
  
244 
Before coating with chitosan, the LoProdyne membrane was functionalized with N,N 
carbonyldiimidazole (CDI) in methylene chloride according to the manufacturer’s 
protocol.  The protocol is found at this website (http://www.pall.com/main/oem-
materials-and-devices/literature-library-details.page?id=4765) and is also copied below: 
 
LoProdyne LP membrane has hydroxyl surface chemistry. The membrane binds very 
little protein in standard binding tests using IgG or BSA. The membrane can be activated 
for covalent attachment using N, N® carbonyldiimidazole (CDI) in methylene chloride as 
follows: 
 
Dissolve 0.49 g CDI in 45 mL MeCl2.  
Add to a glass dish under a fume hood.  
Immerse sheet of LoProdyne LP membrane in this solution for 15 minutes, RT.  
Wash membrane 4X with 40 mL per wash MeCl2, 5 minutes per wash.  
Air dry at 60 °C for 3 minutes. 
Store in vacuum desiccator until use. 
 
Complex solutions 
 
To test whether salts in solution could interfere with electrostatic binding and decrease 
the ability of chitosan membranes to capture and detect nucleic acids, we performed 
preliminary experiments in complex solutions. Ringer’s solution was used to mimic the 
salt concentration of plasma and was made according to the instructions at the following 
website: http://cshprotocols.cshlp.org/content/2008/1/pdb.rec11273.full?text_only=true. 
The information from the website is also pasted below: 
 
Ringer’s solution (pH 7.3-7.4) 
Reagent (amount to add): NaCl (7.2 gm), CaCl2 (0.17 gm), KCl (0.37 gm). 
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Dissolve all reagents into reagent-grade H2O, and bring the final volume to 1 L. 
Adjust the pH to 7.3-7.4. Once thoroughly dissolved, filter through a 0.22-µm filter, 
aliquot into single-use volumes (25-50 mL), and autoclave. 
 
The final salt concentration of the Ringer’s solution is ~125 mM.  5 mM EDTA was also 
tested because plasma is often processed and stored in an anticoagulant such as EDTA. 
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Chapter IX 
 
Real-time, digital LAMP with commercial microfluidic chips reveals the 
interplay of efficiency, speed, and background amplification as a function of 
reaction temperature and time8 
 
Abstract 
 
Real-time, isothermal, digital nucleic acid amplification is emerging as an attractive 
approach for a multitude of applications including diagnostics, mechanistic studies, and 
assay optimization. Unfortunately, there is no commercially available and affordable real-
time, digital instrument validated for isothermal amplification; thus, most researchers 
have not been able to apply digital, real-time approaches to isothermal amplification. 
Here, we generate an approach to real-time digital loop-mediated isothermal 
amplification (LAMP) using commercially available microfluidic chips and reagents, and 
open-source components. We demonstrate this approach by testing variables that 
influence LAMP reaction speed and the probability of detection. By analyzing the 
interplay of amplification efficiency, background, and speed of amplification, this real-
time digital method enabled us to test enzymatic performance over a range of 
temperatures, generating high-precision kinetic and endpoint measurements. We were 
able to identify the unique optimal temperature for two polymerase enzymes, while 
accounting for amplification efficiency, non-specific background, and time to threshold. 
We validated this digital LAMP assay and pipeline by performing a phenotypic antibiotic 
susceptibility test on 17 archived clinical urine samples from patients diagnosed with 
urinary tract infections. We provide all the necessary workflows to perform digital 
LAMP using standard laboratory equipment and commercially available materials. This 
                                               
8This chapter was first published in Analytical Chemistry with authorship belonging to Justin C. Rolando, 
Erik Jue, Nathan G. Schoepp, and Rustem F. Ismagilov. The original manuscript can be found at: 
http://dx.doi.org/10.1021/acs.analchem.8b04324. 
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real-time digital approach will be useful to others in the future to understand the 
fundamentals of isothermal chemistries—including which components determine 
amplification fate, reaction speed, and enzymatic performance. Researchers can also 
adapt this pipeline, which uses only standard equipment and commercial components, to 
quickly study and optimize assays using precise, real-time digital quantification—
accelerating development of critically needed diagnostics. 
 
Introduction 
 
In this paper, we describe a methodology to use commercially available chips, reagents, 
and microscopes to perform real-time digital LAMP. We use this methodology to 
perform a mechanistic study of digital isothermal amplification, and apply the lessons 
learned to perform a phenotypic antibiotic susceptibility test (AST). 
 
Microfluidics-based diagnostics for infectious diseases are advancing as a result of using 
nucleic acid testing, making them amenable to the point of care (POC) and limited-
resource settings where they will have clinical impact. Isothermal amplification methods 
in particular show promise for simplifying nucleic-acid-based POC diagnostics by 
circumventing the stringent thermal cycling requirements of PCR.1 One isothermal 
method that is being actively pursued in bioanalytical chemistry and the field of 
diagnostics is loop-mediated isothermal amplification (LAMP).2-6 
 
LAMP and other isothermal technologies are fast and sensitive, but when performed in a 
bulk format in microliter volumes (e.g., in a tube) they provide only semi-quantitative 
(log-scale) resolution or presence/absence measurements.7-15 As a result, when 
optimizing an assay, it is difficult to quantify how small changes in assay conditions (e.g., 
in primers, reagents, or temperature) impact the reaction’s speed and analytical 
sensitivity. To reliably understand these effects with high precision would require 
hundreds of bulk experiments per condition.16 For the field to be able to take full 
advantage of the capabilities of LAMP, researchers need to be able to optimize reaction 
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conditions by understanding and testing the variables that may influence reaction 
speed and probability of detection. Furthermore, the semi-quantitative measurements 
yielded by bulk isothermal methods are insufficient for analyses requiring precise 
quantification, such as phenotypic antibiotic susceptibility testing.17,18 
 
These problems can be solved using “digital” approaches, which partition single target 
molecules in large numbers of compartments and give a binary (presence/absence) 
readout for each compartment. These “digital” approaches thus allow determination of 
the efficiency of the amplification reaction19 and provide absolute quantification with 
high resolution. Digital isothermal measurements have been used to quantify viral load 
for HCV,16,20,21 HIV,19,20 and influenza,22 perform bacterial enumeration,23-25 optimize 
primers,16 and test for phenotypic antibiotic susceptibility18 using LAMP18-28 and RPA.29 
 
Real-time digital formats are especially valuable for examining the variables that most 
affect non-specific amplification and the speed of amplification. Many excellent 
approaches for end-point19,20,22-28 and real-time16,18,21 digital LAMP (dLAMP) have been 
published. Despite the value that real-time dLAMP can bring to diagnostics, this method 
is difficult to implement—especially for those without a background in micro-electro-
mechanical systems or microfluidics—because there is no commercial system for real-
time, digital isothermal amplification. To achieve statistical significance, a meaningful 
study might require dozens of experiments; such studies are difficult to perform without a 
commercial source of chips. Consequently, the few LAMP mechanistic studies that have 
been performed were not done with high precision. Further, those who would most 
benefit from optimized digital isothermal reactions (e.g. those working on POC 
diagnostics) cannot efficiently improve them. 
 
Here, we demonstrate how to generate high-precision kinetic and endpoint measurements 
using a real-time dLAMP assay that is performed completely with commercially 
available and open-source components (Figure 1). We use this real-time information to 
investigate dLAMP reactions mechanistically, including the interplay of efficiency, 
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speed, and background amplification as a function of reaction temperature and time 
on two enzymes. To illustrate one application of using real-time dLAMP to improve a 
clinically relevant assay, we optimized the assay conditions for a phenotypic AST using 
the real-time dLAMP pipeline and used the optimized protocol to compare our AST of 17 
clinical urine samples to the gold-standard method. 
 
Experimental Section 
 
Microfluidic chips used in this paper were sourced from Applied Biosystems, Foster City, 
CA, USA) Ref A26316, "QuantStudio 3D Digital PCR 20k Chip Kit V2." 
 
LAMP reagents 
 
Our amplification target was the E. coli 23S ribosomal gene, which we used previously as 
a target to perform rapid AST on clinical samples.18 Primers were purchased through 
Integrated DNA Technologies (San Diego, CA, USA) and were described previously.18 
Final primer concentrations were identical for all experiments: 1.6 µM FIP/BIP, 0.2 µM 
FOP/BOP, and 0.4 µM LoopF/LoopB. 
 
LAMP experiments using Bst 3.0 (Figure 2; Figure 3b d, e, f, h-j; Figure 4) contained 
the following final concentrations, optimized previously18: 1x Isothermal Amplification 
Buffer II (New England BioLabs (NEB), Ipswich, MA, USA; Ref. B0374S; containing 
20 mM Tris-HCl 10 mM (NH4)2SO4 150 mM KCl, 2 mM MgSO4, 0.1% Tween 20 pH 
8.8 at 25 °C), 4 mM additional MgSO4 (beyond 2 mM from buffer), 1.4 mM 
Deoxynucleotide Solution Mix, primers: 1.6 µM FIP/BIP, 0.2 µM FOP/BOP, and 0.4 µM 
LoopF/LoopB, 1 mg/mL BSA (New England BioLabs, Ref B90005), 320 U/mL Bst 3.0, 
Ambion RNAse cocktail (ThermoFisher, Waltham, MA, USA; Ref AM2286, 5 U/mL 
RNase A, 400 U/mL TNase T1), 2 µM SYTO 9 (ThermoFisher, Reference S34854), and 
approximately 660 copies/µL template in Ambion nuclease-free water (ThermoFisher, 
Ref AM9932). 
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LAMP experiments using Bst 2.0 (Figure 3a, c, e, g) contained the following final 
concentrations, optimized as shown in Figure S3: 1x Isothermal Amplification Buffer 
(New England BioLabs, Ref. B0537S; containing 20 mM Tris-HCl 10 mM (NH4)2SO4, 
50 mM KCl 2 mM MgSO4 0.1% Tween 20 pH 8.8 at 25 °C), additional 6 mM MgSO4 
(New England BioLabs, Ref. B1003S), 1.4 mM Deoxynucleotide Solution Mix (New 
England BioLabs, Ref N0447S), primers: 1.6 µM FIP/BIP, 0.2 µM FOP/BOP, and 0.4 
µM LoopF/LoopB, 1 mg/mL BSA (New England BioLabs, Ref B90005), 320 U/mL Bst 
2.0 (New England BioLabs, Ref M0537S), Ambion RNAse cocktail (ThermoFisher, Ref 
AM2286, 5 U/mL RNase A, 400 U/mL TNase T1), 2 µM SYTO 9 (ThermoFisher, Ref 
S34854), and approximately 660 copies/µL template in Ambion nuclease-free water 
(ThermoFisher, Ref AM9932). 
 
Template E. coli DNA was extracted from exponential-phase cultures grown in BBL 
Brain-Heart Infusion media (BD, Franklin Lakes, NJ, USA; Ref. 221813) using 
QuickExtract DNA Extraction Solution (Lucigen, Middleton, WI, USA; Ref. QE09050) 
as described previously.18 Serial 10-fold dilutions were prepared in Tris-EDTA buffer (5 
mM Tris-HCl, 0.5 mM EDTA, pH 8.0) containing 2 U/mL RNase A and 80 U/mL RNase 
T1 (ThermoFisher, Ref AM2286). DNA dilutions were quantified as described 
previously18 using the QX200 Droplet Digital PCR (ddPCR) system (Bio-Rad 
Laboratories, Hercules, CA, USA). 
 
Phenotypic antibiotic susceptibility testing (AST) on clinical samples 
 
For the phenotypic AST, we adopted a workflow described previously,17,18 and used 
archived nucleic-acid extractions from a previous study.18 Briefly, clinical urine samples 
from patients with urinary tract infections (UTI) were split and diluted into equal 
volumes of media with or without the presence of an antibiotic. Samples were incubated 
for 15 min at 37 °C, a nucleic-acid extraction was preformed, and these samples were 
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archived at -80 °C until use. LAMP was performed on the archived samples to 
quantify the number of copies of the E. coli 23S ribosomal gene. 
 
We tested our optimized assay on 17 archived clinical UTI samples containing ≥5 × 104 
CFU/ml E. coli that had been categorized previously using the gold-standard broth 
microdilution AST (5 ciprofloxacin-susceptible, 5 ciprofloxacin-resistant, 4 
nitrofurantoin-susceptible, and 3 nitrofurantoin-resistant). 
 
We assessed samples as phenotypically “resistant” or “susceptible” by calculating the 
ratio of the concentration of 23S in the control and antibiotic-treated sample, which we 
call the control:treated (C:T) ratio. The C:T ratio was calculated 10 min after beginning 
to heat the LAMP reaction. A threshold of 1.1 was established previously,17,18 so samples 
with C:T ratios >1.1 indicated that there was DNA replication in the untreated (control) 
group but not in the antibiotic-treated samples; these samples were identified as 
susceptible to the antibiotic. Samples with C:T ratios of <1.1 indicated that DNA 
replication occurred in both the control and antibiotic-treated samples; these samples 
were identified as resistant to the antibiotic. 
 
Results and Discussion 
 
Workflow summary of real-time digital LAMP 
 
To evaluate a pipeline for real-time dLAMP experiments, we chose commercially 
sourced microfluidic chips sold for endpoint digital PCR applications. The chips consist 
of an array of 20,000 uniform partitions (Figure 1), each 60 µm in diameter and an 
estimated 0.75 nL internal volume, which is similar to the volumes typically used in 
dLAMP.16,18,20-23,25,26,28 These chips are loaded by pipetting the sample mixture (in our 
case containing the LAMP reagents: buffer components, enzymes, template, and primers) 
into the plastic “blade” provided with the chips, and dragging the blade at a 70–80° angle 
to the chip to load the sample mixture by capillarity. This is followed by drying and 
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evaporation of the surface layer for 20 sec at 40 °C, and application of the immersion 
fluid. Manual loading requires some skill, though a machine can be purchased to perform 
the task; typically, we were able to load ~18,000 out of the 20,000 partitions. We 
performed our evaluation using two different enzyme mixtures, Bst 2.0 and Bst 3.0 . Our 
amplification target (Figure 1) was the E. coli 23S ribosomal gene that we previously 
used as a target to perform rapid AST on clinical samples.18 
 
 
Figure 9-1. A schematic of the pipeline for performing multiplexed, real-time, digital 
loop-mediated isothermal amplification (LAMP) using only commercially available 
and/or open source components. Microfluidic chips and reagents (e.g. primers, enzymes, 
buffer composition) can be purchased commercially. Multiple instrument configurations 
can be used to capture results. e.g. a customized real-time instrument (instructions for 
building publicly available30) or any commercial microscope. Data analysis is automated 
using a MATLAB script (Supporting Information, S-I). 
 
The instrumentation requirements for real-time isothermal capabilities include a heater 
that can hold a stable temperature, and optical components with high spatial resolution 
that are capable of imaging the fluorescence intensity of the 20,000 individual partitions 
of the chip over time (Figure 2a). Here, we investigated two approaches: using a 
standard laboratory microscope (Leicia DMI-6000B), and using the RTAI,30 which is 
composed of a thermocycler, optical components, a camera, and a light source. 
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We generated a custom MATLAB script to analyze the digital real-time data (details in 
Supporting Information, S-I). The software follows the change in fluorescence in 
individual partitions over time. From these data, we extract each partition’s time to a 
fluorescence intensity threshold and calculate the bulk template concentration. In our 
demonstration, we loaded the acquired images into FIJI31 as a time-stack series and 
manually separated the images of the individual chips to be analyzed separately. To 
process each chip’s image stack, we used the custom MATLAB script that tracks the 
mean intensity of each partition over the course of each experiment. This script could be 
run with only minor modifications with images obtained from different instruments. 
 
To calculate the bulk template concentration over time, we (1) identified the partitions 
that did or did not contain reaction solution, (2) tracked the partitions that met a minimum 
fluorescence intensity and (3) used the previous information to calculate the 
concentration of template in the bulk solution. 
 
A summary of the script is as follows: (i) load the images into memory, (ii) count the 
total number of partitions before heating (iii) identify positive partitions after the 
conclusion of the experiment, (iv) track the intensity of positive partitions for each image 
frame, (v) apply Gaussian smoothing and baseline subtraction, (vi) save the data, and 
(vii) repeat for each image stack. The output of the script contains: the raw traces of 
individual partitions over time, baseline corrected traces of individual partitions over time 
(Figure 2b), the number of partitions exceeding the manually defined minimum 
fluorescence intensity threshold with time (Figure 2f), and the maximum relative rate in 
RFU per 30 sec for individual partitions (Figure 2d). These data provide all the 
necessary information to conduct the analyses detailed in Figure 2. 
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Figure 2. Experimental demonstration of the real-time digital LAMP (dLAMP) approach 
using the commercially available enzyme Bst 3.0. Experiments were run at 70 °C and 
imaged using a commercial microscope. (a) A time course of fluorescence images from a 
subset of 350 partitions out of 20,000 partitions undergoing dLAMP reactions. (Intensity 
range 920-1705 RFU). (b) Fluorescence intensity for a subset of partitions over time.  
Blue traces indicate partitions containing template; red traces indicate fluorescence in the 
absence of template (i.e. non-specific amplification). Partitions turn “on” at the time point 
when the curve passes the threshold at 250 RFU. Vertical traces correspond to time 
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points illustrated in panel (a) and generate endpoint measurements. (c) An “endpoint” 
measurement taken on a subset of partitions at 25 min. Bin width is 100 RFU. 
Fluorescence threshold is 250 RFU. (d) A histogram of the maximum observed change in 
fluorescence of individual partitions using the full chip. Rate threshold is 45 RFU/30 sec. 
(e) Change in observed bulk concentration over time from the full chip using 
fluorescence intensity as threshold (solid lines) and rate (dashed lines). (f) Time at which 
individual partitions in panel (b) cross the fluorescence intensity threshold. (g) Maximum 
rate per partition plotted by time to fluorescence intensity threshold. 
 
Digital, real-time experiments to quantify LAMP performance 
 
We next sought to experimentally evaluate this pipeline (Figure 1). First, we established 
whether the fluorescence from LAMP reactions could be reliably measured from 
individual partitions over time (Figure 2a). We used LAMP reagents for Bst 3.0, 
commercial chips, a resistive heater held at 70 °C, and a commercial microscope. 
Although the microscope is capable of collecting all 20,000 partitions on one chip in a 
single image, for simplicity, in Figure 2a, we cropped the image to include only 350 of 
the 20,000 partitions. Before turning on the heater (t = 0), we measured the 
autofluorescence from SYTO 9 to quantify the total number of partitions loaded with 
reaction solution. (To calculate template concentration using the Poisson distribution32,33, 
we must know the total number of partitions containing the reaction mixture.) 
Autofluorescence from SYTO 9 decreases as the chip is heated and is completely 
eliminated within 3 min. The heater used on the microscope reaches reaction temperature 
within 120 sec. In less than 10 min, an increase in fluorescence was observed within 
some of the individual partitions, indicating amplification of individual template 
molecules inside those partitions. Due to the stochastic nature of amplification initiation, 
some of the partitions fluoresced later. 
 
In the negative-control (no template) partitions, fluorescence was not observed for the 
first 45 min. However, we began to observe non-specific amplification after ~60 min. In 
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these experiments, the negative control contains only 0.05x Tris-EDTA buffer in 
place of template and represents a best-case scenario. We attribute amplification in the 
absence of template to primer dimers and other non-specific LAMP products. 
 
Second, we asked if the signal from non-specific amplification was sufficiently delayed 
to differentiate it from the signal arising from specific amplification in the presence of 
template. To answer this question, we generated real-time fluorescence curves by plotting 
the change in fluorescence of individual partitions as a function of time (Figure 2b). We 
observed specific amplification (blue curves) beginning to initiate at ~7 min and non-
specific amplification beginning to initiate at ~50 min (red curves) and concluded that we 
could discriminate specific and non-specific amplification by time. 
 
Third, we asked whether enzymatic heterogeneity16,21,34 of specific amplification can be 
quantified to differentiate specific from non-specific amplification. We plotted the 
maximum change of fluorescence achieved by each partition of the full chip per 30-sec 
interval (Figure 2d). For the negative-control sample (red bars), we observed non-
specific amplification following a bimodal distribution of rates, with a first peak with 
little to no rate of fluorescence increase and a second peak at ~25 RFU per 30 sec. For the 
sample containing template (blue bars), rates for specific amplification were 
heterogeneous and centered around a rate of 70 RFU/30 sec. We note that in PCR, which 
is gated by temperature cycling, there is no equivalent concept of “rate” as long as 
replication of DNA occurs faster that the duration of each elongation step. We found in 
our dLAMP experiments that the rate of specific amplification was greater than non-
specific amplification. Hence, tracking amplification in real-time made it possible to 
distinguish true positives from false positives (non-specific amplification). 
 
Fourth, we asked if the distribution in time to fluorescence threshold is sufficiently 
narrow to discriminate specific and non-specific amplification. By plotting the number of 
“on” partitions (i.e. partitions that crossed the fluorescence intensity threshold defined in 
Figure 2b) against time, we generated a distribution curve (Figure 2f) that illustrates the 
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number of partitions that turn on per time point. This is related to the derivative of the 
change in concentration over time. This plot contains the time to threshold of all 
partitions within the entire chip, rather than a subset, to minimize sampling bias. In the 
sample containing template (blue curve), most partitions reached the threshold in 7–20 
min, whereas the negative-control sample (red curve) had little non-specific amplification 
until approximately 60 min. Graphing time to threshold illustrates the overall reaction’s 
speed (defined as the location of the peak or mode time to threshold) and efficiency 
(proportional to the area under the curve and illustrated in Figure 2f as the calculated 
concentration). In our experiment, the peak of the sample containing template was narrow 
and well separated from the non-specific amplification of the negative control (Figure 
2f), indicating sufficiently low heterogeneity in amplification rate and time to initiation of 
the reaction. 
 
Fifth, we asked how the calculated bulk concentration changes over time. To answer this 
question, we generated endpoint-style measurements for each 30-sec time point, and 
calculated how the concentration changed over time. To demonstrate how to generate a 
single endpoint-style measurement, we selected one time point (25 min) and plotted RFU 
as a factor of the number of partitions (Figure 2c). Partitions were classified as either 
“on” (>250 RFU threshold) or “off” (<250 RFU threshold). Partitions that are defined as 
having turned “on” contain a template molecule that amplified, whereas partitions that 
are ”off” either lack a template molecule or have not yet begun amplification. The sum of 
the partitions passing the threshold out of the total number of partitions with solution was 
used to determine a precise bulk concentration of template in the sample using the 
Poisson equation, as has been documented elsewhere.32,33 We plotted the calculated 
concentration as it changed over time in Figure 2e (solid lines). 
 
When the aim is to determine a precise concentration, we need to determine the best time 
at which to stop the assay. Deciding the best time to end the assay is complicated because 
each reaction initiates stochastically,16,21 causing the calculated concentration to 
asymptotically approach the true concentration (Figure 2e). It would be ideal for the 
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calculated concentration to rapidly rise to the true bulk concentration and plateau near 
the true concentration; however, the reaction should be stopped before the rise in non-
specific amplification (observed in our example starting at 60 min; red curves, Figure 
2e–f). We tested whether there is heterogeneity in amplification rate (i.e. whether 
partitions with slow amplification rates take longer to reach the fluorescence intensity 
threshold than partitions with fast amplification rates) and found that initiation time was 
stochastic, but the reaction rates for true and false positives were consistent (Figure 2g). 
Hence, two molecules could have the same TTP, yet initiate at different moments, 
resulting in variable amplification rates.  
 
Combining information about the concentration of template (Figure 2e) and the time it 
takes for partitions to turn “on” (Figure 2f) can be used to inform the choice of an 
optimal assay length for endpoint measurements, for situations where real-time 
quantification is not feasible. For example, in Figure 2, the optimal assay length for an 
endpoint readout would be ~45 min. This approach allows one to balance stochastic 
initiation of amplification, overcome enzymatic heterogeneity, and reduce the incidence 
of false positives caused by non-specific amplification. 
 
However, in cases where real-time measurements are desirable, thresholding by rate may 
be used to separate specific and non-specific amplification. For example, to correct for 
the observed increase in non-specific amplification (after 45 min), we implemented a 
threshold (Figure 2d) on the maximum rate per partition, thus eliminating some of the 
non-specific amplification in both the presence and absence of template (compare solid 
and dashed lines in Figure 2e). For example, the measured value at 60 min is 280 copies 
per µL (solid line), and the corrected value is 258 copies per µL (dashed line). In the no-
template control, at 60 min, the measured value is 16 copies per µL (solid line), whereas 
the corrected value is 3 copies per µL (dashed line). The correction is more pronounced 
at 80 min where non-specific amplification is greater.  At 80 min, the measured value in 
the presence of template is 325 copies per µL and the corrected value 266 copies per 
µL—indicating that almost 20% of the signal could arise from non-specific amplification. 
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In the absence of template, the uncorrected value at 80 min is 187 copies per µL; 
however if rate is accounted for, then the value can be corrected to 16 copies per µL, thus 
eliminating the majority of the false positives. 
 
Finally, we note that although we calculated template concentration, the value is precise 
but could be inaccurate if not all target molecules loaded into the chip undergo 
amplification (in other words, if efficiency of amplification is not 100%). Thus, we next 
sought to measure the absolute likelihood of detecting a molecule as a function of 
reaction condition. 
 
Evaluation of the effect of temperature on dLAMP with two different enzymes to 
analyze the interplay of amplification efficiency, background, and speed of 
amplification 
 
After establishing a protocol for generating real-time, digital measurements, we evaluated 
the absolute amplification efficiency of LAMP as a function of temperature for two 
different enzymes. We selected two commercial polymerases that worked well for us 
previously. Both enzymes are in silico homologues on the Bacillus stearothermophilus 
DNA Polymerase I and Large Fragment. NEB describes Bst 3.0 as an improvement of Bst 
2.0 by adding reverse transcriptase activity, increased amplification speed, and increased 
thermostability. We sought to understand the differences in performance between these 
two enzymes at the single template level.  For this experiment, we used the previously 
described RTAI.30 The field of view for this instrument is larger than a microscope, 
allowing up to six samples to be observed concurrently. Hence, both the positive and 
negative controls could be collected in triplicate simultaneously. We expect some 
differences in measurements made on different instruments as a result of differing camera 
sensitivities and differences in the heating mechanism. Indeed, when we ran a single-
concentration amplification reaction under identical conditions and compared 
measurements from the microscope and the RTAI, we found that there was significant 
difference (P = 0.03) in amplification efficiency between the two instruments (Figure 
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S2), with the RTAI generating higher amplification efficiency. Hence, we performed 
all enzyme-performance comparisons on a single instrument. 
 
Amplification efficiency 
 
First, we sought to establish the amplification efficiency of dLAMP, i.e. the fraction of 
template copies loaded that are detected (Figure 3a-b). We calculated the bulk 
concentration of template molecules from the digital measurement and plotted the 
observed template concentration as a fraction of template molecules loaded. To calculate 
the amplification efficiency, we determined template concentration using ddPCR and 
assumed all template molecules amplified. Using the real-time component of our 
measurements, we plotted the percent of copies detected over time compared with 
ddPCR. 
 
We next asked how temperature impacts amplification efficiency. In general, we 
observed greater amplification efficiency at longer amplification times, which aligned 
with our previous observation (Figure 2d–e). Second, when observing at a fixed time, 
increasing temperature increased amplification efficiency to an optimum (green box in 
Figure 3a-b) before activity decreased. 
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Figure 3. Evaluation of reaction conditions (enzymes and temperature) using real-time 
digital LAMP. (a-b) Amplification efficiency (percent template copies detected out of 
copies loaded) of Bst 2.0 (a) and Bst 3.0 (b) as a function of temperature. Green boxes 
indicate the optimal temperature range for the greatest probability of template detection. 
(c-d) Non-specific amplification in template-free buffer samples using Bst 2.0 (c) and Bst 
3.0 (d) for conditions matching panels a-b. (e-f) Distribution of time to fluorescence 
threshold using Bst 2.0 (e) and Bst 3.0 (f). (g) The fractional cumulative distribution 
function (CDF) compares the enzymes at their optimal temperatures (68 °C). (h) 
Fractional CDF plots of Bst 3.0 rate at three temperatures. Error bars are S.D. For all 
datasets, N = 3 chips (technical replicates). CDF plots are the sum of 3 technical 
replicates. 
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Several observations can be made by comparing the results from Bst 2.0 and Bst 3.0 
(Figure 3a-b). Although Bst 2.0 and Bst 3.0 have an identical reported optimal 
incubation temperature in bulk (65°C), we observed they had different optimal 
temperature ranges for amplification efficiency (Bst 2.0 at 66–68 °C; Bst 3.0 at 68–70 
°C). We detected lower amplification efficiency at higher temperatures with Bst 2.0 
compared with Bst 3.0. Bst 2.0 failed to amplify at 72 °C, whereas Bst 3.0 continued 
amplifying until 76 oC. At short amplification times, (such as 10 min), Bst 3.0 had greater 
amplification efficiency than Bst 2.0 (42.8% vs 20.8%, respectively). In contrast, at 
longer amplification times, such at 30 or 45 min, efficiency for the enzymes was similar 
(77.6% vs 71.5% at 45 min, respectively), though Bst 2.0 had slightly greater 
amplification efficiency than Bst 3.0. 
 
We hypothesize that increased temperature improved amplification efficiency 
(presumably by increasing the breathing of dsDNA and facilitating primer annealing) 
until, at higher temperatures, a combination of enzyme denaturation or failure of the 
primers to anneal occurred. Our primers had melting temperatures ranging from 56–61 
°C, when excluding the secondary FIP and BIP anealing regions, as calculated using 
OligoCalc.35 We found that chip-to-chip variability was extremely low. Relative error for 
Bst 2.0 at optimal temperature (68 °C) and 45 min of amplification was ~2% (Figure 2a), 
whereas the predicted Poisson noise for a single chip is 0.7%. Achieving such high 
precision using bulk measurements would require hundreds of experiments. The low 
variability among these measurements indicates that we were correctly determining 
whether a partition contained solution and whether it amplified. 
 
Non-specific background amplification 
 
Next, we quantified the amount of non-specific amplification (Figure 3 c-d) as a function 
of time and temperature. We plotted the number of wells that turned “on” in the absence 
of template relative to the total number of wells filled with LAMP solution. As 
previously stated, these non-specific amplification reactions included buffer in place of 
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template and represent a best-case scenario. We concluded that at least for these 
idealized conditions, non-specific amplification in dLAMP was extremely low. For 
example, a fraction of 0.001 could correspond to 20 partitions turning on from among a 
total of 20,000 possible partitions. For both enzymes, we found the maximum fraction of 
non-specific amplification per total partitions was 0.0012 for times 20 min or less. The 
highest fraction of non-specific amplification observed was 0.017 at 45 min, 
corresponding to fewer than 350 non-specific partitions of the 20,000 total (Figure 3c-d). 
Furthermore, we observed higher temperatures resulted in lower non-specific 
amplification (Figure 3c-d). Finally, at extremely long amplification times (e.g. 60 min 
amplification, data not shown) Bst 2.0 had lower background than Bst 3.0. 
 
Variations in speed and amplification efficiency 
 
Third, we quantified the variation in speed and amplification efficiency across partitions 
in the time to reach fluorescence intensity threshold (Figure 3e-f). We first plotted the 
percent copies detected as a function of time for each temperature. As described 
previously, these curves represent the distribution in the time to threshold across all 
partitions and thus illustrate the interplay of (i) detecting a molecule (area under the curve 
from zero to a given time corresponding to the values plotted in Figure 3a-b), (ii) the 
speed of the reaction (the time at which the peak reaches a maxima) and (iii) several 
parameters of peak width summarized in Table S1. We hypothesize peak width is related 
to both the enzyme amplification rate, overall amplification efficiency, and the time at 
which the reaction initiates. Next, we plotted the peak time to threshold (Figure S1). 
Images were collected in 30-sec intervals and we report the average of three trials. In 
some cases, the difference in time to threshold was less than the imaging time interval. 
For each time point, if fewer than 15 partitions (0.075% of total partitions) were “on,” 
that time point was not included in the calculation of the mode. For these measurements, 
at the start of the reaction, the heat block was at 25 °C and the time to threshold included 
the time for the heat block to come to reaction temperature (~70 sec). Hence, there will 
be minor differences (seconds) in the time for each reaction to reach the fixed 
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temperature. We do not see evidence that this difference manifests in the mode time 
to positive (TTP) measurements. 
 
In reactions with Bst 2.0, below 68 °C, mode TTP was narrowly clustered around 9.5 
min. At 70 °C, mode TTP increased, and the reaction failed to amply beyond 72 °C. In 
reactions with Bst 3.0, the mode TTP decreased from 8.2 ± 0.3 (mode ± S.D.) min at 64 
°C to 6.6 ± 0.3 min at 70 °C, then increased with increasing temperature until 
amplification failed for all partitions at temperatures ≥76 °C. In the negative controls for 
both enzymes (Figure S1), amplification either failed or started after 75 min. 
 
Several observations can be made by comparing the results from Figure 3e-f. We found 
that the optimal temperature for time to threshold corresponded with the optimal 
temperature for amplification efficiency (Figure 3a-b), and that the optimal temperatures 
also had the smallest tailing factors, Full Width at Half Maximum (FWHM) and 
asymmetric factor (i.e. narrowest peak widths) (Figure 3e-f; Table S1). At optimal 
efficiency, Bst 3.0 was approximately 2 min faster in mode TTP, had much narrower 
FWHM, smaller tailing factor, and lower asymmetry than Bst 2.0. Finally, as efficiency 
decreases, measurements of peak shape and width increase. To the best of our 
knowledge, this is the first published quantification that explicitly tests and quantifies the 
time dependence of LAMP efficiency using these enzymes. Real-time digital enables us 
to identify the time point at which the observed concentration most closely approximates 
the true concentration thus optimizing the assay duration. 
 
Rates of amplification (specific and non-specific) 
 
Fourth, we compared the rates of specific and non-specific amplification between Bst 2.0 
and Bst 3.0. The data shown represent the combined rates of three separate trials. We 
found that non-specific amplification rates were similar for the two enzymes (Figure 3g, 
dashed lines), whereas in the presence of template, amplification rates were faster for Bst 
2.0 than Bst 3.0 (Figure 3g, solid lines), despite lower efficiency at short times. 
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Differences in camera sensitivity between the microscope (used for real-time images 
in Figure 2) and the RTAI (used for Figure 3) result in different apparent amplification 
rates. 
 
We also examined the relationship between temperature, efficiency, and maximum rate. 
In the case of Bst 3.0, maximum reaction amplification rate does not correspond with 
optimal efficiency (Figure 3h). 64 °C had the fastest amplification rates, but suboptimal 
efficiency (57.3% at 45 min). Optimal amplification efficiency occurs at 68 °C (71.5% at 
45 min), but slightly slower amplification rate than 64 °C. At 74 °C, we observed both 
poor efficiency (32.7% at 45 min) and slowest reaction rate. We attribute this to a 
combination of decreased enzymatic velocity and decreased primer annealing. 
Additionally, we note that different thresholds for amplification rate would be needed for 
each temperature. This is expected given changes in enzymatic velocity. 
 
Application of the pipeline to a phenotypic antibiotic susceptibility test (AST) using 
clinical samples 
 
We next asked whether we could apply the output of this digital real-time pipeline to 
perform a rapid phenotypic AST. Specifically, we aimed to categorically sort clinical 
samples as phenotypically “susceptible” or “resistant” to an antibiotic in agreement with 
the gold-standard reference method. This study was constructed as a demonstration of the 
capability of the microfluidic chips and the value gained from using this digital real-time 
pipeline to optimize reaction conditions—it was not an assessment of the digital AST 
(dAST) methodology established previously.17,18 We selected the optimal dLAMP 
conditions for Bst 3.0 based on the measurements of mode TTP and amplification 
efficiency established in the previous experiments (Figure 3b)—70 °C and a reaction 
time of 10 min. We used archived clinical urine samples from patients diagnosed with 
urinary tract infections (UTI) containing E. coli. These samples had been categorized as 
phenotypically susceptible or resistant to the antibiotics ciprofloxacin or nitrofurantoin 
using the gold-standard (broth microdilution) method.18 We tested exactly 17 samples 
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and observed 100% categorical agreement with the gold-standard method (0 major 
errors; 0 minor errors). We conclude that the pipeline presented in this paper performs 
well and could be used, among other applications, to optimize reaction conditions for 
speed and sensitivity and apply those conditions to a determination of phenotypic 
antibiotic susceptibility in clinical samples. 
 
 
Figure 4. Phenotypic antibiotic susceptibility tests of 17 clinical urine samples from 
patients infected with a urinary tract infection containing E. coli. Susceptibility to the 
antibiotics nitrofurantoin and ciprofloxacin were tested using dLAMP conditions 
optimized using digital real-time experiments (Figure 3). Urine samples were exposed to 
media without antibiotic (control) or media with an antibiotic (treated) for 15 min and 
then concentrations of nucleic acids were quantified to calculate a control:treated (C:T) 
ratio. Samples were categorized by dLAMP as susceptible (above the susceptibility 
threshold) or resistant (below the threshold). All samples were categorized in agreement 
with the clinical gold-standard method. 
 
Conclusion 
 
We have presented a pipeline to generate real-time, digital isothermal amplification 
measurements using only commercial and open-source components. We used this 
pipeline to examine how small changes in reaction conditions influence the interplay of 
LAMP efficiency, speed, and background by performing 124 real-time dLAMP 
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experiments. As one practical application of this approach, we determined the optimal 
reaction conditions for a phenotypic test of antibiotic susceptibility using 17 clinical urine 
samples from patients diagnosed with urinary tract infections. In all cases, the results of 
the optimized dLAMP assays were in agreement with the clinical gold-standard AST. 
 
These experiments validate that real-time digital measurements enable tests of enzymatic 
performance in dLAMP. Generally, we found that each enzyme had a unique optimal 
temperature for amplification efficiency (probability of detecting a target molecule) and 
for eliminating non-specific amplification. This “optimal” temperature produced the 
fastest mode TTP and the narrowest, most symmetrical distribution curves; interestingly, 
the optimal temperature did not necessarily yield the fastest amplification rate. Together, 
these data suggest that amplification efficiency is an interplay of enzymatic rate, diffusive 
transport, and DNA breathing. When reactions are performed away from optimal 
temperature, the distribution curves broaden and decrease in total area, resulting in 
reduced overall amplification efficiency and slower mode TTP; whereas amplification 
rate decreases with increasing temperature. With regard to the specific enzymes in this 
study, although efficiency was similar at long amplification times (> 20 min), Bst 3.0 had 
a faster mode TTP than Bst 2.0 by approximately 2 min, and more narrow and 
symmetrical distribution curves. However, Bst 2.0 had faster amplification rates than Bst 
3.0, so reactions with Bst 2.0 took longer to initiate, but proceeded more rapidly. For both 
polymerases, non-specific amplification in buffer was extremely low. 
 
In the future, this pipeline can be used to understand the fundamental pieces of LAMP. 
The field of diagnostics would benefit from a thorough mechanistic study of LAMP 
asking which components determine amplification fate, and how components, such as 
primers and heating rate (Figure S2), impact reaction and enzymatic speed. This pipeline 
makes such a mechanistic study possible. For example, in this study we corrected the 
observed concentration by separating true positives from background amplification using 
rate and fluorescence, but we did not explore the origins of non-specific amplicons—
which deserves its own study and development of more precise tools for studies of non
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specific amplification. Finally, this pipeline can be extended to optimize other 
isothermal amplification chemistries that could be suited to other types of diagnostic 
assays. 
 
Ultimately, this pipeline will make digital real-time measurements more accessible to 
researchers, even those who lack microfluidic expertise or specialized equipment. The 
commercially available chips and reagents used here could be coupled with many 
combinations of standard laboratory or field equipment, such as a hot plate and a 
fluorescent stereoscope, or a chemical heater and a cell phone camera. While we believe 
the general trends found in this manuscript will extend to other primer sets, we hope this 
pipeline will enable others to study other primer sets and conditions of interest to them. 
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S-I Summary of MATLAB script functions  
 
In order to quantify the reactions on chips using the Poisson distribution, we needed to 
know the number of partitions that contained solution and the number of partitions that 
were empty.  (It would be naïve to assume that all 20,000 partitions were loaded with 
solution; visual inspection shows that was rare.) We counted the total number of 
partitions with solution using the image of the autofluorescence of SYTO 9 dye before 
heating at time 0 (Figure 2a).   SYTO 9 had uniform autofluorescence independent of 
template presence, making it easy to count all partitions loaded with solution.   
 
To track the mean fluorescence intensity of each partition over time, we solved two 
challenges.  First, when the microfluidic chip was heated (especially during the first 2 
min) the chip moved.  As the chip heated, it lost the initial autofluorescence from SYTO 
9.  Consequently, it was not possible to track this movement with the fluorescence of a 
single fluorophore.  We solved this challenge by creating a mask (using image 
segmentation) that outlined each detectable partition at the chip’s final position using a 
frame at the end of amplification.  An advantage to using only the detectable partitions 
that met a minimum fluorescence intensity (out of a total of 20,000 partitions per chip) 
was reduced overall computation time because only a fraction of the total partitions were 
tracked in real-time. 
 
A second challenge when tracking mean fluorescence intensity of each partition over 
time using only the detectable partitions is that partitions can appear to be different sizes 
because of differences in fluorescence intensity (dark partitions can appear artificially 
smaller and bright partitions can appear artificially larger).  To counteract the effect of 
each partition having a different average intensity, we performed multi-level thresholding 
with tight restrictions for the area and major axis filters.  We set a minimum fluorescence 
intensity (threshold) for each pixel at a given time and used this information to segment 
(define the perimeter) each individual partition.  This threshold was combined with 
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selection criteria for the area and major axis.  The area filter defined the smallest and 
largest partitions while the major axis filter ensured that detected regions were circular. 
We repeated this for different threshold values and merged the resulting partitions.  This 
technique restricted partitions to a specific size and shape while enabling detection over 
many intensity values. 
 
Finally, we used the information from quantifying the number of partitions containing 
solution and tracking mean fluorescence of each partition over time to calculate the 
concentration of template in the bulk solution.  To smooth the traces and reduce the 
noise, we first applied a Gaussian-weighted moving average filter with window length 10 
frames to each intensity curve.  To ensure all partitions start at zero intensity, we 
determined the baseline intensity by calculating the average partition intensity for 
selected frames after heating but prior to detectable amplification (between 2.5 min and 5 
min).  The baseline intensity was subtracted from all frames.  Finally, we manually 
defined a threshold to determine whether a partition would be counted as a “positive” or 
“negative.”  Using the adjusted traces, threshold, and the total number of partitions, we 
determined the fraction of partitions that were “on” for any given time.  Using the 
fraction of partitions that were “off,” we calculated via the Poisson distribution the 
concentration of template detected in the bulk solution for any given time point. From 
this measurement of concentration, we can calculate the amplification efficiency by 
dividing the measured concentration by the known (true) concentration. 
 
The MATLAB script described here has been deposited in the open-access online 
repository GitHub and may be accessed using the following direct link: 
https://github.com/IsmagilovLab/Digital_NAAT_Analyzer  
 
 
S-II Real-time data acquisition parameters  
 
Acquiring real-time data using microscopy 
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Images were acquired in 30-sec intervals on a Leica DMI-6000B (Leica, Buffalo Grove, 
IL, USA) with a 1.25x 0.04NA HCX PL FLUOTAR Objective (506215) and 0.55x 
coupler (Leica C-mount 11541544) using a 1-sec exposure through the L5 (GFP) 
Nomarski prism and a Hamamatsu ORCA-ER CCD camera (Hamamatsu Photonics K.K., 
Hamamatsu City, Shizuoka, Japan; Ref. C4742-80-12AG).  Heating was performed using 
an integrated circuit (IC) board prototype for temperature control developed by Green 
Domain Design (San Diego, CA, USA).  The IC board was connected to a DC power 
supply (Model 3670; Electro Industries, Monticello, MN, USA), a Nichrome wire (12 
ohm) attached to a 5 x 25 x 25 mm aluminum block. A thermistor was mounted within 
the block to measure the temperature of the heating block.  When the temperature of the 
heating block was lower than the set-point temperature, the IC board supplied current to 
the Nichrome wire resistive heater.  With this setup, heating was achieved to 70.0 ± 2 °C 
within 2 min.  Images obtained on the microscope were processed with our MATLAB 
script (Supporting Information, S-I) using the following parameters: Area Bound [5 40] 
pixels, Major Axis [2 9] pixels, Threshold [250] Relative Fluorescence Units (RFU), 
Baseline Smoothing Frames [6 11], Masking Image Frame [175]. 
 
Acquiring data using a custom large-format real-time amplification instrument 
(RTAI)  
 
Images were acquired in 30-sec intervals on a custom-built, public-domain real-time 
amplification instrument (RTAI), described previously,30 using the FAM channel with a 
15-sec exposure at f/5.6.  Heating was achieved using the built-in PCT-200 thermocycler, 
which heats to 70.0 ± 0.3 °C within 70 sec.  The temperature of the thermocycler block 
was held at 25 °C to start all reactions, with the exception of an experiment where the 
block was preheated to the optimal temperature (Figure S2b).  We equipped the 
thermocycler with an aluminum block with two sloped planes (each set at 11°, an angle 
defined by the microfluidic chip manufacturer’s requirements), to segregate bubbles 
formed during the reaction to a specifically designed bubble trap.  It was advantageous to 
  
275 
use this instrument to analyze up to six chips in parallel in a single field of view and 
under a uniform temperature.  By running multiple chips on a real-time instrument we 
achieved “multiplexed” assays (wherein multiple measurements are made 
simultaneously). Images obtained on the RTAI were processed through our MATLAB 
script (Supporting Information, S-I) using the following parameters: Area Bound [4 12] 
pixels, Major Axis [2 5] pixels, Threshold [100] RFU, Baseline Smoothing frames [6 11], 
Masking Image Frame [175]. 
 
S-III Limitations of chips used  
 
A limitation of chips that discretize by capillary action is that solution can spread among 
the partitions. For example, during dLAMP quantification of extractions for three of the 
clinical samples, we observed spreading of one positive partition to its adjacent partitions. 
We attribute this spreading to liquid bridges forming among adjacent wells, resulting in 
transfer of the amplicon among compartments. These bridges could arise from defects in 
surface coatings of commercial chips or from an excess of surface active molecules 
present in some clinical samples. To test whether spreading was due to surface active 
impurities in the samples, samples were diluted in Tris-EDTA (TE) buffer and in the 
subsequent test, spreading was eliminated for one sample.  For the remaining samples, 
dilution reduced the spreading enough that quantification at 10 min was not hindered, 
although some spreading was observed at later times. Quantification of the C:T ratio 
remained consistent (and the susceptibility call the same) because we use a ratiometric 
calculation.  
 
S-IV Calculation of Peak width metrics  
 
The average distribution curve (averaged over three trials) was calculated for each 
temperature and all values normalized to the peak prominence. Time resolution was 
estimated to the nearest 15 second interval. Calculations were based on: John V. 
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Hinshaw. “How Do Your Peaks Measure Up?” Oct 01, 2013, LCGC Europe, Volume 
26, Issue 10, pg 575–582. 
 
Full Width at Half Maximum was calculated at the time difference between the leading at 
tailing edges at 50% peak prominence.  
 
Asymmetric factor was calculated by dividing the time between the peak prominence and 
the tailing edge (“b0.1“) by the time between the peak prominence and the leading edge at 
10% peak height (“f0.1“). (Eq. S1) 
 𝐴𝑠𝑦𝑚𝑚𝑒𝑡𝑟𝑖𝑐	𝐹𝑎𝑐𝑡𝑜𝑟 = 𝑏=.R𝑓=.R  
 
Tailing factor was calculated as the total peak width at 5% of the prominence (or the 
distance from the leading edge to the time of peak prominence (“f0.05”) plus the distance 
from the time of peak prominence to the tailing edge (“b0.05”)) divided by twice the 
distance from the leading edge to the time of peak prominence. (Eq. S2) 
 𝑇𝑎𝑖𝑙𝑖𝑛𝑔	𝐹𝑎𝑐𝑡𝑜𝑟 = 	𝑓=.=¬ +	𝑏=.=¬2𝑓=.=¬  
 
Table 9-S1. Tabular quantification of the time to threshold distribution curves. 
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Figure 9-S1. Bar graphs of the time location of the peak of the distribution curve (time to 
mode positive) using Bst 2.0 (a) and Bst 3.0 (b). We required 15 or greater partitions turn 
on at a given time (0.075% of total partitions), to include the time point for the mode. 
Data are summarized in Table S1 in S-III. 
 
S-VI Hardware and pre-heating considerations 
 
We asked if multiple instrumentation formats could be used to collect the data and if 
hardware format impacted the amplification efficiency. We used the optimal conditions 
for Bst 3.0. First, we compared the performance of the large-format real-time 
amplification instrument (RTAI) to a wide-field microscope fitted with a heat block—a 
set-up that would be accessible to most laboratories. We found that the heater ramp rate 
was slower on the microscope than the RTAI (120 sec versus 70 sec) resulting in 9.0 ±1.0 
min time to mode positive (Figure S2a).   
 
Next, we looked at the effect of pre-heating using the RTAI. We compared the optimal 
conditions using Bst 3.0 and starting from 25 °C (green curve) with the same instrument 
and heating block already at the optimal reaction temperature of 70 °C (orange curve).  
When the block is preheated, we observed the mode time to threshold reduced from 6.7 
±0.3 min to 6.0 ±0.0 min (Figure S2a).  
 
Next, we asked if differences in hardware configuration and the heating rates between the 
instruments would also correspond to differences in probability of detection. We 
observed significant variation in amplification efficiency (RTAI vs RTAI with preheating 
P = 0.002; RTAI vs microscope with heater P = 0.031, RTAI with preheating vs 
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microscope with heater P < 0.001) and concluded that heating rate may impact 
probability of amplification (Figure S2b). Hence, all comparisons made in this study 
were instrument specific. Though it remains to be tested, we suspect more precise 
hardware, with improved heating control, could improve device performance. 
 
 
Figure 9-S2. Effect of hardware and heating on (a) the distribution in time to 
fluorescence threshold and (b) quantification of amplification efficiency (mean 
percentage copies detected ± S.D.) at 40 min. 
 
S-VII Optimization of Bst 2.0 buffer composition 
 
Following the protocol described previously18, buffer conditions for Bst 2.0 were 
optimized in bulk at 713 copies/uL (e.g.  ~4,280 or 0 copies per 6 µL reaction). Optimal 
buffer composition was selected based on fastest bulk time to positive. 
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Figure 9-S3. Magnesium optimization for Bst 2.0. A value of 0.25 indicates that no 
amplification was observed. Amplification was performed at 67.5° C. N=1 for all TTP 
values. 
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